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ABSTRACT OF THE DISSERTATION 
DESIGN AND SYNTHESIS OF NOVEL NUCLEOSIDE ANALOGUES: OXIDATIVE 
AND REDUCTIVE APPROACHES TOWARD SYNTHESIS OF 2'-FLUORO 
PYRIMIDINE NUCLEOSIDES 
by 
Ramanjaneyulu Rayala 
Florida International University, 2015 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor 
Fluorinated nucleosides, especially the analogues with fluorine atom(s) in the 
ribose ring, have been known to exert potent biological activities. The first part of this 
dissertation was aimed at developing oxidative desulfurization-fluorination and reductive 
desulfonylation-fluorination methodologies toward the synthesis of 2'-mono and/or 2',2'-
difluoro pyrimidine nucleosides from the corresponding 2'-arylthiopyrimidine precursors. 
Novel oxidative desulfurization-difluorination methodology was developed for the 
synthesis of α,α-difluorinted esters from the corresponding α-arylthio esters, wherein the 
arylthio group is present on a secondary internal carbon. For the reductive 
desulfonylation studies, cyclic voltammetry was utilized to measure the reduction 
potentials at which the sulfone moiety of substrates can be cleaved.  
The 5-bromo pyrimidine nucleosides and 8-bromo purine nucleosides act as 
crucial intermediates in various synthetic transformations. The second part of the present 
dissertation was designed to develop a novel bromination methodology using 1,3-
dibromo-5,5-dimethylhydantoin (DBH). Various protected and deprotected pyrimidine 
vii 
 
and purine nucleosides were converted to their respective C5 and C8 brominated 
counterparts using DBH.  The effect of Lewis acids, solvents, and temperature on the 
efficiency of bromination was studied. Also, N-bromosuccinimide (NBS) or DBH offered 
a convenient access to 8-bromotoyocamycin and 8-bromosangivamycin. 
Third part of this research work focuses on the design and synthesis of 6-N-
benzylated derivatives of 7-deazapurine nucleoside antibiotics, such as tubercidin, 
sangivamycin and toyocamycin. Target molecules were synthesized by two methods. 
First method involves treatment of 7-deazapurine substrates with benzylbromide 
followed by dimethylamine-promoted Dimroth rearrangement. The second method 
employs fluoro-diazotization followed by SNAr displacement of the 6-fluoro group by a 
benzylamine. The 6-N-benzylated 7-deazapurine nucleosides showed type-specific 
inhibition of cancer cell proliferation at micromolar concentrations and weak inhibition 
of human equilibrative nucleoside transport protein (hENT1). 
 In the fourth part of this dissertation, syntheses of C7 or C8 modified 7-
deazapurine nucleosides, which might exhibit fluorescent properties, were undertaken. 8-
Azidotoyocamycin was synthesized by treatment of 8-bromotoyocamycin with sodium 
azide. Strain promoted click chemistry of 8-azidotoyocamycin with cyclooctynes gave 
the corresponding 8-triazolyl derivatives. Alternatively, 7-benzotriazolyl tubercidin was 
synthesized by iodine catalyzed CH arylation of tubercidin with benzotriazole.  
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1. INTRODUCTION 
In 1909, the term “nucleoside” was proposed by Levene and Jacobs to describe 
carbohydrate derivatives of purines and pyrimidines.1 Nucleosides, held together by 
phosphodiester linkages, are the core components of the biopolymers DNA and RNA. 
Nucleosides are composed of a furanose sugar moiety, linked to either a purine or a 
pyrimidine heterocyclic base via a beta-glycosidic bond. The four nucleosides prevailing 
in RNA are adenosine, guanosine, cytosine and uridine. Whereas, 2'-deoxyadenosine, 2'-
deoxyguanosine, 2'-deoxycytidine and thymidine form the core part in DNA (see Figure 
1 for structures of RNA and DNA nucleosides). Development of drug therapy progressed 
rapidly after the discovery of DNA as the primary genetic material in 19442 and 
subsequent elucidation of its physical structure in 1953.3 Since then, DNA and RNA have 
been regarded as potential targets for drug design, as they play vital role in many 
biological processes. Since nucleosides form the major part of DNA and RNA, 
nucleosides have also been considered prospective targets.  
 
Figure 1. Structures of RNA and DNA nucleosides3 
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1.1. Notable nucleoside analogues with anticancer and antiviral activity 
Pyrimidine nucleoside analogues such as 5-fluoro-2'-deoxyuridine (Floxuridine), 
1-(β-ᴅ-arabinofuranosyl)cytosine (araC) were among the initial nucleoside analogues 
approved  by U.S. Food and Drug Administration (FDA) for cancer treatment (Table 1). 
Remarkable biological activity resulting from slight structural modifications to the 
normal nucleosides prompted various scientists all over the world to develop modified 
nucleoside analogues as anticancer agents. Currently, there are 11 nucleoside based drugs 
approved by FDA for the treatment of cancer.  
Table 1. FDA approved anticancer purine and pyrimidine nucleoside analogues.4 
 Drug Category Year
    
 5-aza-2'-deoxycytidine (Decitabine) 2′-Deoxycytidine 2006 
 O6-methylarabinofuranosyl guanine (Nelarabine) Guanosine 2005 
 5-aza-cytidine (Vidaza) 2′-Deoxyadenosine 2004 
 2'-fluoro-2'-deoxyarabinofuranosyl-2-chloroadenine (Clofarabine) Cytidine 2004 
 N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (Capecitabine) Cytidine 1998 
 2,2-difluoro-2'-deoxycytidine (Gemcitabine) 2′-Deoxycytidine 1996 
 2-chloro-2'-deoxyadenosine (Cladribine) 2′-Deoxyadenosine 1992 
 2'-deoxycoformycin (Pentostatin) Adenosine 1991 
 Arabinofuranosyl-2-fluoroadenine (Fludarabine) Purine analogue 1991 
 5-fluoro-2'-deoxyuridine (Floxuridine) 2′-Deoxyuridine 1970 
 Arabinofuranosylcytosine (Cytarabine) Cytidine 1969 
 6-thioguanine (Lanvis) Guanine 1966 
 5-fluorouracil (Adrucil) Uracil 1962 
 6-mercaptopurine (Purinethol) Purine 1953 
    
Parallel to the anticancer drugs, researchers also developed various nucleoside 
analogues with antiviral properties. The sounding success of prominent antiviral drugs 
such as Acyclovir (anti-HSV), and Zidovudine (anti-HIV) revealed the potential value of 
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modified nucleoside analogues as antiviral agents (Table 2). There are currently 13 FDA 
approved nucleoside based drugs used in the treatment of various viruses. Most recent of 
them being Sofosbuvir, an anti-HCV drug, which is considered to be a huge step forward 
in HCV treatment.5,6  
Table 2. Antiviral properties of purine and pyrimidine nucleoside analogues.4 
 Drug Category Year
    
 2'-deoxy-2'-fluoro-2'-methyluridine-5'-phosphate (Sofosbuvir) Uridine 2013 
 Tenofovir disoproxil fumarate, mixture of purine analogues (Tenofovir) Purine 2008 
 1-2-deoxy-β-L-erythro-pentofuranosylthymine (Telbivudine) Thymidine 2006 
 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (Emtricitabine) Cytidine 2003 
 2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) Thymidine 2001 
 2',3'-dideoxy-3'-thiacytidine (Lamivudine) Cytidine 1998 
 2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) Thymidine 1994 
 3'-azido-3'-deoxythymidine (Zidovudine) Thymidine 1987 
 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one (Acyclovir) Guanosine 1982 
 (E)-5-(2-bromovinyl)-2'-deoxyuridine (Brivudine) Uridine 1980 
 9-β-D-arabinofuranosyladenine (Vidarabine) Adenosine 1976 
 5-ethyl-2'-deoxyuridine (Edoxudine) Thymidine 1969 
 5-iodo-2'-deoxyuridine (Idoxuridine) Uridine 1962 
    
 
1.2. Importance of fluorine substitution 
 Fluoro organic compounds have been known to possess a wide variety of 
biological activity and several of them are used as drugs for the treatment of various 
types of diseases.7,8 Introduction of fluorine atom(s) into the organic molecules 
dramatically changes their electronic and steric properties, which  often leads to the 
molecules rendering potent biological activities.9,10 Though a fluorine atom is close in 
size to a hydrogen atom, presence of fluorine causes various electronic changes because 
of its electronegativity. Moreover, fluorine atoms can also act as hydrogen bond 
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acceptors. Also, a fluorine atom can serve as a replacement for hydrogen, since the Van 
der Waals radius of fluorine (1.35 Ǻ) is so close to that of a hydrogen atom (1.1 Ǻ). The 
C-F bond strength (484 kJ/mol) is also greater than that of a C-H bond (411 kJ/mol), 
offering a measure of increased biological and chemical stability to the structure.  
1.3. Prominent nucleoside analogues with fluorine atom in sugar moiety 
 Of the variety of nucleoside analogues with biological activity, the class of fluoro 
nucleosides is known to possess a wide range of medicinal and biological activity.11 
Prominent examples of fluorinated nucleoside analogues include: 2'-deoxy-2',2'-
difluorocytidine (1, Gemcitabine)12,13 the phospharamidate analogue of 2'-deoxy-2'-
fluoro-2'-C-methyluridine (2, Sofosbuvir) and 2-chloro-1-(2'-deoxy-2'-
fluoroarabinofuranosyl)uracil (3, Clofarabine)14,15 (Figure 2). Gemcitabine (1) and 
Clofarabine (3) are potent anti-cancer drugs that are commonly used in the treatment of 
various types of cancers.13,16 Sofosbuvir  (3) acts as potent inhibitor of Hepatitis C virus 
replication.5,6  
 
Figure 2. Examples of the prominent nucleoside drugs with fluorine modifications in 
sugar moieties. 
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 Over the last 25 years, several research groups have published improved methods 
for the synthesis of gemcitabine. Some of these synthetic approaches followed Hertel’s 
original approach and differ mainly in employing either different protecting groups on the 
ribose or different coupling conditions to improve stereoselectivity/isomer-separation. 
Additionally gemcitabine was also synthesized from various furanose and pyranose 
derivatives. The synthesis of gemcitabine has been subject to an excellent review 
published recently.21  
Even though the synthesis of gemcitabine is widely studied from the stand point 
of sugar-base coupling, much less attention has been paid toward the synthesis from 
parent nucleosides. To our knowledge, only three literature examples have described the 
synthesis of gemcitabine via direct carbohydrate fluorination of the parent nucleoside 
derivatives.  
A 1996 patent from Eli Lily reported the synthesis of 2'-deoxy-2',2'-
difluorocytidine derivative 6 by treating the corresponding 2'-keto cytidine derivative 5 
with DAST and Pyr.HF reagent combination (Figure 4). Whereas a more recent Chinese 
patent (2013) described the similar transformation with the new deoxyfluorinating agents 
Xtalfluor-M and Xtalfluor-E.  
 
Figure 4. Synthesis of 2'-difluorocytidine derivatives from 2'-keto derivatives by 
deoxyfluorination 
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Synthesis of difluorouridine derivative 10 by desulfurization-difluorination of the 
corresponding dithiouridine derivative 9 with DBH/Py.9HF reagent combination was 
reported in a 2007 patent (Figure 5). However, the crucial uridine-2'-dithioketal precursor 
9, was prepared by coupling the uracil base with the pre-constructed dithioacetal ribose 
derivative 8, which in turn was prepared from the open chain ribonolactone derivative 
7.22 
 
Figure 5. Synthesis of 2'-deoxy-2'-2'-difluorouridine derivative by desulfurization-
difluorination of the corrssponding 2'-dithioketal derivative 
1.4.2. Mechanism of action of gemcitabine 
The mechanism of action of gemcitabine has been widely studied13,16-20 and is 
only discussed briefly here. Gemcitabine (dFdC) is a prodrug and must be metabolized to 
the active triphosphate form 2′,2′-difluoro-2′-deoxycytidine triphosphate (dFdCTP) to 
exert biological activity (Figure 6). Human nucleoside transporters (hNTs), an important 
class of membrane proteins, mediate the cellular uptake of gemcitabine. Gemcitabine is 
converted into its monophosphate (dFdCMP) by deoxycytidine kinase (dCK); to its 
diphosphate (dFdCDP) by pyrimidine nucleoside monophosphate kinase (UMP-CMP 
kinase); and subsequently to the active metabolite triphosphate by nucleoside diphosphate 
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kinase. Gemcitabine may become inactivated through deamination by cytidine deaminase 
(CDA) and, when in the monophosphate form by deoxycytidylate deaminase (dCTD). 
The product of gemcitabine deamination by CDA is 2′,2′-difluoro-2′-deoxyuridine 
(dFdU), which is cytotoxic itself. Also, dFdU monophosphate (dFdUMP) could inhibit 
the activity of thymidylate synthase, directly effecting the deoxynucleotide triphosphate 
(dNTP) pool. Gemcitabine can also become inactivated by dephosphorylation of the 
monophosphate form by 5′-nucleotidases (5′-NTs), converting nucleotides back to 
nucleosides. These enzymes play a critical role in the balance of dNTP pools and, 
therefore, in gemcitabine metabolism. In this way, the rate-limiting step of 
phosphorylation by dCK may be also be affected, compromising the overall beneficial 
cytotoxicity of gemcitabine.  
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Figure 6. Gemcitabine cellular metabolism.18  
hNT: human nucleoside transporter; dFdCMP: gemcitabine monophosphate; dFdCDP: 
gemcitabine diphosphate; dFdCTP: gemcitabine triphosphate; dFdU: 2′,2′-difluoro-2′-
deoxyuridine, dFdUMP: 2′,2′-difluoro-2′-deoxyuridine monophosphate. 
 
The most important mechanism of action of gemcitabine is inhibition of DNA 
synthesis. When dFdCTP is incorporated into DNA, a single deoxynucleotide is 
incorporated afterwards, and stops chain elongation. The non-terminal position of 
gemcitabine makes DNA polymerases unable to proceed, as well as inhibits removal of 
gemcitabine by exonucleases. 
An additional mechanism of action of gemcitabine is inhibition of 
deoxycytidylate deaminase (dCTD), by dFdCTP and indirectly by dFdCDP.23,24 By 
covalently binding to the active site, dFdCDP inhibits Ribonucleotide reductase (RNR), 
which catalyzes the reduction of ribonucleotides to deoxyribonucleotides.25-31 The 
covalent inhibition of RNR causes decrease in the dNTP pool and consequently reduces 
dCTD activity.32,33 In addition, decrease in the dNTP pool stimulates dFdC 
phosphorylation, thereby increasing the level of dFdCTP, making dFdCTP more likely to 
be incorporated into DNA competing with the NTPs.25,27 In addition, another important 
mechanism of gemcitabine is the induction of apoptosis through caspase signaling. In 
response to cellular stress, Gemcitabine activates p38 mitogen-activated protein kinase 
(MAPK) to trigger apoptosis in tumour cells, but not in normal cells.  
The widely accepted mechanism of covalent inhibition of RNR by dFCDP in the 
presence and absence of reductant is shown in Figure-7.31 Crucial steps in RNR 
mechanism include generation of tyrosine (Y122) radical from R2 subunit of RNR, 
abstraction of a hydrogen radical from Cysteine (C439) in R1 subunit of RNR by Y122 
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preparation of numerous fluoro/gem-difluoro organic compounds.39,40 Various reagents or 
reagent-combinations have been developed for oxidative desulfurization-fluorination 
reactions over the years. Of which, desulfurization-difluorination of aldehyde and ketone 
dithiolanes with oxidants such as N-halosuccinimides (NBS, NIS) or 1,3-dibromo-5,5-
dimethylhydantoin (DBH) and pyridinium poly(hydrogen fluoride) (PPHF)41 and 
desulfurization-difluorination of alkyl aryl thioethers with DBH and Olah’s reagent 
(Py.9HF)42,43 share similar mechanistic traits (Scheme 1). 
 
Scheme 1. Oxidative desulfurization-difluorination of aldehyde, ketone dithiolanes; and 
alkyl aryl thioethers.  
Hara’s research group has developed three reagents or reagent combinations for 
oxidative desulfurization-fluorination reactions. First among them was Iodine 
pentafluoride (IF5),44-47 which mainly causes the desulfurization-difluorination of benzyl 
sulfides (Scheme 2). Later, an air- and moisture-stable IF5-pyridine-HF reagent48,49 was 
developed for the desulfurization-difluorination of benzyl sulfides, thioacetals, and 
dithianes. Recently, an air-stable fluorinating agent BrF3-KHF250 was also developed for 
12 
 
desulfurization-difluorination of benzyl sulfides, dithioacetals, and 
(phenylthio)glycosides. 
 
Scheme 2. Hara's oxidative desulfurization-difluorination of benzylic sulfides. 
Interesting point to note is that none of the above mentioned methods provide 
access to gem-difluoro products from alkyl aryl thioethers where in the thioether is 
present on an internal secondary carbon atom (See Figure 13 in Section 2). 
1.6. 5-Bromopyrimidines and 8-bromopurines: Syntheses and importance 
 The C-5 halogenated pyrimidine and C-8 halogenated purine nucleosides are 
widely used as substrates in reactions involving direct displacement of halo groups with 
nucleophiles.51,52 Especially, 5-bromopyrimidine and 8-bromopurine nucleoside 
derivatives have been shown to possess interesting synthetic and biological 
properties.51,52 Also, the halogenated pyrimidine and purine nucleoside derivatives are 
often used in transition metal catalyzed cross-coupling reactions53 resulting in the  
syntheses of a variety of nucleoside analogues with biological activity and/or fluorescent 
probes.54 For example, a number of 5-substituted uracil derivatives, especially 
arabinofuranosyl- and 2'-deoxyuridines, have been investigated extensively for the 
clinical treatment of viral diseases.55 The 5-bromo and 5-iodo uridine derivatives are used 
as substrates for high yield coupling with terminal alkynes to generate 5-alkynyluracil 
nucleosides with antiviral activity56,57 and the 5-alkynyl products can also be transformed 
into bifurane derivatives which possess potent and selective inhibition of Varicella-Zoster 
13 
 
virus.56,58 Moreover, radiolabeled 5-bromo- and 5-iodouracil  nucleosides have 
applications in cellular biochemistry.59  
 Halogenated pyrimidine52 and purine51 nucleosides have been prepared by direct 
treatment with halogens or halonium ion (X+) sources but most of these methods utilize 
harsh reaction conditions. Various C5-bromouridine derivatives have been synthesized 
using Br2/Ac2O/AcOH,52 Br2/H2O,60 N-bromosuccinimide (NBS) in DMF61 or ionic 
liquids,62 combination of 3-chloroperoxybenzoic acid/HBr in aprotic solvents,63 ceric 
ammonium nitrate (CAN)/LiBr in protic or aprotic solvents,64 or KBr/Oxone.65 The C5-
bromination of cytidine nucleosides has been accomplished with Br2/CCl4/hν66 or NBS in 
DMF61 or ionic liquids.62 On the other hand, the synthesis of C8-bromo purine 
nucleosides has been typically achieved with Br2/AcOH/AcONa67 or NBS/DMF.61 
Hence, a universal brominating reagent for C5-bromination of pyrimidines and C8-
bromination of purines and also development of a bench-friendly bromination 
methodology is warranted.  
1.6.1. 1,3-dibromo-5,5-dimethylhydantoin, an important brominating reagent 
 The 1,3-dibromo-5,5-dimethylhydantoin (DBDMH or DBH, Figure 8) is a useful 
reagent for various organic transformations68-70 including  aromatic bromination.71-75  
Enhanced efficiency of DBH towards aromatic bromination in the presence of acids has 
been known.72-74 Moreover, Lewis acid-catalyzed benzylic bromination with DBH has 
also been reported.76 DBH also efficiently oxidizes thiols to disulfides with DBH.77,78 In 
addition, α-bromination of aliphatic ketones is achieved with DBH in combination with 
p-toluenesulfonic acid (TsOH).79 Interestingly, compared to NBS, DBH can donate two 
bromines and can be doubly efficient.  
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Figure 8. Structures of DBH and NBS 
1.7. Selected aspects of the chemistry of 7-deazapurine nucleosides 
The 7-deazapurine nucleosides, namely, tubercidin, sangivamycin and 
toyocamycin (19a-c, Figure 9) are a group of natural products isolated from the species 
Streptomyces. Analogues and derivatives of these 7-deazapurine nucleoside antibiotics 
have been synthesized and subjected to extensive biological testing.80-84 Chemical 
modifications of the parent 7-deazapurine antibiotics as well as sugar-base coupling has 
provided access to a sizeable number of biologically active 7-deazapurine compounds.85-
96  
 
Figure 9. Structures of 7-deazapurine nucleosides 
Noteworthy examples of such molecules include: (a) 5-iodotubercidin 20,97 an up-
field activator of the p53 pathway; (b) sangivamycin analogues such as 6-
hydrazinosangivamycin 2298 and 4-Amino-6-bromo-7-(β-L-xylofuranosyl)pyrrolo[2,3-
d]pyrimidine-5-carboxamide (xylocidine, 23),99 in vitro down-field inhibitors of PKC and 
CDK in cancer cell lines; (c) a methyl-substituted tubercidin 21,100 which acts against the 
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replication of polio and dengue viruses; (d) the anti-HSV agent xylotubercidin;101 (e) 
substituted toyocamycin analogues 24102 and 2'-β-C-methyl derivative of toyocamycin,103 
sangivamycin,103 and tubercidin104,105 that have activity against HCV; (f) 2'-deoxy-2'-
fluoroarabinotubercidin106 and 2-amino-2'-deoxy-2'-fluoroarabinotubercidin,107,108 which 
exhibit antiviral activity; (g) 4N,5-diaryltubercidin derivatives 25, which act as adenosine 
kinase inhibitors;96,109,110 and (h) tubercidin derivatives such as 4-(het)aryl,111 5-
(het)aryl112 and some 4-substituted-5-(het)aryl113 compounds 26 with nanomolar 
cytostatic activity against several cancer cell lines. Important base-modified analogues 
are shown in Figure 10. 
 
Figure 10. Important base-modified 7-deazapurine nucleoside derivatives.  
 Direct alkylation of exocyclic amino groups on 7-deazapurine nucleosides has not 
been noted. However, 4-N-methyltubercidin (6-N-methyl-7-deazaadenosine) 28 was 
reported to be synthesized from the reaction of tubercidin with methyl iodide followed by 
1N sodium hydroxide (Scheme 3).86 Thus, treatment of tubercidin with CH3I (rt, 24 h, 
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DMA) gave the corresponding N1-methyltubercidin hydroiodide 27 after recrystallization 
from methanol. Base treatment of this cationic intermediate (1N NaOH 100 oC, 1.25 h) 
produced 4-N-methyltubercidin 28 via Dimroth rearrangement.86  
 
Scheme 3. Synthesis of 4-N-methyltubercidin by Dimroth-rearrangement approach 
Even though direct alkylation or Dimroth type rearrangement has been scarce in 
7-deazapurine chemistry, the 4-N-substituted-7-deazapurine derivatives have been widely 
prepared by aromatic nucleophilic substitution (SNAr). For example, SNAr displacement 
of chloro group from 4-cholo analogues86,113 or triazolyl group from 4-N-(1,2,4-triazol-4-
yl) intermediates114 gave access to various other 4-N-modified tubercidin derivatives. 
Also, 4-N-substituted toyocamycin derivatives were prepared from the SNAr 
displacement of chloro group from the corresponding 4-chloro compounds.102 Likewise, 
the 7-N-benzylformycin was prepared via 7-chloro derivative of the C-nucleoside 
antibiotic formycin (3-β-D-ribofuranosylpyrazolo[4,3-d]pyrimidine).115  
1.8. Nucleoside transport inhibitors  
As discussed in previous sections (Chapter 1, Sections 1.1-1.3), nucleoside based 
drugs have been in use for the treatment of various infections. Since the hydrophilic 
nature of nucleosides limits their cell permeability, nucleoside-specific membrane 
transport carriers (NT) facilitate and regulate the cellular uptake and therapeutic actions 
17 
 
of many nucleoside based drugs.116,117 The nucleoside transporter proteins are classified 
into two categories: equilibrative NT (ENT) and concentrative NT (CNT). Human 
equilibrative NTs (hENTs) are found in the outer plasma membrane and some 
intracellular membranes of most, if not all, human cells.118 
 Nitrobenzylmercaptopurine ribonucleoside (NBMPR, 29a) and structurally 
related hENT1 probes such as 6-N-(4-nitrobenzyl)adenosine (29b)119 and 5'-S-{2-(6-[3-
(fluorescein-5-yl)thioureido-1-yl]hexanamido)}ethyl-6-N-(4-nitrobenzyl)-5'-
thioadenosine (FITC-SAHENTA)120 inhibit hENT1 with nM affinity (Figure 11). 
Discovery and development of such nucleoside transport inhibitors has greatly aided 
investigations on the structure, function, and cell surface abundances of hENT1 
proteins.116,120,121 
 
Figure 11.  Structures of Important nucleoside transport inhibitors. 
2. RESEARCH OBJECTIVES 
(i) The first research objective of this dissertation was to develop novel fluorination 
methodologies for the synthesis of mono-fluoro and geminal-difluoro uridine analogues 
from their parent nucleoside precursors. These strategies were envisioned to eliminate the 
current need to couple fluorinated sugar precursors with nucleosides bases, a process 
which has severe regiochemical and stereochemical limitations. On the basis of literature 
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precedence,122 I would explore the possibility of insertion of the fluorine or geminal-
difluoro unit into the 2'-position of ribose moiety of nucleosides using oxidative 
desulfurization-fluorination of substrates of type 30 and 31 with 1,3-dibromo-5,5-
dimethylhydantoin (DBDMH or DBH) and Olah’s reagent (Py.9HF) (Figure 12).  
 
Figure 12. Different classes of 2'-arylthionucleosides for oxidative desulfurization-
fluorination and reductive desulfonylation-fluorination procedures. 
 A complementary approach was designed based on reductive-
desulfonylation/fluorination processes of 2'-arylsulfonyl-2'-deoxyuridine 32 or 2'-
arylsulfonyl-2'-deoxy-2'-fluorouridine 33 with electrophilic fluorine reagents (Figure 12). 
Treatment of sulfone 32 or α-fluorosulfone 33 with organic electron donors such as 
tetrakis(dimethylamino)ethylene (TDAE), Murphy’s reagent, would be expected to lead 
to the reductive cleavage of sulfone moiety and generation of C2'-centered carbanion. 
The intermediate carbanion would then be quenched with fluoronium ion (F+) to give 
mono- or di- fluorinated uridine derivatives. Alternatively, treatment of 2'-arylsulfonyl-2'-
deoxyuridine 32 with a base would lead to abstraction of the most acidic proton H2' and 
then the intermediary carbanion would be quenched with electrophilic fluorine (F+) to 
give products of type 33.  
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(ii) Since nucleosides are complex molecules and also because of the lack of literature 
precedence for the desulfurization-difluorination of aryl-alkyl thioethers wherein the 
arylthio unit is positioned on a secondary internal carbon atom, I planned to perform 
model studies on simpler aryl-alkyl thioether substrates of type 34-37 (Figure 13). The 
proposed substrates would have different functional groups such as ester (34), keto (35), 
alkane (36) and lactone (37), and mimic the C2' of ribose unit in the pyrimidine 
nucleoside precursor (30, Figure 12), which also has a carbon at the carbonyl oxidation 
state (as an aminal group) on the α-carbon atom.  
 
Figure 13. Various aryl-alkyl thioether substrates for model oxidative desulfurization-
difluorination reactions 
(iii) Since DBH is a source of electrophilic bromine (Br+) and as bromonium ions are 
known to brominate pyrimidines at C-5 position and purines C-8 position, I explored the 
bromination at C-5 of pyrimidines and C-8 of purines with DBH. The goal of this part of 
my dissertation was to develop an efficient bromination methodology, which could be 
applicable for the bromination of all DNA and RNA nucleosides, and which would also 
be compatible with commonly used protection groups in nucleoside chemistry.  
(iv) The next goal of my dissertation was to investigate the behavior of gemcitabine and 
its 2'-modified analogues such as 2'-deoxy-2'-fluorocytidine (38) and 2′-deoxy-2′-fluoro-
2′-C-methylcytidine (PSI-6130, 39) in one electron oxidation systems and evaluate if 
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stereo electronic differences at C2'-position among these substrates would allow us to 
detect C2' and/or C3' sugar radicals using electron spin resonance (ESR) spectroscopy 
studies (Figure 14). This part of my dissertation was planned in collaboration with Dr. 
Michael D. Sevilla’s research group of Oakland University. 
 
Figure 14. Gemcitabine and its analogues for one electron oxidation studies 
(v) Since 6-N-(4-nitrobenzyl) derivatives of adenosine and other adenine nucleosides 
possess potent nucleoside transport inhibition activity, in the next goal, I proposed to 
synthesize novel 6-N-benzyl-7-deazapurine nucleoside derivatives (40a-d) of 7-
deazaadenosine antibiotics (19a-c) in order to test their biological activity (Figure 15). I 
envisioned two methods for achieving the synthesis of the target molecules (40a-d). One 
involved alkylation of the 7-deazaadenosine antibiotics (19a-c) at N1 with a benzyl 
bromide followed by a base-promoted Dimroth rearrangement. The second route 
employed diazotization–fluorodediazoniation followed by SNAr displacement of fluoride 
with a benzyl amine. 
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Figure 15. Structures of 7-deazapurine antibiotics and the proposed 6-N-benzyl 
analogues. 
(vi) I also intended to synthesize 7-deazapurine nucleoside derivatives with various novel 
modifications at C-8 and C-7 position (Figure 16). For example, 8-bromo-7-deazapurine 
derivatives (41, Y = Br) are envisioned as substrates for the synthesis of novel 8-azido-7-
deazapurine analogues (41, Y = N3). These 8-azido-7-deazapurine nucleosides might act 
as substrates for Copper-catalyzed and copper-free click reactions with alkynes and 
cycloalkynes respectively. The resultant novel 8-triazolyl-7-deazapurine derivatives (41, 
Y = triazolyl) might possess fluorescent properties because of extended conjugation. 
 
Figure 16. Structures of various 8-modified-7-deazapurine derivatives 
Also, the 8-bromo-7-deazapurine substrates (41, Y = Br) can be converted to the 
corresponding 8-alkynyl-7-deazapurine counterpart 42. The crucial 8-alkynyl 
intermediates 42 might give access to α-halovinyl (43, Z = Cl, Br), β-ketosulfone (43, Z = 
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OH), and α-vinylazide (44) derivatives, analogous to recent findings on similar 
modifications at C5-position of pyrimidines (unpublished results from our research 
group).  
3. RESULTS AND DISCUSSION 
3.1. Bromination of nucleobases with 1,3-dibromo-5,5-dimethylhydantoin 
 Since DBH is known to be a good source of bromonium ion (Br+), I envisioned a 
novel bromination protocol toward C5-bromination of pyrimidines and C8-bromination 
of purines.   
3.1.1 Bromination at C5 position of pyrimidine nucleosides with DBH 
To test my hypothesis, I initially treated 2',3',5'-tri-O-acetyluridine 45a with 1.1 
equivalents of DBH in CH2Cl2  at ambient temperature (Scheme 4; Table 3, entry 1). 
After 28 h of reaction time TLC showed conversion of most of the substrate to a new 
spot, which was less polar than the substrate spot. The less polar spot was isolated by 
aqueous workup (95%) and 1H-NMR of the crude material was very clean and implied a 
single compound. Characteristic doublet for H5 at 5.73 ppm was missing in 1H-NMR and 
the doublet for H6 (7.33 ppm) collapsed to a singlet (7.82 ppm), indicating the formation 
of 2',3',5'-tri-O-acetyl-5-bromouridine (46a; 95%). Furthermore, structure of the product 
was confirmed by comparing NMR data with literature NMR data for 2',3',5'-tri-O-
acetyl-5-bromouridine.64 To optimize the amount of DBH required for the bromination, I 
treated 45a with 0.55 eqiuv. of DBH. But the TLC showed only 60% conversion to 46a 
even after 48 h of reaction time. Although, two bromonium ions (Br+) can be delivered 
by one equivalent of DBH, it seemed that 1.1 equiv. of DBH is required for complete 
conversion of 45a to 46a at room temperature.  
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Role of Lewis acids 
Since it was reported that Lewis acids enhance the efficiency of bromination by 
DBH,76 I decided to compare the rate of bromination in presence of Lewis acids. 
Remarkably, treatment of 45a with 0.55 equiv. of DBH in presence of 0.55 equiv. of 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) significantly enhanced the rate of 
bromination yielding 46a after only 6 h (94% yield) (entry 2). The efficiency of 
bromination did not differ much when 1.1 equiv. of TMSOTf was used (entry 3). Also, 
replacing TMSOTf with other organic acids such as p-toluenesulfonic acid (TsOH, 0.75 
equiv.) required 0.75 equiv. of DBH for complete conversion of 45a to 46a (entry 4). 
Next, I studied the effect of temperature and role of solvents on bromination in order to 
establish optimal reaction conditions.   
 
Scheme 4. Bromination of uracil-derived nucleosides 1 with 1,3-dibromo-5,5-
dimethylhydantoin (DBH). See Table 3 and 4 for specific reaction parameters. 
Effect of Temperature 
Treatment of 45a with equimolar quantities of DBH and TMSOTf (0.55 equiv.) at 
40 oC in CH2Cl2 afforded 46a quantitatively in only 2 h (entry 5).  Whereas, analogous 
24 
 
treatment of 45a with DBH/TMSOTf at 0 oC gave 46a in only 65% yield after 8 h (TLC) 
and required 1.1 equiv. of DBH for complete conversion (entry 6).  
Role of Solvents 
Treatment of 45a with 0.55 equiv. of DBH at room temperature in CH3CN gave 
46a after 11 h (entry 7). Analogous treatment of 45a with DBH in presence of TMSOTf 
(0.55 equiv.) yielded 46a after only 2.5 h (entry 8). Moreover, the DBH/DMF system was 
much more effective than CH3CN or CH2Cl2 affording 46a in much shorter time (entries 
9-10). In addition, bromination of 45a with DBH in the presence or absence of TMSOTf 
was less efficient in polar protic solvent MeOH, producing 46a in low yields. Hence, it 
can be concluded that bromination of 45a with DBH and/or TMSOTf was very efficient 
in polar aprotic solvents such as CH3CN or DMF. However, it is noteworthy that prior 
removal of these polar solvents from crude reaction mixture was required before 
proceeding to aqueous workup, which is not the case with CH2Cl2.  
Table 3.  Effect of various reaction parameters on C5-bromination of 2',3',5'-tri-O-
acetyluridine 45a with DBHa 
Entry Solvent 
Temp.  
(oC) 
DBH 
(equiv.)
TMSOTf
(equiv.) 
Time
(h) 
Yieldb,c 
46a (%) 
1 CH2Cl2 25 1.1 - 28 95 
2 CH2Cl2 25 0.55 0.55d 6 94 
3 CH2Cl2 25 0.55 1.10 6 91 
4 CH2Cl2 25 0.75 0.75e 8 94 
5 CH2Cl2 40 0.55 0.55 2 98 
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6 CH2Cl2 0 1.1f 0.55 3 98 
7 CH3CN 25 0.55 - 11 86g 
8 CH3CN 25 0.55 0.55 2.5 90 
9 DMF 25 0.55 - 0.6 95 
10 DMF 25 0.55 0.55 0.3 98 
a Bromination was performed on 0.1 mmol scale of 45a. b Isolated yield after aqueous 
work-up. c Purity of the product 46a was determined by TLC and 1H NMR and was 
higher than 97% unless otherwise noted. d Reaction without TMSOTf showed 60% 
conversion to 46a (TLC) after 48 h and complete conversion after 68 h with purity over 
90% (1H NMR). e TsOH was used instead of TMSOTf. f Reaction with 0.55 eq. of DBH 
was complete in 65% after 8 h.  g With purity over 90%. 
 
Extension to other protected uridine nucleosides 
I also wanted to test the applicability of the optimized bromination procedure for 
the 5-bromination of the other uracil nucleosides. Thus, treatment of 1-(2,3,5-tri-O-
acetyl-β,D-arabinofuranosyl)uracil 45b with DBH and TMSOTf yielded the 
corresponding C5-brominated analogue 46b in 91% yield after 10 h (Scheme 4; Table 4, 
entry 2). Replacing CH2Cl2 with polar aprotic solvent such as CH3CN generated 46b in 
98% yield after only 2 h (entry 3). In addition, treatment of 3',5'-di-O-acetyl-2'-
deoxyuridine 45c  with DBH produced the 5-bromo counterpart 46c in 72% isolated yield 
after 18 h (entry 4). 46c was also obtained after only 2.5 h in the presence of TMSOTf 
(entry 5). Moreover, the rate of bromination increased five-fold when the reaction was 
carried out at 40 oC (entry 6).   
C5-Bromination of unprotected uridine nucleosides with DBH 
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On the basis of the successful C5-bromination of protected uridine nucleosides, I 
envisioned the extension of DBH bromination protocol for the C5-bromination of 
unprotected uridine nucleosides. Thus, bromination of uridine 45d with DBH in DMF 
yielded 5-bromouridine 46d in 75% crystallized yield after only 20 minutes (Scheme 4; 
Table 4, entry 7). Analogously, treatment of 1-(β,D-arabinofuranosyl)uracil 45e and the 
acid sensitive 2'-deoxyuridine 45f  with DBH at ambient temperature produced the 
corresponding 5-brominated products in good yields (entries 8 and 9).  
Extension to cytidine nucleosides 
With the successful application of C5-bromination of uridine nucleosides with 
DBH, I imagined the extension of the DBH-bromination methodology toward the 
synthesis of C5-brominated cytidine analogues. Thus, treatment of cytidine 47a with 
0.55 equiv. of DBH at room temperature in DMF produced 5-bromocytidine 47b after 
only 30 minutes (72% yield, Figure 17; Table 4, entry 10).  
Table 4. Bromination at C5 position of the pyrimidine based nucleosides 45a-f and 57-
59a 
Entry Substrate Product Solvent
Temp.
(oC) 
DBH 
(equiv.)
TMSOTf 
(equiv.) 
Time 
(h) 
Yieldb
(%) 
1 45a 46a CH2Cl2 25 0.55 0.55 6 94c
2 45b 46b CH2Cl2 25 0.55 0.55 10 91c
3 45b 46b CH3CN 25 0.55 0.55 2 98c
4 45c 46c CH2Cl2 25 1.10 - 18 72d
5 45c 46c CH2Cl2 25 0.55 0.55 2.5 90c
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a Bromination was performed on 0.25-2.0 mmol scale. b Isolated yield. c After aqueous 
work-up with purity higher than 97% (1H NMR). d After column chromatography. e After 
crystallization. f Direct crystallization of the crude reaction mixture from MeOH gave 
48b in 46% yield. 
 
 
Analogously, bromination of 4-N-benzoylcytidine 48a proceeded smoothly 
generating 48b (entry 11), which implies that the presence of an electron withdrawing 
group on the cytosine ring (N4-benzoyl) does not affect the efficiency of bromination.  
Protection group compatibility 
I also found that DBH bromination methodology was compatible with common 
protection groups used in nucleoside chemistry. Thus, treatment of 5'-O-(tert-
butyldimethylsilyl)-2',3'-O-isopropylideneuridine 49a with 0.55 equiv. of DBH in 
DMF afforded the corresponding 5-bromo product 49b in quantitative yield (Figure 
17; Table 4, entry 12). It was already shown that base-labile acetyl groups were stable 
during DBH-bromination (e.g., Table 3). Therefore, it can be concluded that acid 
6 45c 46c CH2Cl2 40 0.55 0.55 0.5 93c
7 45d 46d DMF 25 0.55 - 0.33 75e
8 45e 46e DMF 25 0.55 - 1 65d 
9 45f 46f DMF 25 0.55 - 0.75 80d 
10 47a 47b DMF 25 0.55 - 0.5 72d 
11 48a 48b DMF 25 0.55 - 0.5 74d, f 
12 49a 49b DMF 25 0.55 - 0.5 98c 
13 45d 46d MeOH 25 0.55 - 1 70e 
14 47a 47b MeOH 25 0.55 - 1 68d 
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labile as well as base labile protection groups are stable toward DBH-bromination 
protocol.    
 
Figure 17. Selected pyrimidine nucleoside precursors (series a) and their brominated 
products (series b). 
C5-Bromination of unprotected pyrimidine nucleosides with DBH in MeOH 
 Since DMF has to be removed from the crude reaction mixture before purification 
of the brominated products, I used a low-boiling polar solvent such as MeOH as a 
replacement for DMF. To my surprise, treatment of uridine 45d with DBH (0.55 equiv.) 
in MeOH at room temperature for 1 h yielded 5-bromouridine 46d in 70% yield 
(crystallization) (Scheme 4; Table 4, entry 13). Analogously, cytidine 47a was also 
brominated using DBH in MeOH generating 5-bromocytidine 47b (Figure 17; Table 4, 
entry 14) after only 1 h in 68% yield (column chromatography). Therefore, it can be 
concluded that DBH/MeOH system offers a convenient access to the unprotected 5-
bromopyrimidine nucleosides.  
3.1.2 Bromination at C8 position of purine nucleosides with DBH 
 Next, I planned the extension of the DBH and DBH/TMSOTf combination toward 
the synthesis of 8-bromo purine nucleosides. Thus, treatment of adenosine 50a with DBH 
(1.75 equiv.) in DMF at room temperature gave 8-bromoadenosine 50b (48% yield) after 
5 h at ambient temperature (Figure 18, Table 5, entry 1). Analogous treatment of 2'-
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deoxyadenosine 51a with DBH (1.5 equiv.) afforded 8-bromo-2'-deoxyadenosine 51b in 
68% yield in 3.5 h (entry 2). 
 
Figure 18. Selected purine nucleoside precursors (series a) and their brominated products 
(series b). 
The 2',3',5'-tri-O-acetylguanosine 52a was converted to the 8-bromo derivative 
52b upon treatment with 0.55 equiv. of DBH in DMF at room temperature for 2.5 h 
(entry 3). Replacement of DMF with CH3CN decreased the rate of bromination yielding 
52b after 4 h at room temperature (entry 4). On the other hand, treatment of guanosine 
with 0.75 equiv. of DBH in DMF at ambient temperature produced 8-bromoguanosine in 
48% yield after recrystallization from water (entry 5). Use of TMSOTf did not improve 
the yield of 8-bromoguanosine 53b, though less equiv. of DBH was required for 
complete conversion (entry 6). Treatment of inosine or acetyl protected inosine with 
DBH or DBH/TMSOTf in DMF failed to afford 8-bromoinosine, which was in 
accordance with the reported failed bromination attempts of inosine with NBS in 
DMF.123  
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Table 5. Bromination of selected purine nucleosides at ambient temperature (see Figure 
11 for structures)a 
           
 
 
 
 
aBromination was performed on 0.5-1 mmol scale. b Isolated yield. c After column 
chromatography. d Reaction showed formation of the product in approximately 80% yield 
(TLC).  e Isolated yield after aqueous work-up. f Reaction with 0.55 equiv. of DBH was 
completed in 24 h. g After crystallization from water. Bromination was quantitative as 
judged by TLC. i After filtration from reaction. j Reaction showed formation of the 
product in approximately 70% yield (TLC).  
 
In conclusion, DBH and/or DBH/TMSOTf also effected bromination of purine 
nucleosides at the C8-position, although reactions usually required higher equivalency of 
DBH, longer reaction times, and produced the corresponding brominated products in 
lower yields when compared to the pyrimidine analogues.    
C8-Bromination of unprotected purine nucleosides with DBH in MeOH 
Entry Substrate Product Solvent
DBH 
(equiv.)
TMSOTf
(equiv.) 
Time 
(h) 
Yieldb
(%) 
1 50a 50b DMF 1.75 - 5 48c,d
2 51a 51b DMF 1.50 - 3.5 68c,d
3 52a 52b DMF 0.55 - 2.5 83c
4 52a 52b CH3CN 0.55 - 4 98e
5 53a 53b DMF 0.75f - 2.5 51g
6 53a 53b DMF 0.60 0.55 0.5 48g
7 50a 50b MeOH 1.75 - 16 47c, j 
8 51a 51b MeOH 1.50 - 3.5 70j 
9 53a 53b MeOH 0.55 - 1 50g 
10 54a 54b MeOH 0.55 - 0.5 72i 
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Next, I designed the extension of the DBH/MeOH system toward the synthesis 
of 8-bromo purine nucleosides. Thus, treatment of adenosine 50a with DBH (1.75 
equiv.) in MeOH at room temperature gave 8-bromoadenosine 50b (47% yield) after 
16 h at ambient temperature (Figure 18, Table 5, entry 7). Analogous treatment of 2'-
deoxyadenosine 51a with DBH (1.5 equiv.) showed only ~70% conversion to 8-
bromo-2'-deoxyadenosine 51b (entry 8, TLC scale reaction). Interestingly, treatment 
of guanosine 53a with DBH (0.55 equiv.) in MeOH at room temperature yielded 8-
bromoguanosine 53b in 50% yield after recrystallization of the crude reaction mixture 
from water (entry 9). In contrast, treatment of 2'-deoxyguanosine 54a with DBH in 
MeOH at room temperature for 30 minutes led to the solidification of product 54b 
from the reaction. The resultant solid was collected by vacuum filtration and was 
>95% pure on 1H-NMR (entry 10). In conclusion, DBH/MeOH system works very 
efficiently with guanine nucleosides and moderately efficient with adenine 
nucleosides.  
3.1.3. Bromination at C8 position of 7-deazapurine nucleosides with NBS and DBH 
Encouraged by my findings of bromination of purine nucleosides at C8 position 
with DBH, I further explored possibility of bromination of 7-deazapurine antibiotics 
(19b-c) with DBH as well as with NBS (Scheme 5). Previously, 8-bromotoyocamycin 
(55) was prepared either from coupling 8-bromo-7-deazapurine derivative to the ribose 
sugar derivative124 or by treating 19c with Br2/H2O125. I achieved the synthesis of 
compound 55 by two procedures, both proceeding by electrophilic aromatic substitution. 
One involved electrophilic aromatic substitution using N-bromosuccinimide (NBS) in 
anhydrous dimethylformaldehyde (DMF). The second route employed substitution using 
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1,3-dibromo-5,5-dimethylhydantoin (DBH/DBDMH) in MeOH. Thus, treatment of 19c 
with NBS in DMF at ambient temperature for 2.5 h yielded 55 in 45% after column 
chromatography. Reaction took 4 h to complete when DMF was replaced with MeOH to 
give 55 in 64% after recrystallization. However, bromination of 19c using DBH in 
MeOH proceeded efficiently in 30 min by which time product solidified out of solution, 
was collected by vacuum filtration and the mother liquor was recrystallized to give 55 in 
85% overall yield. The DBH/MeOH method was the most efficient of the three for 
synthesizing 55 in terms of yield, reaction time, product isolation. 
 
Scheme 5. Synthesis of 8-bromo-7-deazanucleosides. Reagents and conditions: d) NBS 
(1.1-1.5 eq), DMF, rt, 1-2.5 h; e) DBH (0.75-1.1 eq), MeOH, rt, 30-45 min. 
Over the years, the synthesis of 8-bromosangivamycin 56 has mainly been 
achieved by conversion of 55 to 56 using concentrated ammonium hydroxide and 50% 
hydrogen peroxide solution.124 Owing to the successful preparation of 55, we envisioned 
the synthesis of 56 using NBS/DMF and DBH/MeOH systems. Thus, treatment of 
sangivamycin (19b) with NBS in DMF at ambient temperature for 1.5 h gave 8-
bromosangivamycin (56) in 63% yield after column chromatography. Even though the 
reaction proceeded faster in DBH/MeOH system (30 min) the yield was low (40%), 
which can be attributed to the presence of some unidentified byproducts. Fortunately, 
there is literature precedence for convenient synthesis of 56 from 55.124 Thus, treatment 
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of 55 with NH4OH/50%H2O2 system gave 56 in 86% yield after vacuum filtration from 
the reaction mixture.  In summary, an efficient bromination methodology for the 
synthesis of 8-bromotoyocamycin and 8-bromosangivamycin was developed using 
NBS/DMF and DBH/MeOH systems.  
3.1.4. Plausible mechanism of bromination of nucleobases with DBH 
Bromination of nucleosides using DBH is expected to proceed via aromatic 
electrophilic bromination pathway with bromonium ion (Br+) as the bromine source from 
DBH.  
Plausible mechanism for C-5 bromination of pyrimidines by DBH 
 Carbocation intermediate (type A) is generated upon reaction of pyrimidine base 
57 with DBH (Scheme 6). The intermediate A is highly unlikely to exist in resonance 
with the intermediate B, because of the presence of electropositive carbonyl group 
adjacent to the N1 centered cation. Abstraction of the proton from C5 by the anion C 
regenerates the aromaticity, thus providing the 5-bromopyrimidine product 58.  
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Scheme 6. Plausible mechanism of C-5 bromination of pyrimidine nucleosides by DBH. 
Plausible mechanism for C-8 bromination of purines by DBH 
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 I hypothesize that the N7-C8 double bond of purine 59 abstracts a bromonium ion 
(Br+) from DBH to give nitrogen centered cation A, which is stabilized by three 
resonance structures B-D (Scheme 7). Then aromaticity is regenerated by abstraction of 
proton at C8 position in A', probably by hydantoin intermediate E, to give the 8-
bromopurine product 60.   
 
Scheme 7. Plausible mechanism of C-8 bromination of purine nucleosides by DBH. 
 
Plausible mechanism for TMSOTf activation of DBH:126 
 Upon reaction with TMSOTf (61), DBH generates a silylenol intermediate A 
along with a reactive bromonium triflate (TfOBr) intermediate B. Intermediate B acts as 
the actual bromonium ion (Br+) source for the bromination of the pyrimidine/purine 
substrate 62 to generate the corresponding brominated product 63 along with triflic acid 
(TfOH, C) (Scheme 8). Triflic acid C is reacts with the silylenol intermediate A to give 
another silylenol intermediate D and one more equivalent of TfOBr (E). Second 
equivalent of substrate 62 gets brominated with E to release TfOH (F), which then reacts 
with the silylenol intermediate D to give 5,5-dimethylhydantoin (DMH, G) and TMSOTf.  
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Scheme 8. Plausible mechanism of TMSOTf enhanced DBH bromination. 
3.2. Attempted synthesis of 2'-deoxy-2',2''-difluoropyrimidine nucleosides 
 Because of the ease of preparation of 2'-S-aryl-2'-deoxy-2'-thiouridine (64, Figure 
19) and 2'-deoxy-2'-α-fluorosulfone derivative (65), I explored the possibility of 
introduction of mono and/or difluoro unit into the C2' position using oxidative 
desulfurization-(di)fluorination and reductive desulfonylation-fluorination methods. The 
oxidative fluorination processes were envisioned to proceed via (i) desulfurization-
difluorination of the uridine-2'-thioethers (substrate 64, X = H) or (ii) desulfurization-
fluorination of uridine α-fluorothioethers (substrate 64, X = F) by using halonium ion 
(Br+, I+) reagents as oxidants and a nucleophilic fluorine source (F-) for quenching the 
intermediary C2'-carbocation. Whereas, the reductive fluorination processes were 
proposed to proceed via (i) abstraction of the C2'-proton (from substrate 65, X = H) using 
a base and quenching the intermediary C2'-carbanion with electrophiles such as F+, H+, 
CH3+, etc.; or (ii) cleavage of the sulfonyl moiety (from substrate 65, X = H or F) with 
single electron transfer reagents and quenching the resultant C2'-carbanion with 
electrophiles such as F+, H+, CH3+, etc.  
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Figure 19. General scheme for the proposed C2'-quarternization of 2'-arylthiouridine 
derivatives 
3.2.1. Oxidative desulfurization-fluorination approaches 
The oxidative fluorination approach is modeled on Haufe’s desulfurization-
difluorination of aryl-alkyl thioethers using DBH and Olah’s reagent (Py.9HF) for the 
synthesis of gem-difluoroalkanes (Scheme 9).42,43 
 
Scheme 9. General scheme for Haufe’s desulfurization-difluorination of aryl-alkyl 
thioethers. 
3.2.1.1. Model desulfurization-fluorination studies 
To apply Haufe’s desulfurization-difluorination methodology to nucleoside 
substrates, it is necessary to test the general applicability of the method on model 
compounds first. As the C2'-position, where the thioether functionality is present, is in α-
position to an aminal carbon, substrates with an aminal or electron withdrawing group on 
the α-position should be used in model studies. Another reason for conducting model 
reactions on such substrates which would mimic C2' of ribose unit in the pyrimidine 
nucleoside substrates is because all previous desulfurization-difluorination protocols were 
successful only for the compounds where the sulfenyl/phenylthio group is present on the 
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terminal and primary carbon. Therefore, I developed a desulfurization-difluorination 
protocol of α-thioesters, where in the sulfenyl group is present in the middle of the chain 
on a secondary carbon.  
Initially, open chain aryl-alkyl thioethers (of type 72-75, Scheme 10) with an ester 
group on the α-position (prepared conveniently from commercially available ethyl 2-
bromoalkanoate 71a or 71b) were tested for desulfurization-difluorination protocol. 
Thus, treatment of ethyl 2-(phenylthio)octanoate 72 with DBH (3 eq.) and Olah’s reagent 
(6 eq.) in CH2Cl2 at ambient temperature for 2 h gave ethyl 2,2-difluorooctanoate 77 in 
80% yield after only aqueous workup (Table 6, entry 1). However, analogous treatment 
of 72 with DBH/Py.9HF for 4 h gave 77 in 90% yield after aqueous workup (entry 2). To 
study the effect of temperature, phenylthioether 72 was treated with DBH (3 eq.) and 
Olah’s reagent (6 eq.) in CH2Cl2 at 35 oC and the difluoro product 77 was obtained in 
85% yield after only 1 h (entry 3). But 77 was obtained in 95% yield after stirring the 
reaction for 2 h at 35 oC (entry 4).  
 
Scheme 10. Desulfurization-difluorination of α-thioesters. 
To test the influence of the substituent on the para position of aromatic ring of the 
thioether substrates, 4-chlorophenyl thioether (73-74) and 4-methoxyphenyl thioether 
(75) were selected. Thus, treatment of ethyl 2-((4-chlorophenyl)thio)hexanoate 73 with 
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DBH (3 eq.) and Olah’s reagent (6 eq.) in CH2Cl2 at ambient temperature for 1 h gave 
ethyl 2,2-difluorohexanoate 76 in 80% yield after only aqueous workup (Table 6, entry 
5). However, difluoro ester 76 was obtained in 90% yield when the reaction was stirred 
for 2 h (entry 6). In addition, treatment of 4-chlorophenyl thioether 73 with DBH (3 eq.) 
and Olah’s reagent (6 eq.) in CH2Cl2 at 35 oC generated the difluoro product 76 in 95% 
yield after only 1 h (entry 7). Interestingly, no geminal bromo-fluoro by product was 
observed in crude NMR and GC-MS. When less equivalents of DBH (3 equiv. vs 2 
equiv.) and Olah’s reagent (6 equiv. vs 4 equiv.) were used, decreased yield of the 
difluoro product 76 (80%) was observed (entry 8). Thus, 3 equiv. of DBH and 6 equiv. of 
Olah’s reagent were found to be optimal for the desulfurization-difluorination reactions.  
DBH vs NBS vs NIS  
Treatment of ethyl 2-((4-chlorophenyl)thio)octanoate 74 with N-
bromosuccinimide (NBS; 3 eq.) and Olah’s reagent (6 eq.) in CH2Cl2 at 35 oC  for 2 h 
followed by aqueous workup showed complex 1H-NMR spectrum and the 
difluoroocatnoate 77 was only found to be 25% according to the 19F-NMR of the crude. 
There was no increase in % of difluoro product 77 even after stirring for 4 h at 35 oC 
(entry 9). Analogous treatment of 74 with N-iodosuccinimide (NIS; 3 eq.) and Olah’s 
reagent (6 eq.) in CH2Cl2 at 35 oC for 24 h gave very complex 1H-NMR and 19F-NMR, 
with the difluoroproduct 77 was found to be 5% (entry 10). Thus, DBH was proven to be 
more effective than other halogen oxidants such as NBS or NIS, as observed by Haufe, et 
al.43 
Table 6. Desulfurization-difluorination studies of α-thioester derivatives with 
DBH/Py.9HFa 
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Entry Substrate X Oxidant 
(eq) 
Py.9HF 
(eq) 
Temp. 
(
o
C) 
Time 
(h) 
Yieldb 
1 72 H DBH (3) 6 25 2 80% 
2 72 H DBH (3) 6 25 4 90% 
3 72 H DBH (3) 6 35 1 85% 
4 72 H DBH (3) 6 35 2 95% 
5 73 Cl DBH (3) 6 25 1 85% 
6 73 Cl DBH (3) 6 25 2 90% 
7 73 Cl DBH (3) 6 35 1 95% 
8 73 Cl DBH (2) 4 35 1 80% 
9 74 Cl NBS (3) 6 35 4 25% 
10 74 Cl NIS (3) 6 35 24 5% 
11 75 OCH3 DBH (3) 6 35 16 70% 
a Reactions were typically carried out in 0.5 mmol scale in CH2Cl2 
b Yields were determined based on conversion of substrate to product as determined by 
1H, 13C, 19F NMR and/or GC-MS. 
Continuing with my optimization studies, I then treated ethyl 2-((4-
methoxyphenyl)thio)hexanoate 75 under the established conditions of DBH/Py.9HF 
(3equiv./6equiv.) in CH2Cl2 at 35 oC. However, the reaction was very sluggish in nature 
and gave ethyl 2,2-difluorohexanoate 76 in 70% NMR purity after 16 h of stirring (entry 
11). Thus, it was concluded that 4-chlorophenyl thioethers reacted faster than the 
corresponding phenyl and 4-methoxyphenyl thioethers, as noted by Haufe, et al.43 
The variations in reactivity with change in the para substituent of the aromatic 
group of the thioether can be explained by the plausible mechanism proposed by Haufe, 
et al., for the desulfurization-difluorination reactions.43  
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Scheme 11. Proposed mechanism for the oxidative desulfurization-difluorination of 
alkyl-aryl thioethers by DBH/Py.9HF 
The electron-donating groups (such as OMe) on the phenyl ring are thought to 
stabilize the cationic charge on the resonance stabilized carbenium-sulfonium ion 
intermediate (type C, Scheme 11) and thus promote the first fluorination step; while 
electron-withdrawing substituents (such as Cl) are thought to ease the elimination of 
arylsulfenyl bromide (from type E) in the last step and therefore promote the second 
fluorination step. The proposed mechanism was supported by the observation that 4-
chlorophenyl thioether took half the time than the regular phenyl thioether (Table 6, 
entries 1-4 vs 5-7); whereas 4-methoxyphenyl thioether reaction never went to 
completion under analogous reaction conditions (entry 11).  
Ester vs aldehyde vs ketone vs alkane 
Next, I attempted to extend the desulfurization-difluorination of 2o alkyl-aryl 
thioethers to substrates with other functional groups on the α-position of the thioether 
moiety. Thus, the 2-((4-chlorophenyl)thio)-3-phenylpropanal (78)127 and 2-((4-
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chlorophenyl)thio)-1-phenylpropan-1-one (79),128 which have a carbonyl functional 
group on the α-carbon similar to an ester; and α-thioalkane (80), which does not have a 
carbonyl group on the α-carbon; were prepared from their corresponding α-bromo 
counterparts (Figure 20).  
 
Figure 20. α-Thioaldehyde, α-thioketone and α-thioalkane substrates for attempted 
desulfurization-(di)fluorination reactions. 
However, treatment of α-thioaldehyde 78 with DBH (3 equiv.) and Py.9HF (6 
equiv.) in CH2Cl2 at 35 oC for 1 h, followed by aqueous workup showed complex 1H-
NMR spectrum and no signals in the 19F-NMR. And similar results were obtained when 
α-thioketone 79 and α-thioalkane 80 were treated with DBH/Py.9HF under analogous 
reaction conditions. No fluorination was observed with either of the three substrates even 
after using excess amounts of DBH and Py.9HF, at higher temperatures and for 
prolonged reaction times. Thus it was implied that my protocol for the deseulfurization-
difluorination of secondary/internal thioethers works for compounds with only ester 
functional groups on the α-carbon.  
As a result of functional group similarities between esters and lactones, I then 
tried to extend the application of the desulfurization-defluorination methodology towards 
the synthesis of gem-difluorinated lactone derivatives. Thus, treatment of  2-phenylthio-
5-pentanolide 81129 with DBH (4 equiv.) and Py.9HF (8 equiv.) in CH2Cl2 at 35 oC for 2 
h, followed by aqueous workup gave yellow oil, which showed complex 1H-NMR 
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(Scheme 12). The 19F-NMR of the crude material showed triplets in the range of -100 
ppm (J = 15.8 Hz), in agreement with the literature 19F-NMR peaks for gem-
difluorolactones,130 thus indicating the presence of the gem-difluorinated product 82. 
Increase in duration of the reaction gave even more complex 19F-NMR spectrum. 
Therefore, considering the volatile and unstable nature of the difluorolactones, I chose to 
pursue less volatile 2,3-dideoxy-2-thioribonolactone precursors of type 83.  
 
Scheme 12. Attempted synthesis of α,α-difluoro-δ-valerolactone 82. 
Thus, treatment of (S)-(+)-2-phenylthio-4-benzyloxymethyl-4-butanolide 83131 
with DBH (4 equiv.) and Py.9HF (8 equiv.) in CH2Cl2 at 35 oC for 16 h, followed by 
aqueous workup showed complex TLC and multiple products on 1H-NMR (Scheme 13). 
The 19F-NMR of the crude material showed multiplets in the region of -140 ppm and -
150 ppm. And HRMS showed m/z corresponding to α-fluorosulfide 84 and α-
fluorosulfoxide 85. This indicates that monofluorination occurred, albeit in very low 
yield.  
 
Scheme 13. Attempted synthesis of α,α-difluoro-γ-butyrolactone 86. 
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3.2.1.2. Oxidative desulfurization-fluorination approaches with uridine derivatives 
Although my attempts in oxidative desulfurization-difluorination of 2,3-dideoxy-
2-(phenylthio)-2-S-ribonolactone precursor (83) were partially encouraging, I next 
attempted analogous fluorination on 2'-S-aryl-2'-thiouridine analogues 89/90 and 2'-S-
aryl-2'-deoxy-2'-fluoro-2'-thiouridine analogue 93, since the substrates were readily 
available for us (Scheme 14). The precursors 2'-S-(4-chlorophenyl)-2'-thiouridine 87 and 
2'-S-(4-methoxyphenyl)-2'-thiouridine 88 were synthesized in three steps from uridine 
following the well-established procedure of preparing 2,2'-anhydroarabinouridine132 from 
uridine followed by ring opening with thiolates.133,134 The precursor 2'-S-(4-
chlorophenyl)-2'-thiouridine 87 was prepared by a slight modification of the published 
procedure.121 The 4-chlorothiphenol reagent was stirred with PPh3 in DMF for 30 min at 
room temperature before refluxing with 2,2'-anhydroarabinouridine, to reduce all the 
possible disulfide to the free thiol. Subsequent protections of 3',5'-hydroxyl groups and/or 
N3 with either acetyl or benzyl protection groups gave the desired 2'-S-aryl-2'-thiouridine 
precursors 89/90 . The second class of substrates required for desulfurization-fluorination 
reactions is α-fluoro thioether derivatives 93, which can be synthesized from thioether 90 
by oxidation to the corresponding sulfoxides and subsequent fluorination of sulfoxides 
92135,136 with DAST/SbCl3, as reported.134 In addition, sulfone precursors for reductive 
desulfonylation-fluorination reactions were also readily prepared, following literature 
protocols.134 Thus, oxidation of the 2'-S-aryl-2'-thiouridine precursors 89/90 with meta-
chloroperoxybenzoic acid (mCPBA) at ambient temperature gave the corresponding 2'-
deoxy-2'-arylsulfonyluridine derivatives 91/92. Analogously, 2'-deoxy-2'-fluoro-2'-(4-
methoxyphenyl)sulfonyluridine derivative 95 was obtained by treatment of 2'-deoxy-2'-
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fluoro-2'-(4-methoxyphenyl)sulfonyluridine derivative 94 with mCPBA at ambient 
temperature.  
 
Scheme 14. Synthesis of 2'-arylthio substrates for the desulfurization-fluorination 
reactions. 
Treatment of 3',5'-di-O-acetyl-2'-S-(4-chlorophenyl)-2'-thiouridine 89a with 
DBH/Py.9HF at -78 oC, under Argon atmosphere for 2 h showed three new spots on TLC 
(Scheme 15). Aqueous workup followed by column chromatography yielded three 
different products in 41%, 18% and 30% respectively. The first product was established 
to be 5-bromo-3',5'-di-O-acetyl-2'-S-(4-chlorophenyl)-2'-thiouridine (96a, 41%). 
Signature peak (d or dd) for H5 at 5.67 ppm in 1H-NMR was missing and the 
corresponding doublet for H6 (7.17 ppm) was collapsed to a singlet (6.98 ppm), implying 
a C5-brominated product, which probably was caused by DBH. The remaining two 
products were C5-brominated sulfoxide diastereoisomers [97 (R/S-S)]. Doublet of 
doublets for H2' was found at 3.92 ppm for the faster moving sulfoxide and at 3.72 for 
45 
 
the slower moving isomer. In comparison, peak for H2' for the C5-brominated product 96 
was at 3.47 ppm, and for the substrate 89a was at 3.78 ppm. 
Fluorination attempts of 89a employing Py.9HF/NBS also gave the corresponding 
5-brominated derivative 96a as major product (conditions not shown in scheme), while 
no desired fluorination was observed (19F-NMR; data not shown). Based on these 
findings, a novel and efficient protocol for C5-bromination of pyrimidine nucleosides and 
C8-bromination of purine nucleosides with DBH and/or Lewis acids has been 
developed.137 Analogous treatment of 89a with the recently developed NIS/DAST 
system138,139 at rt as well as at 35 oC gave the corresponding 5-iodinated analogue 96b in 
73% and 60% isolated yields respectively, with no indication of the fluorinated products. 
 
Scheme 15. Oxidative desulfurization-difluorination of 2'-S-aryl-2'-thiouridine analogue 
89a. Conditions A: DBH (1.1 eq), Py.9HF (excess), CH2Cl2, -78 oC, 2 h; Conditions B: 
NIS (3 eq), DAST (6 eq), CH2Cl2, 0 oC (6 h), then rt (32 h); Conditions C: NIS (3 eq), 
DAST (6 eq), CH2Cl2, 35 oC, 24 h.  
Treatment of 89a with DBH (3 eq.)/Py.9HF (6 eq.)/CH2Cl2/35 oC/24 h gave a 
complex reaction mixture showing formation of the 5-bromo-2'-α-fluorosulfoxide 99a 
(<10% according to 1H, 19F NMR of the crude; data not shown; Figure 21). Changing the 
acetyl protection group for a benzyl group did not improve the outcome of the reaction. 
Treatment of the fully benzylated 89b with DBH (5 eq.)/Py.9HF (10 eq.)/CH2Cl2/35 
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oC/overnight gave a complex mixture indicating the formation of 5-bromo-2'-α-
fluorosulfide 98 or 5-bromo-2'-α-fluorosulfoxide 99b (1H, 19F-NMR of the crude). 
 
Figure 21.  Products for attempted fluorination of 2'-S-(4-chlorophenyl)-2'-thiouridine 
derivatives 89a and 89b 
Similarly, treatment of fully benzylated 2'-S-(4-methoxyphenyl)-2'-thiouridine 
90b with NIS (2.1 eq.)/Py.9HF (3 eq.) gave the corresponding 5-iodocounterpart (100, 
29%) and the α-fluorothioether (94b, 12%) (Scheme 16). Analogous treatment of 90b 
with the recently developed NIS/DAST system138,139 yielded the α-fluorothioether 94b in 
44% isolated yield when 2.1 equiv. of NIS and 6 equiv. of DAST were used. 
Interestingly, the 5-iodo derivative 100 was not observed with NIS/DAST system. 
However, both the reactions failed to generate the desired geminal difluoro uridine 
product. On the other hand, treatment of 90b with DBH (3 eq.)/Py.9HF (6 eq.)/35 oC 
generated a complex reaction mixture Thus, it is noteworthy to conclude that NIS/DAST 
system provided clean conversion of sulfide 90b to the mono-fluorinated analogue 94b in 
respectable yield. 
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Scheme 16. Attempted oxidative desulfurization-fluorination of 2'-S-(4-methoxyphenyl)-
2'-thiouridine analogue 90b. Conditions A: NIS (2.1 eq), Py.9HF (3 eq); Conditions B: 
NIS (2.1 eq), DAST (6 eq). 
Next, the α-fluorothioether 94b, was also directly explored as substrate for the 
second fluorination step leading to the expected gem-difluorouridine derivative. 
Unfortunately, treatment of 94b with DBH/Py.9HF at -78 oC gave the corresponding 5-
brominated derivative as major product (101, 50%), with no indication of the geminal 
difluoro product (Scheme 17). The introduction of the desired second fluorine atom was 
unsuccessful even when excess reagents, higher temperatures, and longer reaction times 
were employed. 
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Scheme 17. Attempted oxidative desulfurization-fluorination of 2'-fluoro-2'-S-(4-
methoxyphenyl)-2'-thiouridine analogue 94b with DBH/Py.9HF. 
 
3.2.2. Reductive desulfonylation-fluorination approaches 
Since the oxidative desulfurization-difluorination approaches on 2'-arylthiouridine 
derivatives were overshadowed by the formation of 5-halogenated byproducts and were 
not very promising for the introduction of the geminal difluoro unit, I turned my attention 
to reductive fluorination approaches of 2'-arylsulfonyluridine substrates. Reductive 
desulfonylation-(di)fluorination protocols are to the best of my knowledge, unknown 
processes, while chemical and electrochemical-induced reductive desulfonylation 
reactions have been known for years.140-150 Chemical and electrochemical redox 
48 
 
strategies have rarely been reported in nucleoside series, except some reductive 
dehalogenation or desulfonylation protocols en route to 2',3'-dideoxy-2',3'-didehydro 
nucleosides with anti-HIV and anti-HBV properties.151-160 
This part of the dissertation was completed in collaboration with Dr. Maurice 
Medebielle of Université Claude Bernard Lyon 1, France; Dr. Gamal Giuglio and Dr. 
Julie Broggi of Aix-Marseille Université, France. 
3.2.2.1. Cyclic voltammetry studies of 2'-arylsulfonyl uridine derivatives 
Initially, our collaborators performed cyclic voltammetry studies with various 2'-
deoxy-2'-S-(arylsulfonyl)-2'-thiouridine and 2'-deoxy-2'-fluoro-2'-S-(arylsulfonyl)-2'-
thiouridine substrates to find out the reduction potential at which the sulfone moiety 
could be cleaved. Sulfone derivatives 92a and 92b (see Scheme 14 for structures), were 
found to be reduced in two irreversible reduction steps in DMF containing 0.1 M n-
Bu4NPF6 on a glassy carbon electrode, at almost identical reduction potentials [- 2.73 V 
and - 2.95 V for 92a; - 2.73 V and - 2.92 V for 92b (peak potentials at 0.2 V/s, Figure 
22). For both substrates, the first irreversible reduction step (Epc1) corresponded to the 
cleavage of the C2'-S bond with the expulsion of the p-methoxybenzenesulfinate,161 that 
can be irreversibly oxidized at + 0.02 V (Epa2). The irreversibility of the first reduction 
step (Epc1) is an indication that the first electron transfer is followed by a chemical 
reaction producing a new product that is in turn reduced at a more negative potential 
corresponding to the second reduction step (Epc2). Additional irreversible oxidation steps, 
only observed after scanning first to reduction potentials and then switching to anodic 
values, located at + 0.57 and + 0.81 V (92a, Epa3 and Epa4) and + 0.51 V (92b, Epa3) (peak 
potentials at 0.2 V/s) were also noticed.  
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Figure 23. Cyclic voltammetry of α-fluorosulfones 95a (2.64 mM) and 95b (2.91 mM) 
in DMF + NBu4PF6 0. 1 M; glassy carbon electrode. 
The data obtained by cyclic voltammetry in DMF indicated that the cleavage of 
the C2'-S bond, although possible will require (i) quite negative potential under 
electrochemical activation and (ii) strong chemical reducing agents. Also glycosidic bond 
cleavage may operate as well at such negative potentials as it is apparently the case for 
substrates 92a-b. However, from cyclic voltammetry data, it is not obvious to conclude 
what the possible reduction products resulting after the expulsion of the p-
methoxybenzenesulfinate are, at least on the time scale of the cyclic voltammetry. 
Tentative isolation and characterization of the reductive products, either with the use of 
chemical reducing agents or using electrochemical activation, was therefore necessary. 
For 95a (--) E
pc1
 = - 2.66 V; E
pa1
 = + 0.025 V 
For 95b (--) E
pc1
 = - 2.67 V; E
pa1
 = + 0.025 V 
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3.2.2.2. Reductive desulfonylation-fluorination studies of 2'-deoxy-2'-arylsulfonyl 
uridine and 2'-deoxy-2'-fluoro-2'-arylsulfonyl uridine substrates 
During preparation of sulfone substrates for the reductive fluorination approaches, 
I observed an interesting result. Purification of 3',5'-di-O-acetyl-2'-deoxy-2'-[(4-
chlorophenyl)sulfonyl]uridine (91a) on silica gel column resulted in the overall 
elimination of acetic acid to generate 2',3'-didehydro-2',3'-dideoxysulfone 102 as a major 
product, which has same Rf value as starting material and thus inseparable (1.5:1 ratio of 
102:91a; 1H-NMR) (Scheme 18). Structure of the product was confirmed by 1H-NMR 
(doublet at 7.01 ppm with coupling constant of 1.9 Hz for H3') and also by comparing 
spectral data with similar 2'-phenylselenonyl derivatives prepared by Chattopadhyaya, et 
al.162 Generation of the elimination product 102 was indicative of the increased acidity of 
C2'-H in C2'-sulfones 91a.  
 
Scheme 18. Stability studies of sulfones 91a-b on silica gel chromatography or with 
treatment of base. 
To avoid elimination of the acetate group from C3', a stable benzyl protection 
group was employed (pKa of AcOH = 5 vs pKa of BnOH = 15). As expected, N3-benzyl-
3',5'-di-O-benzyl-2'-deoxy-2'-[(4-chlorophenyl)sulfonyl]uridine (91b) with benzyl 
protecting group (poor leaving group) installed on 3',5' and N3 positions was stable 
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during silica gel column purification. Since the C2'-H in C2'-sulfones 91a-b is quite 
acidic, I envisioned abstraction of C2'-proton with base followed by entrapment of the 
resultant of C2'-carbanion with fluoronium ion (F+) source. However, treatment of 
sulfone 91b with KH and Selectfluor in THF/DMF (-78 oC) led to the elimination of 3-N-
benzyluracil 103 (63%) via the glycosidic bond cleavage (Scheme 18). I also isolated 3,5-
di-O-benzyl-1,2-dideoxy-1,2-didehydro-2-[(4-chlorophenyl)sulfonyl]ribose (104; 71%) 
from the reaction mixture, whose structure was established using spectroscopic data. The 
singlet from the olefinic proton H1 at 7.4 ppm was diagnostic for the vinyl sulfone sugar 
104. It was also found that treatment of sulfone 91b with base only, without Selectfluor, 
also affected glycosidic bond cleavage to give 103 and 104, consistent with 
base/Selectfluor system. 
Since the base/F+ system proved to be too harsh for the sulfone substrates, I 
imagined an alternative reduction pathway implying the selective cleavage of the sulfone 
moiety using organic electron donors. Organic electron donors (OED) are powerful 
reducing agents able to selectively cleave C-X (e.g., X = halogen) bonds by stepwise 
transfer of one or two electron(s) under mild reaction conditions.163-170 Previous literature 
studies report the efficient reduction of aryl iodides and bromides to aryl anions, as well 
as the reductive cleavage of phenylalkylsulfones in excellent yields.171 With redox 
potentials spanning from - 0.62 V to - 1.24 V vs SCE in DMF (~ - 0.93 V to - 1.55 V vs 
Ag/Ag+ 0.01 M) (Figure 24), OED could allow us to reductively cleave the aryl-alkyl 
sulfone in the 2'-sulfone precursors 92a-b and 2'-α-fluorosulfone precursors 95a-b.172 
Indeed, in view of the high reduction potential of the arylsulfone moiety compared to 
OED, transferring one electron would theoretically appear difficult. Nevertheless, as 
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pointed out by Murphy et al.,38 effective redox potentials of organic reducers in solution 
are much higher than their thermodynamic redox potential determined by electrochemical 
methods. It is explained by the formation of intimate charge-transfer complexes and ion 
pairing that eases the electron transfer. Additional π-π stacking between the SED and 
nucleoside may help to form intimate complex and facilitate the reduction. Hopefully, the 
generated carbanion intermediate could then be used in electrophile trapping reactions. 
 
Figure 24. Structures of organic electron donors used for the reductive desulfonylation. 
Thus, treatment of sulfone 92a was treated with tetrakis(dimethylamino)ethylene 
(TDAE)  in DMF (-78 oC to rt) for 1.25 h followed by aqueous workup and silica gel 
column chromatography gave furan derivative 105, the enol type (open chain sugar) 
product 106, and the 3'-acetoxy elimination product 107 as major products (Scheme 19). 
The anticipated reduction of sulfone moiety was never observed, indicating that the 
TDAE initially acted as a base and then probably as a reducing agent. It is noteworthy to 
mention that when 92a was treated with 4-dimethylamino pyridine (DMAP) in DMF at 
room temperature, almost quantitative formation of 105 was produced, a result 
supporting the basic pathway (not shown in scheme; data not given).  
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Analogous treatment of 92a with one equivalent of the more powerful Murphy’s 
Super Electron Donor (N,N,N',N'-Tetramethyl-7,8-dihydro-6H-dipyrido[1,2-a;2',1'-
c][1,4]diazepine-2,12-diamine; SED)171 in DMF at ambient temperature for 15 min 
yielded furan derivative 105 (95%). The nucleoside base uracil 105a was also identified 
(but not isolated) by 1H-NMR in the aqueous phase along with other impurities. 
 
Scheme 19. Reduction studies of acetyl protected sulfone substrates 91a with TDAE and 
Murphy’s SED. 
Since the acetyl protection group in 92a is base labile and is prone to elimination 
from the intermediate C2'-carbanion, I decided to use benzylated sulfone substrates. 
However, treatment of N3-benzyl-3',5'-di-O-benzyl-2'-deoxy-2'-[(4-
chlorophenyl)sulfonyl]uridine (92b) with Murphy’s reagent in DMF for 15 min at 
ambient temperature resulted in a similar, rapid glycosidic bond cleavage producing 3-N-
benzyluracil 103 (69%) and 3,5-di-O-benzyl-1,2-dideoxy-1,2-didehydro-2-[(4-
methoxyphenyl)sulfonyl]ribose (108; 70%) respectively (Scheme 20). This result is in 
accordance with the result obtained when 92b was treated with base (Scheme 18) and 
indicated that SED (in stoichiometric amount) was probably acting exclusively as base 
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and not as reducing agent. Also, analogous treatment of 92b with SED for 30 min at 
room temperature generated uracil derivative 103 (in 86%), furan derivative 109 as a 
mixture with vinyl sulfone 108.  
 
Scheme 20. Reduction studies of benzyl protected sulfone substrate 91b with Murphy’s 
SED. 
Since the 2'-sulfone substrates were too labile under the desired reaction 
conditions, the corresponding α-fluorosulfone substrates (95a-b, see Scheme 14 for 
structures) were chosen for the further reductive-desulfonylation reactions. Initially, 
stability of the acetyl protected 2'-(4-methoxyphenylsulfonyl)-2'-deoxy-2'-fluorouridine 
95a towards tetrakis(dimethylamino)ethylene (TDAE) was evaluated. Thus, treatment of 
95a (2'R/S, ~1:4.5) with 2 equiv. or 4 equiv. of TDAE in DMF at -20 °C for 1 h or at 
room temperature for 3 h resulted in recovery of unchanged starting material 95a along 
with 3'-deacetylated byproduct. Longer reaction time (12 h) and higher temperature (60 
oC) produced only a mixture of mono- and di-deacetylated byproducts but no further 
degradation or glycosidic bond cleavage were observed. Replacement of DMF with 
MeCN gave similar results. Addition of TDAE at 0 oC or above did not cause the 
reduction of the sulfonyl moiety, indicating that TDAE should be added at low 
temperatures. Also, replacement of TDAE with other reducing agents such as samarium 
iodide did not affect the reduction of sulfonyl unit. 
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On the other hand, treatment of α-fluorosulfone derivative 95a with 1 equiv. of 
Murphy’s Super Electron Donor (SED) in DMF at rt or 120 oC, overnight gave the 3'-
deacetylated product (110) along with unchanged SM (Scheme 21). Similar results were 
obtained with increased equiv. of SED (3 eq.) at rt. However, previously known 
fluorovinyl compound 111173 was obtained in 46% yield when 95a was treated with 3 eq. 
of SED (DMF, 120 oC, overnight) after acidic workup (10% HCl). The structure of 111 
was established by 19F-NMR (δ -133.8 ppm, t, J = 4.6 Hz) and LC-MS [ESI+ m/z 271 
(MH)+]. This result indicated that reductive cleavage of sulfone took place with excess 
SED at high temperature. Noticeably, when 95a was treated with 4-dimethylamino 
pyridine (DMAP) in DMF at room temperature, was recovered intact indicating that 
base-induced pathway is not operating with such α-fluorosulfone.  
 
Scheme 21. Stability studies of acetyl protected α-fluorosulfone 95a with Murphy’s SED. 
 To avoid the base-promoted elimination of the 3'-acetyl protection group, benzyl 
protected α-fluorosulfone derivative 95b was employed to study the reduction of sulfone 
with SED. However, treatment of N3-benzyl,3',5'-di-O-benzyl protected sulfone 95b 
under analogous reaction conditions (3 eq. SED, DMF, 120 oC, 3 h) produced a complex 
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reaction mixture (Scheme 22). Careful silica gel column chromatography allowed for 
separation of two major products, which are found to be glycosidic bond cleavage 
products furan 112 and 3-N-benzyluracil 103. Trace amounts of sulfone cleavage product 
113 was also isolated from the column. Intriguingly, in the furan derivative 112 sulfone 
moiety was intact and elimination of fluorine was observed. Formation of 112 could have 
been happened from either the reduction of glycosidic bond followed by base induced 
fluoride elimination or vice versa.  
 
Scheme 22. Stability studies of benzyl protected α-fluorosulfones 95b with Murphy’s 
SED 
 Analogous treatment of 95b with 3 equiv. of SED in DMF at room temperature 
gave only trace amounts of 112 and 103 along with unchanged SM. Addition of degazed 
water at 80°C to the crude, in order to favour the reduction product 113 (to enhance H-
abstraction), did not change the outcome of the reaction. The elimination product 112 and 
3-N-benzyluracil 103 were obtained in 80% and 60% isolated yields respectively.  
Next, in order to prepare gem-difluorouridine analogues, I attempted to insert a 
second fluorine atom at C2'-position of 2'-arylsulfonyl-2'-deoxy-2'-fluorouridine 
derivative 95a using reductive-desulfonylation/fluorination approach. If successful this 
method could be expanded toward the synthesis of other 2'-alkyl-2'-deoxy-2'-fluoro 
uridine nucleosides. Especially an intriguing target in that class of nucleosides would be 
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2'-C-methyl-2'-deoxy-2'-fluorouridine because of the potent anti-HCV activity possessed 
by the corresponding cytidine analogue (PSI 6130).5  
 
Scheme 23. Attempted synthesis of 2'-2''-difluorouridine by reductive desulfonylation-
fluorination of 2'-arylsulfonyl-2'-deoxy-2'-fluorouridine 95a with TDAE/Selectrfluor 
Since 95a was barely reactive towards TDAE at low temperatures with no 
indication of the generation of putative C2' anion, I tried a combination of TDAE and UV 
light activation to enhance the electron transfer. Thus, treatment of 95a with 5 equiv. of 
TDAE at -60 °C and Selectfluor under uv light irradiation produced a mixture of 2',3'-
dideoxy-2',3'-didehydro-2'-fluorouridine 111 and 1-(2-deoxy-2-fluoro-β,D-
arabinofuranosyl)uracil 114 in addition to the acetyl deprotected byproducts (Scheme 
23). Interestingly, no significant by-products resulting from the glycoside bond cleavage 
was observed. It is noteworthy that when the TDAE was added at 0 °C or room 
temperature, neither 111 nor 114 were formed, which means the TDAE did not act as a 
reductant when added at higher remperatures. Furthermore, no formation of the target 2'-
deoxy-2',2'-difluorouridine derivative was observed, while the reduction of the employed 
electrophilic fluorine reagents was detected. 
59 
 
 
Scheme 24. Reductive-desulfonylation/methylation of 2'-arylsulfonyl-2'-deoxy-2'-
fluorouridine 95a with TDAE/MeI 
Since fluoronium ion (F+) is the most difficult cation to work with, I chose to test 
our hypothesis using CH3+. However, treatment of 95a with TDAE/MeI under analogous 
reaction conditions yielded acetyl deprotected, N3-methylated analogue 115 as the major 
product (Scheme 24).  
3.3. One electron oxidation of gemcitabine and analogues 
Our laboratory has a long history of studying the mechanism of ribonucleotide 
reductase (RNR) enzyme via chemical modeling studies.174,175 In collaboration with Prof. 
Stubbe of MIT, we have also been involved in studying mechanism-based inhibitors of 
RNR by 2'-azido-2'-deoxynucleostides176,177 and probing the mechanism of RNR 
catalyzed reaction with labeled natural substrates.178 Recently, in collaboration with Dr. 
Sevilla’s group from Oakland University, we began investigating the generation of 
radicals upon 1e- oxidation of various nucleoside substrates.179  
Building on this interest, I wanted to explore the possibility of formation of sugar-
based radicals in the one-electron (1e-) oxidation of 2'-fluorocytidine analogues such as 
2'-fluoro-2'-deoxycytidine (FdC, 38), 2'-deoxy-2',2''-difluorocytidine (dFdC, gemcitabine, 
1), and 2'-deoxy-2'-fluoro-2'-C-methylcytidine (MeFdC, PSI 6130, 39) (Figure 25). Each 
of the three substrates has different stereo and electronic properties which should interact 
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with the resultant radical differently. Comparing to 2'-fluoro-2'-deoxycytidine, 
gemcitabine has an extra fluorine atom, which causes H3' to be more acidic because of its 
negative inductive effect (-I). Thus I was also hoping that we might capture and analyze 
the elusive C3' radical, postulated by Stubbe, et al.31 as a critical intermediate in the 
reduction of RNA monomer to DNA monomer. The presence of a positive inductive 
effect (+I) causing methyl group makes PSI 6130 a versatile candidate and it would be 
interesting to study the influence of different substituents at 2'-position (H vs F vs CH3) 
on radical generation. Electron spin resonance (ESR) spectroscopy was employed to 
study the results generated during 1e- oxidation of the selected substrates. 
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Figure 25. Selected substrates for 1e- oxidation studies  
3.3.1. Detection of C2' and C3' sugar radicals 
The ESR spectrum after γ-irradiation of 2'-deoxy-2'-fluorouridine 38 (7.5 M 
LiCl/D2O sample of 2'-dC (2 mg/ml) at pH ca. 10) showed a central anisotropic doublet 
(ca. 16 G) assigned to α proton at C5 in the 2'-F-dC pi-cation radical (C•+) 116 and is in 
keeping with the coupling reported for the C5-H alpha proton coupling in the dC cation 
radical in single crystals (Scheme 25).180 
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Scheme 25. One elctron oxidation of 2'-deoxy-2'-fluorocytidine 
One-electron oxidation of gemcitabine 1 results in the formation of metastable pi-
cation radical 1a, which is unstable even at ca. 155 K (Scheme 26). The metastable C•+ 
1a quickly deprotonates at C3' in the sugar moiety producing C3'• 117 via a proton-
coupled electron-transfer (PCET) mechanism. The presence of 2nd fluorine atom at 2' 
position may have increased the acidity of C3'H. Since the presence of one additional 
fluorine led to such a drastic behavior, I was very interested to study one electron 
oxidation of 2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130; 39), which is very active 
against HCV.181 PSI 6130 has a methyl group (+I) instead of a fluorine atom (-I). 
 
Scheme 26. One electron oxidation of gemcitabine 
The anti-HCV analogue PSI-6130 (39) also generated C3'-radical 39a via pi-
cation radical 118, upon γ-irradiation. But C3'-radical in PSI-6130 was unstable and 
immediately converted to C2'-radical 119 via loss of hydrogen fluoride (Scheme 27). All 
the results were in accordance with theoretical model studies and ESR spectroscopy.182 
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This is the first non-enzymatic example of C3'-radical studies on gemcitabine and PSI-
6130 and support the mechanism of inhibition of ribonucleotide reductase by these 
compounds.  
 
Scheme 27. One electron oxidation of PSI-6130 
3.4. Synthesis and biological activity of 6-N-benzyl-7-deazapurine nucleoside 
derivatives 
3.4.1. Synthesis of 6-N-benzyl-7-deazapurine nucleosides 
I wanted to prepare 6-N-benzylated 7-deazaadenosine analogues (122a-d) using 
the Dimroth rearrangement, which is widely studied on various adenine nucleosides and 
other heterocycles.115,183 Initial alkylation takes place at N1 when adenine nucleosides are 
treated with alkyl/aryl halides to form an N6-centered cationic intermediate (120a; 
Scheme 28). Treatment of the N1-alkylated intermediate 120a with base leads to ring-
opening, C-C bond rotation, and subsequent ring-closing to give the N6-alkylated 
adenosine product 121. Interesting thing to note in the Dimroth rearrangement sequence 
is that N1 of substrate becomes N6 in the product, which was established based on 
isotope labeling studies.184,185  
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Scheme 28. General mechanism of Dimroth rearrangement on Adenosine184,185 
Thus, treatment of tubercidin (19a) with benzyl bromide in DMF (48 h at 40 oC) 
showed a baseline spot on TLC, which suggests ionic intermediate(s) (Scheme 29). 
Evaporation of solvent; treatment of crude with acetone and ether; and vacuum filtration 
gave a hygroscopic white precipitate. The ionic intermediate was immediately dissolved 
in methanol and refluxed with dimethylamine (2 M solution in THF) (20 h at 65 oC). 
TLC showed conversion of majority of the base line spot to a less polar product. Aqueous 
workup followed by column chromatography gave 4-N-benzyltubericin 122a (67%). 
Structure of the product was established by NMR and HRMS. For comparison, I 
synthesized the previously known 6-N-benzyladenosine (121)115 from adenosine (120) by 
following same reaction conditions (BnBr/DMF-Me2NH/MeOH). I noticed that the TLC 
during the course of both the reactions was very similar. Therefore it is reasonable to 
assume that initial alkylation occurred at N3 (same as ring nitrogen N1 in adenosine) in 
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tubercidin, and treatment of the 3-N-benzyl intermediate with Me2NH/THF in MeOH 
resulted in Dimroth-type rearrangement to give 4-N-benzyltubercidin (122a).  
 
Scheme 29. Synthesis of 4-N-benzylated tubercidin and sangivamycin by Dimroth 
rearrangement approach. 
It is well-established that the 6-N-(4-nitrobenzyl) derivatives of adenosine and 
other adenine nucleosides act as potent nucleoside transport inhibitors.119 To evaluate the 
nucleoside transport inhibition properties in a related system, I endeavored to synthesize 
4-N-(4-nitrobenzyl) derivatives of the 7-deaza antibiotics. Thus, following the protocol 
for the synthesis of 122a, reaction of tubercidin 19a with 4-nitrobenzyl bromide (24 h at 
80 oC) followed by treatment of the corresponding N-3 alkylated cationic intermediate 
with Me2NH/MeOH produced 4-N-(4-nitrobenzyl)tubercidin (122b, 56%, Scheme 29). 
An analogous base line spot was observed when sangivamycin (19b) was treated with 4-
nitrobenzyl bromide (48 h at 40 oC). Isolation of this ionic intermediate immediately 
followed by treatment with Me2NH/MeOH yielded 4-N-(4-nitrobenzyl)sangivamycin 
(122c, 45%). Structures of products 122b-c were established by NMR and elemental 
analysis. 
Since tubercidin and sangivamycin underwent Dimroth-type rearrangement when 
treated with BnBr followed by Me2NH, I envisioned the synthesis of 4-N-(4-
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nitrobenzyl)toyocamycin (122d) via similar synthetic pathway. However, upon treatment 
of toyocamycin (19c) with 4-nitrobenzyl bromide (63 h at 40 oC), a major less polar spot 
than substrate was observed on TLC, as opposed to a more polar spot in case of 
tubercidin and sangivamycin (Scheme 30). Isolation of the new spot by column 
chromatography and careful spectroscopic evaluation showed the compound as 4-N-(4-
nitrobenzyl)toyocamycin (122d; 46%). Since there was no N3-benzylated cationic 
intermediate, there was no need for Me2NH/MeOH treatment. Therefore, a direct 
alkylation of the exocyclic amine (N4) of toyocamycin was proposed for the formation of 
122d.  
 
Scheme 30. Synthesis of 4-N-(4-nitrobenzyl)toyocamycin by direct alkylation. 
The direct alkylation of the exocyclic amino group of toyocamycin has not been 
previously noted. However, direct alkylation on the exocyclic amino group of adenine 
and guanine with quinone methides is known.186 The exocyclic amine nitrogen N4 may 
have become more nucleophilic than the endocylcic nitrogen N3, as a result of the 
electron withdrawing pull of the cyano group at C5. Another possibility could be that the 
cylindrical cyano group might exist in synperiplanar orientation with the exocyclic amine 
group, thereby diminishing the lone-pair donation on N4 toward N3 of the amidine, 
which is part of the planar hetrocyclic system.187  
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Alternatively, the preparation of 6-N-(4-nitrobenzyl)tubercidin derivative (122b) 
was envisioned based on synthesis of 6-fluorotubercidin analogue by diazotization-
fluorodediazoniation120,188,189 followed by SNAr displacement of 6-fluoro group with 4-
nitrobenzylamine.120,190 Thus, using standard protocol, tubercidin (19a) was treated with 
acetic anhydride in pyridine to give 2',3',5'-tri-O-acetyltubercidin (123, 86%; Scheme 31). 
The acetylated tubercidin (123) was then treated with sodium nitrite (NaNO2) in freshly 
prepared ~55% HF-pyridine at -10 oC191,192 for 15 min to yield the protected 4-
fluorotubercidin 124 (82%), probably via diazotive-fluorodeamination. The mechanism 
of this reaction is expected to be similar to ‘Balz-Schiemann’ type reaction for the 
preparation of arylfluorides from arylamines using NaNO2 and 70% HF-pyridine.191 
NaNO2 in the presence of acid (H+) generates nitrosonium ion (NO+) in situ and aryl-NH2 
attacks the resultant NO+ to form diazonium ion 123a subsequently. Loss of N2 followed 
by quenching of intermediate arylcation 123b with fluoride ion (F-) gives the product 
arylfluoride 124. I observed that the concentration of HF was crucial in the preparation of 
124. When commercial 70% HF-pyridine reagent was used, the reaction did not yield the 
corresponding 4-fluoro product 124. This observation indicated that pH of the reaction, 
which in turn depends on the percent of HF used, was critical for such diazotive-
fluorodeamination reactions.192  
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Scheme 31. Synthesis of 2',3',5'-tri-O-acetyl-4-fluorotubercidin (124) by diazotive-
fluorodeamination. 
Treatment of 4-fluorotubercidin derivative 124 with 4-nitrobenzylamine 
hydrochloride  in presence of trimethylamine (Et3N) in MeOH gave 2',3',5'-tri-O-acetyl-
4-N-(4-nitrobenzyl)tubercidin (125, 47%; Scheme 32). Trimethylamine converts 4-
nitrobenzylamine hydrochloride to 4-nitrobenzylamine in situ, and the free amine 
subsequently displaces the fluoride ion, probably, by aromatic nucleophilic substitution 
(SNAr).120 Acetyl deprotection of compound 125 using methanolic amonia (NH3/MeOH) 
at ambient temperature gave 122b (85%; overall 32% yield). Out of the two methods for 
the preparation of 122b, Dimroth alkylation pathway (56% yield) was better in terms of 
number of steps and overall yield. 
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Scheme 32. Synthesis of 4-N-(4-nitrobenzyl)tubercidin (122b) from 2',3',5'-tri-O-acetyl-
4-fluorotubercidin (124). 
3.4.2. Biological activity of 6-N-benzyl-7-deazapurine nucleoside derivatives 
Nucleoside transport inhibition activities were measured in Dr. James D. Young’s 
laboratory of University of Alberta. While antiviral and anti-proliferation activities were 
studied in Dr. Jan Balzarini’s laboratory of Rega Institute for Medical Research. 
3.4.2.1. Nucleoside transport inhibition activity 
Inhibition of the initial rate of 3H-uridine (20 µM) uptake by recombinant hENT1 
produced in the Xenopus oocyte heterologous expression system was determined as 
described previously.118 The 4-N-(4-nitrobenzyl)tubercidin (122b) and 4-N-(4-
nitrobenzyl)sangivamycin (122c) fully inhibited labelled uridine uptake, whereas 4-N-
benzyltubercidin (122a) and 4-N-(4-nitrobenzyl)toyocamycin (122d) analogues exhibited 
weak inhibition (<45%). Dose-response evaluations indicated that sangivamycin 
analogue 122c (IC50 = 123 ± 31 nM) was a better inhibitor of uridine transport by hENT1 
than the tubercidin analogue 122b (IC50 > 1000 nM). However, the sangivamycin 
analogue 122c was a weaker inhibitor of hENT1-mediated transport than 6-N-(4-
nitrobenzyl)adenosine, NBMPR, and other derivatives119 containing a nitrogen atom at 
the 7-position in the adenine ring. 
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3.4.2.2. Antiviral activity 
Table 7. Antiviral activity in human embryonic lung (HEL) cell cultures-part 1 
Compd 
EC50 (µM)* 
HSV-1  
(KOS) 
HSV-2 
(G) 
Vaccinia 
virus 
Vesicular 
stomatitis virus 
HSV-1 
TK - KOS ACV 
122a >100 >100 >100 >100 >100 
122b >100 >100 34 >100 >100 
122c >100 >100 34 >100 >100 
122d >100 >100 100 >100 >100 
        *Effective concentration required to reduce virus plaque formation by 50%.  
      Virus input was 100 plaque forming units (PFU). 
The 4-N-benzyl-7-deazapurine derivatives (122a-d) weakly inhibited Herpes 
Simplex Virus (HSV; 1 & 2) and Vesicular stomatitis virus (EC50: >100 μM) (Table 7). 
But Vaccinia virus was reasonably inhibited by 4-N-(4-nitrobenzyl)tubercidin (122b) and 
4-N-(4-nitrobenzyl)sangivamycin (122c) (EC50: 34 μM) and to a weak extent by 4-N-
benzyltubercidin (122a) and 4-N-(4-nitrobenzyl)toyocmycin (122d) (EC50: >100 μM). 
Cytomegalovirus (CMV) and Varicella Zoster Virus (VZV) were inhibited at ~20 
µM concentrations by 4-N-benzyltubercidin (122a), 4-N-(4-nitrobenzyl)sangivamycin 
(122c) and 4-N-(4-nitrobenzyl)sangivamycin (122d) analogues (Table 8).  But 4-N-(4-
nitrobenzyl)tubercidin (122b) was not very potent (EC50: >100 μM). 
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Table 8. Antiviral activity human embryonic lung (HEL) cell cultures-part 2 
Compd 
EC50 (µM)* 
CMV 
(AD - 169 strain)
CMV 
(Davis 
strain) 
VZV 
(TK + VZV 
strain) 
VZV 
(TK - VZV strain) 
122a >20 >20 >20 >20 
122b >100 >100 >100 >100 
122c >20 >20 >20 >20 
122d >20 >20 >20 >20 
   *Effective concentration required to reduce virus plaque formation by 50%.  
   Virus input was 100 plaque forming units (PFU). 
 
3.4.2.3. Inhibition of Cell Proliferation 
Inhibition of the proliferation of murine leukemia (L1210) cells and human T-
lymphocyte (CEM), cervix carcinoma (HeLa), prostate cancer (PC-3), and kidney 
carcinoma (Caki-1) cells by the 7-deazaadenine nucleoside analogues (122a-d) was 
evaluated (Table 9). The 4-N-benzyltubercidin (122a) showed marked inhibition of the 
proliferation of PC-3 cells (IC50: 0.92 µM) and HeLa cells (IC50: 7.4 µM) but no 
significant activity was found with its nitrobenzyl analogue 122b (IC50: >50 µM). The 4-
N-(4-nitrobenzyl)sangivamycin (122c) and 4-N-(4-nitrobenzyl)toyocamycin (122d) 
analogues inhibited proliferation of L1210, HeLa, and PC-3 cells at ∼0.9–9.4 µM with 
the sangivamycin analogue 122c showing more potent effects (0.92–3.4 µM). It is 
intriguing that cytostatic activity of the 6-N-benzyl-7-deazapurine analogues was highly 
dependent on the nature of the tumor cell lines. Proliferation of HeLa and PC-3 tumor 
cells was highly inhibited by 122a, 122c, and 122d whereas proliferation of L1210 cells 
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was sensitive only to 122c and 122d. The CEM and Caki-1 cells were weakly sensitive to 
the antiproliferative effects of any of the 6-N-benzyl-7-deazapurine compounds 122a–
122d. 
Table 9. Inhibitory effects on the proliferation of cells in culture 
Compd 
IC50 (µM)* 
L1210 CEM HeLa PC-3 Caki-1 
122a 172 ± 47 182 ± 20 7.4 ± 2.2 0.92 ± 0.67 116 ± 23 
122b 125 ± 28 ≥250 143 ± 4 76 ± 10 132 ± 30 
122c 0.92 ± 0.04 115 ± 28 1.8 ± 0.2 3.4 ± 0.9 116 ± 23 
122d 5.5 ± 1.5 109 ± 16 9.4 ± 3.0 5.6 ± 3.3 98 ± 10 
   * Half-maximal inhibitory concentration (IC50); data represent the mean_ 
      SD of at least n=2–3 independent experiments; Cell lines: murine leukemia 
      (L1210); human CD4+ T-lymphocytes (CEM); human cervix carcinoma 
      (HeLa); human prostate adenocarcinoma (PC-3); human kidney carcinoma 
      (Caki-1). 
   
3.5. C7- and C8-modified-7-deazapurine nucleoside derivatives 
Building upon my interest in working with 7-deazaadenosine nucleosides, I 
envisioned the synthesis of various 7-substituted or 8-substituted 7-deazaadenosine 
analogues, which might have fluorescent properties. 
3.5.1. Strain promoted click reactions of 8-azido-7-deazanucleosides with 
cyclooctynes 
Initially, I imagined the conversion of 8-halo-7-deazapurines to the corresponding 
8-azido-7-deazapurines, which could serve as substrates for Strain-promoted Azide-
Alkyne Cycloaddition reactions (SPAAC, Cu-free click chemistry) with 
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cyclooctynes.193,194 I expect that the resulting triazolyl products might have fluorescent 
properties due to increased conjugation in the 7-deazapurine base part. The Cu-free click 
chemistry is a rapidly growing field, with various applications for in vivo imaging 
emerging continuously over the past few years.193,195-199  
Thus, 8-Bromotubercidin (126) was prepared by treatment of tubercidin 19a with 
N-bromosuccinimide in presence of potassium acetate (KOAc) in DMF at ambient 
temperature (30 min), as reported in literature.200 I envisioned the preparation of 8-azido-
7-deazaadenosine derivatives (127-129, Scheme 33) by nucleophilic aromatic 
substitution of 8-bromo-7-deazaadenosine derivatives (55, 56 and 126) with sodium 
azide. However, Attempts to synthesize 8-azidotubercidin via nucleophilic aromatic 
substitution of 126 with sodium azide were unsuccessful, even after using harsh 
conditions (NaN3 (1-5 eq), DMF, rt-153 °C, N2, 24 h; NaN3 (3 eq), TsOH (3 eq), EtOH, 
reflux, 24h). Lack of reaction is possibly a consequence of the low electron deficiency of 
the pyrrole ring in tubercidin 19a when compared to that of other 7-deazanucleosides 
19b-c. To explain in other words, C8-bromination probably proceeds via electrophilic 
aromatic substitution, whereas C8-azidation is expected to proceed via nucleophilic 
aromatic substitution. I envisioned the presence of electron withdrawing groups in the 
pyrrole ring on 8-bromo-7-deaza nucleosides will enhance the electron deficiency, there 
by promoting nucleophilic displacement of bromide with azide. So I chose to pursue 8-
bromotoyocamycin and 8-bromosangivamycin substrates, both of which have an electron 
withdrawing substituent on the 7-position of the pyrrole ring.  
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Scheme 33. Synthesis of 8-bromo-7-deazaadenosine and 8-azidotoyocamycin 
derivatives.  
Treatment of 8-bromosangivamycin 56 with NaN3 in DMF at 70 ºC for 16 hrs 
gave a slightly more polar product, which was thought to be 8-azidosangivamycin. UV 
spectra of the reactions always showed at least 12 nm bathochromic shift. However, ions 
corresponding to neither product (128) nor substrate (56) were detected in the high-
resolution mass spectroscopy (HRMS). Instead, peaks at m/z 258 and 317 were observed, 
which were unable to be identified with a list of possible products. Similar results were 
obtained when DMSO or MeOH were used as the reaction solvents. 
Next, I synthesized 8-azidotoyocamycin 129 by treating 8-bromotoyocamycin 55 
with NaN3 in DMF at room temperature for 16 h. This transformation was light and, 
possibly, heat sensitive requiring the reaction, purification, and characterization to be 
carried out in the dark with limited heating to give 8-azidotoyocamycin (129; 46%). The 
light sensitivity of the product also limited us in recording the analytical data for the 
compound. Moreover, this azidation (55 to 129) was unsuccessful in MeOH or water, 
indicating that polar aprotic solvents are probably the best solvents for these types of 
aromatic nucleophilic substitution reactions.  
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Scheme 34. Click reaction between 8-azidotoyocamycin and cyclooctynes 130 and 131. 
Reagents and conditions: g) Cyclooctyne 130 or 131 (1 eq), ACN:H2O (3:1), rt, 4 h. 
Having 8-azidotoyocamycin (129) in hand, my next goal was to see if the SPAAC 
reactions would take place between 129 and cyclooctynes. Thus, treatment of 129 with 
symmetrically fused cyclopropyl cyclooctyne 130 in an aqueous solution of acetonitrile 
(ACN) at ambient temperature (4 h) gave the corresponding triazolyl product 132 (59%, 
Scheme 34). Analogous reaction of 129 with a strain modulated dibenzylcyclooctyne 131 
produced triazole 133 (47%). These preliminary results indicated that the SPAAC 
reactions were taking place as expected. With the extended conjugation in the 
deazapurine part, I expect the triazole products to have fluorescence properties and that 
could lead to various interesting biological applications.   
3.5.1. Attempted synthesis of 8-alkynyl-7-deazanucleosides via Sonagashira reaction 
 Since the attempted synthesis of 8-azido analogues of tubercidin and 
sangivamycin were unsuccessful, I envisioned the synthesis of 8-vinylazido derivatives 
(136) from the corresponding 8-alkynyl-7-dezapurine derivatives (135), which in trun 
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could be prepared in two steps via Sonagashira coupling of 8-halo-7-deazapurines (55, 56 
and 126) with trimethylsilylacetylene (Scheme 35). The vinylazides 136 could be used as 
substrates for strain-promoted click reactions to give the corresponding triazolyl products 
(137). Also, the crucial 8-alkynyl derivative 135 could also be converted to the 
corresponding halovinyl sulfone and β-keto sulfones (not shown in scheme). This part of 
the dissertation is envisioned based on recent literature relating to transformations of 
alkynes to the corresponding (i) halovinyl sulfones;201-203 (ii) β-keto sulfones;204 and (iii) 
vinylazides.205 
 
 
Scheme 35. Proposed scheme for the synthesis and subsequent transformations of 8-
alkynyl-7-deazapurine nucleoside analogues 135. 
 Initially, treatment of 8-bromotubercidin (126) with trimethylsilylacetylene 
(TMSA) in the presence of trimethylamine (Et3N) and catalytic amounts of 
bis(triphenylphosphine)palladium dichloride [(PPh3)2PdCl2] and copper iodide (CuI) 
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(anhydrous DMF, 110 oC, sealed flask) showed unchanged starting material as major 
product (Scheme 35; Table 10, entry 1). Doubling the amounts of CuI and Et3N did not 
change the outcome of the reaction (entry 2).  
Table 10. Reaction conditions for the attempted Sonagashira cross-coupling reactions on 
8-bromo tubercidin and toyocamycina 
Entry Substrate 
(PPh3)2PdCl2
(mol %) 
CuI 
(mol %) 
Et3N TMSA Temp. Time 
1 126 3% 9% Excess 3 eq. 110 oC 48 h 
2 126 3% 15% Excess 6 eq. 110 oC 48 h 
3 126 10% 20% 4 eq. 3 eq. 50 oC 16 h 
4 126 15% 30% 11 eq. 10 eq. 50 oC 5 h 
5 55 1% 2% 7 eq. 1.2 eq. 80 oC 48 h 
6 55 10% 20% 5 eq. 3 eq. 50 oC 24 h 
7 55 20% 10% 5 eq. 3 eq. 50 oC 24 h 
8 55 15% 30% 14 eq. 10 eq. 50 oC 22 h 
aReactions were typically performed on 0.1 mmol scale in anhydrous DMF. Reaction 
progress was monitored by TLC. 
Treatment of 126 with 0.1 euqiv. of Pd and 0.2 equiv. Cu catalysts under 
analogous reaction conditions showed a minor less polar spot on TLC (entry 3). 
Encouraged by the observation, I treated 8-bromotubercidin 126 with 0.15 equiv. of Pd 
catalyst, 0.3 equiv. of Cu catalyst, 11 equiv. of Et3N, and 10 equiv. of TMSA in 
anhydrous DMF for 5 hrs at 50 oC. TLC of the crude reaction mixture was complex, but 
there was a major less polar spot (~50% in comparison with unchanged substrate) (entry 
4). 1H-NMR of the isolated material showed ~55:45 ratio of substrate to product 
(126:134a). The mixture of products was then treated with tetrabutylammonium fluoride 
(TBAF) and the major product was isolated by column chromatography. But 1H-NMR of 
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the isolated spot showed absence of the characteristic acetylenic proton peak and was 
very similar to the 1H-NMR of 8-bromotubercidin 126, and no signals for the 8-alkynyl 
product 134a were observed. Thus, it can be concluded that Sonagashira cross-coupling 
of 8-bromotubercidin with trimethylsilylacetylene is a low-yielding reaction.  
Because of the ease of preparation and availability of precursors, I used 8-
halotoyocamycin derivatives for initial Sonagashira reactions before proceeding to 8-
halosonagashira substrates.  However, analogous treatment of 8-bromotoyocamycin (55) 
with trimethylsilylacetylene [(PPh3)2PdCl2/CuI/Et3N/DMF/40 oC) also gave unchanged 
starting material as major product, even after varying the reaction conditions (Scheme 35; 
Table 10, entries 5-8).  
 To simplify the purification process, I decided to use protected 8-halo-7-
deazapurine derivatives as substrates. Thus, 2',3',5'-tri-O-acetyltoyocamycin (138) was 
prepared in 97% isolated yield by treating toyocamycin (19c) with Ac2O/Py (Scheme 36). 
Treatment of 2',3',5'-tri-O-acetyltoyocamycin (138) with DBH (1.1 eq., CH2Cl2, 18 h) 
gave the corresponding 8-bromo-2',3',5'-tri-O-acetyltoyocamycin (139) in 79% isolated 
yield. However, treatment of 139 (107 mg) with 0.02 equiv. of Pd catalyst, 0.1 equiv. of 
Cu catalyst, 0.1 equiv. of Et3N, and 4 equiv. of TMSA in anhydrous DMF for 19 h at 40 
oC gave a complex reaction mixture. Silica gel column chromatography gave three major 
fractions. The NMR analysis showed the first two products to be unchanged starting 
material 139 (27 mg, 25%), and debrominated product 138 (7 mg, 8%). The third fraction 
(4 mg) was more polar than the substrate on TLC, was blue on TLC plate under 365 nm 
lamp. But 1H-NMR of this material did not have characteristic product peaks and 
structure of this blue spot could not be determined.  
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Scheme 36. Attempted synthesis of 8-alkynyltoyocamycin derivative 140 via sonagashira 
coupling. 
 As iodo is a better substrate than bromo in Sonagashira coupling, I envisioned the 
use of 8-iodo-7-deazapurine analogues as substrates. Thus, toyocamycin 19c was 
converted to the corresponding tri-O-(tert-butyldimethylsilyl) protected counterpart 141 
using standard procedures (TBDMSCl/Imidazole/DMF/35 oC; 58%) (Scheme 37). The 
reaction was sluggish and required longer hours of stirring and more equivalents of 
reagents than usual. Treatment of silylated toyocamycin 141 with Lithium 
diisopropylamide (LDA, 5 equiv.) and iodine (I2, 1.5 equiv.) in dry THF [-78 oC (2 h) to 
ambient (48 h)] gave the corresponding 8-iodotoyocamycin analogue 142 in 16% isolated 
yield. Unchanged substrate 141 was also isolated form the column (58%). However, 
treatment of 8-iodo analogue 142 with trimethylsilylacetylene, (PPh3)2PdCl2 (10% mol), 
CuI (20% mol), Et3N (excess), TMSA (4 equiv.) in DMF at 40 oC for 48 h gave 
unchanged starting material 142 as major product even after for 2 days. Strangely, no 
trace of deiodinated product 141 or acetylenic product 143 was observed on TLC.  
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 Scheme 37. Attempted synthesis of 8-alkynyltoyocamycin derivative 143 via 
sonagashira coupling. 
Considering the cost of 7-deazapurine substrates, I stopped proceeding further in 
this direction. 
3.5.2. Iodine catalyzed direct C-H activation of 7-deazapurine nucleosides  
 Since I was unable to synthesize the 8-azido or the corresponding vinylazide 
analogues of tubercidin and sangivamycin, I explored other possibilities for incorporation 
of an aromatic moiety (e.g. triazolyl) based on direct on C-H activation.206 Incidentally, a 
recent research paper by Dr. Yotphan, et al. described iodine-catalyzed direct activation 
of indoles with azoles mediated by tert-butylhydroperoxide (TBHP) (Scheme 38).207  
 
Scheme 38. Iodine catalyzed oxidative cross-coupling of Indoles and Azoles.207 
 Because tubercidin 19a is structurally similar to indole, I imagined oxidative 
cross-coupling of tubercidin with triazoles to generate the corresponding C7 and/or C8 
triazolyl substituted analogues. Thus, initial treatment of tubercidin 19a with 
benzotriazole (2 equiv.), I2 (0.2 equiv.), and TBHP (5-6 M solution in decane, 1 equiv.) in 
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anhydrous DMF at ambient temperature after 7 h showed unchanged tubercidin as the 
major product on TLC (Scheme 39). No product formation was observed even after 
stirring the reaction mixture at 40 oC for 7 hrs.  Additional I2 (0.2 equiv.), and TBHP (1 
equiv.) were added and the reaction mixture was stirred at 40 oC for 48 h, by which time 
the TLC showed ~15% conversion to a more polar product. Analogous treatment of 
tubercidin 19a with benzotriazole (2 equiv.), I2 (0.4 equiv.), and TBHP (2 equiv.) in 
anhydrous DMF at 35 oC for 72 h also showed ~10% conversion to a less polar product. 
Additional TBHP (1 equiv.) was added and the reaction mixture was stirred at 35 oC for 
24 h (total: 96 h), by which time the TLC showed ~30% conversion to a more polar 
product. The new spot was isolated by silica gel chromatography in 18% yield and was 
single product on 1H, 13C NMR. Comparison of 1H-NMR data with substrate revealed 
the following: (i) singlet for H2 was still present (shifted to 8.22 ppm from 8.05 ppm); (ii) 
Doublet for H8 (7.35 ppm) collapsed to a singlet (7.04 ppm); and (ii) doublet for H7 (at 
7.6 ppm) is absent. This confirms the structure of the product to be 7-
(benzotriazolyl)tubercidin 144.  
 
Scheme 39. Iodine catalyzed oxidative cross-coupling of tubercidin and benzotrizole. 
Fluorescence analysis of the triazolyl compound 144 showed emission at 420 nm 
with the best quantum yield being ~0.002 units (in MeOH). The fluorescence is stronger 
in basic pH between 7 and 12 and at pH ~2, it is non-fluorescent. The average lifetime is 
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about 3.8 ns with two well-defined lifetimes of 1 ns (10%) and 4.1 ns (90%). However, 
the compound seems to be highly sensitive to UV light, since increase in fluorescence 
upon irradiation with 280 nm light was observed. 
Conversely, treatment of acetyl-protected tubercidin (123) with I2 (0.2 eq.), TBHP 
(1eq.), in DMF at room temperature for 12 h gave a mixture of three products (Scheme 
40). TLC of the reaction mixture showed ~30% conversion to a less polar spot. Isolation 
of the new spot by column chromatography followed by 1H-NMR analysis showed the 
spot as a mixture of three different products (19% yield, 60:25:15 mixture). It is 
suspected that the mixture of products are 7-substituted analogue 145, 8-substituted 
counterpart 146 and probably 7,8-dibenzotriazolyltubercidin (not shown in scheme). 
 
Scheme 40. Iodine catalyzed oxidative cross-coupling of acetylated tubercidin and 
benzotriazole. 
In addition, treatment of sangivamycin (19b) with benzotriazole (2 eq.), I2 (0.4 
eq.), TBHP (2 eq.), in anhydrous DMF at 120 oC for 24 h showed unchanged starting 
material on TLC (Scheme 41). On the other hand, treatment of toyocamycin (19c) with 
benzotriazole (2 eq.), I2 (0.4 eq.), TBHP (2eq.), in anhydrous DMF at 80 oC for 48 hrs 
resulted in 30% conversion to new spot on TLC. The isolated spot was not the expected 
product 147c and exact structure could not be established by spectroscopic data. These 
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results reiterate the literature reports that indoles with electron deficient pyrrole rings 
react sluggishly with azoles.207  
 
Scheme 41. Attempted synthesis of iodine catalyzed oxidative cross-coupling of 
sangivamycin or toyocamycin and benzotriazole. 
4. EXPERIMENTAL SECTION 
The 1H (400 MHz), 13C (100.6 MHz), and 19F (376 MHz) NMR spectra were 
recorded at ambient temperature in solutions of CDCl3 or DMSO-d6. Reaction progress 
was monitored by TLC on Merck Kieselgel 60-F254 sheets with product detection by 254-
nm light. Products were purified by column chromatography using Merck Kiselgel 60 
(230-400 mesh) or by automated flash chromatography using a CombiFlash system. UV 
spectra were recorded with a Varian Cary 100 Bio UV-visible spectrophotometer. 
Reagent grade chemicals were used and solvents were dried by reflux and distillation 
from CaH2 under N2 unless otherwise specified, and an atmosphere of N2 was used for 
reactions. Purity of the synthesized compounds was determined to be ≥95% by elemental 
analysis (C, H, N) and/or HPLC on Phenomenex Gemini RP-C18 column with 
CH3CN/H2O solvent system as mobile phase. Elemental analyses were performed by 
Galbraith Laboratories, Knoxville, TN. Mass spectra (MS) were obtained with 
atmospheric pressure chemical ionization (APCI) technique or electro-spray ionization 
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(ESI) techniques. High-resolution mass spectra were obtained in ESI-TOF mode unless 
otherwise noted.  
Chemical shifts (δ) are reported in parts per million (ppm) referenced to the 
residual solvent peak, and coupling constants (J) are given in Hertz (Hz). Multiplicity is 
reported using standard abbreviations: singlet (s); doublet (d); triplet (t); multiplet (m); 
broad (br); inverted commas indicate observed multiplicity. UV spectra were recorded 
with a Varian Cary 100 Bio UV-visible spectrophotometer. 
Some of the data were reprinted with permission from the following papers:  
(i) Adhikary, Amitava; Kumar, Anil; Rayala, Ramanjaneyulu; Hindi, Ragda M.; 
Adhikary, Ananya; Wnuk, Stanislaw F.; and Sevilla, Michael D., “One-electron 
oxidation of Gemcitabine and analogs: Mechanism of formation of C3′ and C2′ 
sugar radicals”, J. Am. Chem. Soc. 2014, 136 (44), 15646−15653. Copyright © 
2014, American Chemical Society. 
(ii) Rayala, Ramanjaneyulu; Theard, Patricia; Ortiz, Heysell; Yao, Sylvia; Young, 
James D.; Balzarini, Jan; Robins, Morris J., Wnuk, Stanislaw F., “Synthesis of 
Purine and 7-Deazapurine Nucleoside Analogues of 6-N-(4-
Nitrobenzyl)adenosine; Inhibition of Nucleoside Transport and Proliferation of 
Cancer Cells”, ChemMedChem 2014, 9, 2186-2192. Copyright © 2014 WILEY-
VCH Verlag GmbH & Co. KGaA, Weinheim. 
(iii) Rayala, Ramanjaneyulu; Wnuk, Stanislaw F., “Bromination at C-5 of pyrimidine 
and C-8 of purine nucleosides with 1,3-dibromo-5,5-dimethylhydantoin”, 
Tetrahedron Letters 2012, 53 (26), 3333-3336. Copyright © 2012, Elsevier Ltd. 
Cytostatic activity assays  
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All assays were performed in 96-well microtiter plates. To each well of 200 µL were 
added (5−7.5) × 104 tumor cells and a given amount of the test compound. The cells were 
allowed to proliferate for 48 h (murine leukemia L1210), 72 h (human lymphocytic 
CEM), 96 h (human cervix carcinoma HeLa), 144 h (human prostate cancer PC-3), or 
168 h (human kidney Caki-1) at 37 °C in a humidified CO2-controlled atmosphere. At the 
end of the incubation period, the cells were counted in a Coulter counter. The IC50 (50% 
inhibitory concentration) was defined as the concentration of the compound that inhibited 
cell proliferation by 50%. 
General procedure for the bromination of protected nucleosides. DBH and/or 
TMSOTf were added to a stirred solution of substrate in CH2Cl2. The resulting brownish-
orange solution was stirred at room temperature for time given in the corresponding table 
(Tables 3, 4, and 5; Section 3.1.) or until TLC showed absence of starting material and 
formation of less polar product. The reaction mixture was diluted with CHCl3 and was 
washed with saturated NaHCO3/H2O and brine. The organic layer was dried (MgSO4) 
and concentrated in vacuo to yield the corresponding brominated product as a colorless 
foam with purity over 98% (1H NMR). 
General procedure for the bromination of unprotected nucleosides.  
Procedure A. DBH was added to a stirred solution of substrate in DMF. The resulting 
pale-yellow solution was stirred at room temperature for time given in the corresponding 
table (Tables 3, 4, and 5; Section 3.1.) or until TLC showed absence of starting material 
and formation of less polar product. Volatiles were evaporated and the residue was co-
evaporated with MeCN. The resulting pale solid was crystallized or purified by column 
chromatography to give the corresponding brominated product as colorless crystals. 
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Procedure B. DBH was added to a stirred suspension/solution of substrate in MeOH. 
The resulting pale solution was stirred at room temperature for time given in the 
corresponding table (Tables 3, 4, and 5; Section 3.1.) or until TLC showed absence of 
starting material and formation of less polar product. Products were isolated by (a) 
filtration, if the products precipitated from the reaction mixture; (b) if no was precipitate 
observed, then volatiles were evaporated and the residue was crystallized or column 
chromatographed to give the corresponding brominated product as colorless crystals. The 
isolated brominated products were usually >98% pure by 1H-NMR. 
5-Bromo-2',3',5'-tri-O-acetyluridine (46a)64. UV (MeOH) λmax 275 nm, λmin 240 nm; 1H 
NMR (CDCl3) δ 9.75 (br s, 1H, NH), 7.82 (s, 1H, H6), 6.06 (d, J = 4.7 Hz, 1H, H1'), 
5.34-5.29 (m, 2H, H2', H3'), 4.38-4.30 (m, 3H, H4', H5', H5''), 2.18 (s, 3H, Ac), 2.10 (s, 
3H, Ac),  2.08 (s, 3H, Ac). 
5-Bromo-1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)uracil (46b).208 UV (MeOH) 
λmax  276 nm, λmin  239 nm; 1H NMR (CDCl3) δ 9.33 (br s, 1H, NH), 7.77 (s, 1H, H6), 
6.22 (d, J = 4.1 Hz, 1H, H1'), 5.35 (dd, J = 3.7, 4.1 Hz, 1H, H2'), 5.04 (“q”, J = 1.9 Hz, 
1H, H3'), 4.38 (dd, J = 5.8, 12.1 Hz, 1H, H5'), 4.32 (dd, J = 3.9, 12.1 Hz, 1H, H5''), 4.16-
4.12 (m, 1H, H4'), 2.09 (s, 3H, Ac), 2.07 (s, 3H, Ac), 1.98 (s, 3H, Ac); 13C NMR 
(CDCl3): δ 170.5, 169.6, 168.6 (3 x Ac), 158.6 (C4), 149.2 (C2), 139.8 (C6), 96.3 (C5 ), 
84.4 (C1'), 80.7 (C4'), 76.1 (C3'), 74.4 (C2'), 62.5 (C5'), 20.8, 20.6, 20.4 (3 × Ac); MS 
(ESI) m/z 447 (100, [79Br], MH-), 449 (98, [81Br], MH-).  
5-Bromo-3',5'-di-O-acetyl-2'-deoxy-uridine (46c)64. UV (MeOH) λmax 277 nm, λmin 241 
nm; 1H NMR (CDCl3) δ 9.59 (br s, 1H, NH), 7.89 (s, 1H, H6), 6.29 (“dd”, J = 5.8, 8.0 
Hz, 1H, H1'), 5.24-5.21 (m, 1H, H3'), 4.40 (dd, J = 3.1, 12.2 Hz, 1H, H5'), 4.34-4.28 (m, 
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2H, H4', H5''), 2.54 (ddd, J = 2.3, 5.8, 14.3 Hz, 1H, H2'), 2.23-2.15 (m, 1H, H2''), 2.17 (s, 
3H, Ac),  2.11 (s, 3H, Ac). 
5-Bromouridine (46d)64. UV (MeOH) λmax 279 nm, λmin 241 nm; 1H NMR (DMSO-d6) δ 
11.81 (br s, 1H, NH), 8.48 (s, 1H, H6), 5.73 (d, J = 4.5 Hz, 1H, H1'), 5.42 (d, J = 5.3 Hz, 
1H, 2'OH), 5.27 (t, J = 4.7 Hz , 1H, 5'OH), 5.07 (d, J = 5.4 Hz, 1H, 3'OH), 4.04 (q, J = 
4.9 Hz, 1H, H2'), 3.98 (q, J = 5.0 Hz, 1H, H3'), 3.88-3.85 (m, 1H, H4'), 3.71-3.66 (m, 1H, 
H5'), 3.60-3.55 (m, 1H, H5''). 
5-Bromo-1-(β-D-arabinofuranosyl)uracil (46e)209. UV (MeOH) λmax 280 nm, λmin 242 
nm; 1H NMR (DMSO-d6) δ 11.82 (br s, 1H, NH), 8.07 (s, 1H, H6), 5.96 (d, J = 4.6 Hz, 
1H, H1'), 5.63 (d, J = 5.3 Hz, 1H, 2'OH), 5.48 (d, J = 4.5 Hz , 1H, 3'OH), 5.17 (t, J = 5.4 
Hz, 1H, 5'OH), 4.03 (“q”, J = 4.5 Hz, 1H, H2'), 3.91 (q, J = 4.2 Hz, 1H, H3'), 3.74 (“q”, J 
= 4.5 Hz, 1H, H4'), 3.66-3.55 (m, 1H, H5', H5''). 
5-Bromo-2'-deoxyuridine (46f)64. UV (MeOH) λmax 279 nm, λmin 241 nm; 1H NMR 
(DMSO-d6) δ 11.79 (br s, 1H, NH), 8.39 (s, 1H, H6), 6.10 (t, J = 6.5 Hz, 1H, H1'), 5.25 
(d, J = 4.3 Hz , 1H, 3'OH), 5.17 (t, J = 4.8 Hz, 1H, 5'OH), 4.26-4.22 (m, 1H, H3'), 3.79 
(q, J = 3.2 Hz, 1H, H4'), 3.66-3.54 (m, 2H, H5', H5''), 2.18-2.08 (m, 2H, H2', H2''). 
5-Bromocytidine (47b)62. UV (MeOH) λmax 289 nm, λmin 265 nm; 1H NMR (DMSO-d6) 
δ 8.39 (s, 1H, H6), 7.83 (br s, 1H, NH), 6.99 (br s, 1H, NH), 5.71 (d, J = 3.2 Hz, 1H, 
H1'), 5.37 (d, J = 5.0 Hz, 1H, 2'OH), 5.23 (t, J = 4.8 Hz , 1H, 5'OH), 5.00 (d, J = 5.4 Hz, 
1H, 3'OH), 3.98-3.92 (m, 1H, H2'), 3.85-3.83 (m, 1H, H3'), 3.70 (ddd, J = 2.7, 4.8, 12.1 
Hz, 1H, H5'), 3.56 (ddd, J = 2.5, 4.9, 12.1 Hz, 1H, H5''). 
4-N-Benzoyl-5-bromocytidine (48b). mp 193-195 oC; UV (MeOH) λmax 252, 335 nm (ε 
8900, 13 900), λmin 228, 292 nm (ε 7300, 4200); 1H NMR (DMSO-d6) δ 12.81 (br s, 1H, 
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NH), 8.79 (s, 1H, H6), 8.10-8.24 (br s, 2H, Bz), 7.62 (t, J = 7.3 Hz, 1H, Bz), 7.53 (t, J = 
7.6 Hz, 2H, Bz), 5.70 (d, J = 3.6 Hz, 1H, H1'), 5.57 (d, J = 3.9 Hz, 1H, 2'OH), 5.41 (t, J = 
4.6 Hz , 1H, 5'OH), 5.10 (d, J = 5.9 Hz, 1H, 3'OH), 4.07-4.13 (m, 1H, H2'), 4.04 ("q", J = 
5.9 Hz, 1H, H3'), 3.90-3.96 (m, 1H, H4'), 3.74-3.82 (m, 1H, H5'), 3.63 (ddd, J = 2.1, 4.4, 
12.2 Hz, 1H, H5''); 13C NMR (DMSO-d6)  δ 177.8 (Bz), 154.5 (C2), 147.2 (C4 ), 142.1 
(C6), 136.1 (Bz), 132.8, 129.4, 128.4, 95.0 (C5), 89.7 (C1'), 84.5 (C4'), 74.2 (C2'), 68.6 
(C3'), 59.5 (C5'); MS (ESI) m/z 426 (100, [79Br], MH+), 428 (98, [81Br], MH+). Anal. 
Calcd for C16H16BrN3O6 • 0.5 MeOH (442.24): C, 44.81; H, 4.10; N, 9.50. Found: C, 
44.62; H, 3.71; N, 9.13.   
5'-O-(Tert-butyldimethylsilyl)-2',3'-O-isopropylideneuridine (49b)210. UV (MeOH) 
λmax 276 nm, λmin 241 nm; 1H NMR (CDCl3) δ 9.23 (br s, 1H, NH), 7.91 (s, 1H, H6), 5.91 
(d, J = 3.1 Hz, 1H, H1'), 4.73 (dd, J = 2.3, 6.2 Hz, 1H, H2'), 4.68 (dd, J = 3.1, 6.1 Hz, 1H, 
H3'), 4.39 (“q”, J = 2.4 Hz, 1H, H4'), 3.93 (dd, J = 2.1, 11.7 Hz, 1H, H5'), 3.80 (dd, J = 
2.8, 11.7 Hz, 1H, H5''), 1.58 (s, 3H, CH3), 1.35 (s, 3H, CH3), 0.90 (s, 9H, 3 x CH3), 0.11 
(s, 6H, 2 x CH3). 
8-Bromoadenosine (50b)211. UV (MeOH) λmax 264 nm, λmin 232 nm; 1H NMR (DMSO-
d6) δ 8.12 (s, 1H, H2), 7.58 (br s, 2H, NH2), 5.83 (d, J = 6.8 Hz, 1H, H1'), 5.52 (dd, J = 
3.9, 8.6 Hz, 1H, 5'OH), 5.48 (d, J = 6.3 Hz, 1H, 2'OH), 5.25 (d, J = 4.4 Hz , 1H, 3'OH), 
5.09 (q, J = 6.1 Hz, 1H, H2'), 4.20-4.17 (m, 1H, H3'), 3.99-3.96 (m, 1H, H4'), 3.68 (dt, J 
= 3.9, 12.1 Hz, 1H, H5'), 3.55-3.49 (m, 1H, H5''). 
8-Bromo-2'-deoxyadenosine (51b)54. 1H NMR (DMSO-d6) δ 8.11 (s, 1H, H2), 7.51 (br 
s, 2H, NH2), 6.29 (“dd”, J = 6.7, 7.9 Hz, 1H, H1'), 5.34 (d, J = 4.2 Hz , 1H, 3'OH), 5.29 
(“dd”, J = 4.4, 7.7 Hz, 1H, 5'OH), 4.50-4.46 (m, 1H, H3'), 3.90-3.87 (m, 1H, H4'), 3.65 
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(“dt”, J = 4.5, 11.9 Hz, 1H, H5'), 3.51-3.45 (m, 1H, H5''), 3.28-3.21 (m, 1H, H2'), 2.19 
(ddd, J = 2.7, 6.5, 13.2 Hz, 1H, H2''). 
8-Bromo-2',3',5'-tri-O-acetylguanosine (52b)212. UV (MeOH) λmax 263 nm, λmin 220 
nm; 1H NMR (DMSO-d6) δ 10.95 (br s, 1H, NH), 6.63 (br s, 2H, NH2), 6.01 (“dd”, J = 
4.5, 6.3 Hz, 1H, H1'), 5.88 (“d”, J = 4.4 Hz, 1H, H2'), 5.65 (t, J = 6.3 Hz , 1H, H3'), 4.42 
(dd, J = 3.7, 11.9 Hz, 1H, H5'), 4.34-4.30 (m, 1H, H4'), 4.21 (dd, J = 6.3, 11.9 Hz, 1H, 
H5''), 2.11 (s, 3H, Ac), 2.07 (s, 3H, Ac),  1.99 (s, 3H, Ac). 
8-Bromoguanosine (53b)213. UV (MeOH) λmax 261 nm, λmin 223 nm; 1H NMR (DMSO-
d6) δ 10.87 (br s, 1H, NH), 6.51 (br s, 2H, NH2), 5.68 (“d”, J = 6.3 Hz, 1H, H1'), 5.44 
(“d”, J = 6.2 Hz, 1H, H2'), 5.09 (d, J = 5.0 Hz , 1H, 2'OH), 5.01 (q, J = 6.0 Hz, 1H, 
5'OH), 4.95 (t, J = 5.9 Hz, 1H, 3'OH), 4.15-4.12 (m, 1H, H3'), 3.87-3.84 (m, 1H, H4'), 
3.68-3.62 (m, 1H, H5'), 3.54-3.48 (m, 1H, H5''). 
8-Bromo-2'-deoxyguanosine (54b).214,215 UV (MeOH) λmax 261 nm, λmin 221 nm; 1H 
NMR (DMSO-d6) δ 10.80 (br s, 1H, NH), 6.49 (br s, 2H, NH2), 6.15 (“t”, J = 7.3 Hz, 1H, 
H1'), 5.25 (d, J = 4.3 Hz, 1H, 3'OH), 4.86 (t, J = 5.9 Hz, 1H, 5'OH), 4.41-4.37 (m, 1H, 
H3'), 3.81-3.78 (m, 1H, H4'), 3.65-3.59 (m, 1H, H5'), 3.52-3.46 (m, 1H, H5''), 3.19-3.12 
(m, 1H, H2'), 2.13-2.07 (m, 1H, H2''). 
8-bromotoyocamycin (55).  
Method A. NBS (195.8 mg, 1.1 mmol) was added to a stirred solution of 19c (291.3 mg, 
1 mmol) in anhydrous DMF (8 mL) in a flame dried flask and the resulting pale-yellow 
solution was stirred at room temperature for 2.5 h, by which time TLC showed >90% 
conversion to a less polar product. Volatiles were removed from the clear, brown solution 
using high vacuum rotary evaporator on a hot water bath (<80 oC). The resulting brown 
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gummy solid was purified using column chromatography (10%, MeOH/EtOAc) and 
recrystallizaed from MeOH to give 55 as a colorless solid (166.6 mg, 45%): mp: 200-202 
ºC; UV (MeOH): λmax 286 nm (ε 15 000), λmin 250 nm (ε 2200); 1H NMR (DMSO-d6): δ 
8.20 (s, 1H, H2), 7.09 (br s, 2H, NH2), 5.94 (d, J = 6.6 Hz, 1H, H1'), 5.46 (d, J = 6.2 Hz, 
1H, 2'-OH), 5.30-5.33 ("q", J = 4.1 Hz, 1H, 5'-OH), 5.25 (d, J = 4.8 Hz, 1H, 3'-OH), 5.08 
(q, J = 6.0 Hz, 1H, H2'), 4.21 (m, 1H, H3'), 3.96 (q, J =3.8 Hz, 1H, H4'), 3.69 (dt, J 
=4.20, 12.0 Hz, 1H, H5'), 3.50-3.57 (m, 1H, H5''); 13C NMR: δ= 156.1, 153.2, 149.9, 
121.7, 114.1 (CN), 102.1, 91.0 (C1'), 87.4, 86.5 (C4'), 71.1 (C2'), 70.6 (C3'), 62.0 (C5'). 
Rf (EtOAc:iPrOH:H2O, 4:1:2) 0.69 (Rf 19c 0.68); HRMS (ESI): m/z [M+H]+ calcd for 
C12H13BrN5O4+: 370.0145 and 372.0125; found 370.0093 and 371.9937. 
Method B. DBH (552 mg, 1.93 mmol) was added to a suspension of 19c (750 mg, 2.57 
mmol) in MeOH (120 mL) in a flame dried flask and the resulting yellow suspension was 
stirred at room temperature for 5 min, by which time the solution became >80% clear. 
After 15 min TLC showed >95% conversion to a less polar product and product began to 
solidify out of the solution. After 30 min the colorless solid was collected using vacuum 
filtration (710 mg). Volatiles in the mother liquor were removed using rotary evaporator 
and the resulting colorless solid was recrystallized from MeOH (104 mg) to give 55 (814 
mg, 85%): characterization data were in agreement with those reported in method 1.  
8-bromosangivamycin (56).  
Method A. NBS (267.1 mg, 1.5 mmol) was added to a stirred solution of 19b (309.2 mg, 
1 mmol) in anhydrous DMF (8 mL) in a flame dried flask and the resulting pale-yellow 
solution was stirred at room temperature for 1 h, by which time TLC showed >90% 
conversion to a less polar product. Volatiles were removed from the clear, brown solution 
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using high vacuum rotary evaporator on a hot water bath (<80 oC). The resulting brown 
gummy oil  was column chromatographed (15%, MeOH/EtOAc) to give 56 as an off-
white solid (244.5 mg, 63%): mp: 174-175 ºC; UV (MeOH): λmax 286 nm (ε 14 100), λmin 
256 nm (ε 5500); 1H NMR (DMSO-d6): δ 8.09 (s, 1H, H2), 8.00 (br s, 1H, NH2), 7.76 (br 
s, 1H, NH2), 5.99 (d, J = 6.6 Hz, 1H, H1'), 5.55 (dd, J = 4.0 Hz, 1H, 5'-OH), 5.37 (d, J = 
6.3 Hz, 1H, 2'-OH), 5.18 (d, J = 4.6 Hz, 1H, 3'-OH), 5.13 (q, J = 6.1 Hz, 1H, H2'), 4.20 
("q", J = 4.2 Hz, 1H, H3'), 3.95 (q, J = 3.5 Hz, 1H, H4'), 3.68 (dt, J = 3.4, 12.0 Hz, 1H, 
H5'), 3.49-3.55 (m, 1H, H5''); 13C NMR: δ = 165.8 (C=O), 157.1, 152.2, 149.6, 112.5, 
112.2, 90.5 (C1'), 86.2 (C4'), 71.1 (C2'), 70.8 (C3'), 62.23 (C5'); Rf (EtOAc:iPrOH:H2O, 
4:1:2) 0.45 (Rf 19b 0.35); HRMS (ESI): m/z [M+H]+ calcd for C12H15BrN5O5+: 388.0251 
and 390.0231; found 388.0265 and 390.0229. 
Method B. DBH (101.6 mg, 1.1 mmol) was added to a clear, colorless solution of 19b 
(100 mg, 0.0323 mmol) in MeOH (25 mL) in a flame dried flask and the resulting yellow 
solution was stirred at room temperature for 30 min, by which time TLC showed >90% 
conversion to a less polar product. Volatiles were removed from the clear, yellow 
solution using rotary evaporator. The resulting off-white solid was purified using column 
chromatography (10%, MeOH/EtOAc) to give 56 as a colorless solid (49.2 mg, 39%): 
characterization data were in agreement with those reported in method 1.  
Ethyl 2-(phenylthio)octanoate (72). Thiophenol (260 μL, 280 mg, 2.54 mmol) was 
added to a stirred solution of NaH (60%, dispersion in paraffin liquid; 100.4 mg, 4.18 
mmol) in anhydrous DMF (4 mL) at 0 oC. The resulting suspension was stirred at 0 oC for 
30 minutes and at ambient temperature for 30 minutes, by which time bubbles (H2 gas) 
ceased. The reaction flask was chilled again and Ethyl 2-bromooctanoate 71b (540 μL, 
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630 mg, 2.51 mmol) was added at 0 oC. The resultant clear, colorless solution was stirred 
at 0 oC for 20 min and at ambient temperature for 2 hours, by which time TLC showed 
exclusive conversion to a slightly more polar spot. Volatiles were evaporated and co-
evaporated with toluene (1 x) (vacuum pump) and the resulting pale gum was partitioned 
between CHCl3 (20 mL) and NH4Cl/H2O (20 mL). The aqueous layer was extracted with 
CHCl3 (2 x 5 mL) and the combined organic phase was washed with NaHCO3/H2O (25 
mL), brine (25 mL), and dried (MgSO4). Volatiles were evaporated in vacuo and the 
residue was column chromatographed (10% EtOAc in hexanes) to give 72216 (633 mg, 
90%) as a pale oil: 1H NMR (CDCl3) δ 7.49-7.46 (m, 2H, Ph), 7.35-7.25 (m, 3H, Ph), 
4.16-4.09 (m, 2H, CH2), 3.66 (dd, J = 6.6, 8.4 Hz, 1H, H2), 1.96-1.87 (m, 1H, H3), 1.82-
1.73 (m, 1H, H3'), 1.51-1.37 (m, 2H, H4, H4'), 1.36-1.26 (m, 6H, H5, H5', H6, H6', H7, 
H7'), 1.19 (t, J = 7.1 Hz, 3H, CH3), 0.90 (“t”, J = 6.8 Hz, 3H, CH3); 13C NMR (CDCl3) δ 
172.4, 133.8, 132.7, 128.9, 127.7, 61.0, 50.9, 31.7, 31.5, 28.8, 27.2, 22.5, 14.1, 14.0. 
Ethyl 2-((4-chlorophenyl)thio)hexanoate (73). Treatment of ethyl 2-bromohexanoate 
71a (500 μL, 610.5 mg, 2.74 mmol) with 4-chlorothiophenol/NaH/DMF as described for 
the preparation of 72 gave 73217 as a pale yellow oil (763.6 mg, 97%):  1H NMR (CDCl3) 
δ 7.41-7.37 (m, 2H, Ph), 7.30-7.26 (m, 2H, Ph), 4.17-4.09 (m, 2H, CH2), 3.61 (dd, J = 
6.6, 8.4 Hz, 1H, H2), 1.94-1.84 (m, 1H, H3), 1.81-1.69 (m, 1H, H3'), 1.51-1.27 (m, 4H, 
H4, H4', H5, H5'), 1.19 (t, J = 7.1 Hz, 3H, CH3), 0.91 (“t”, J = 7.1 Hz, 3H, CH3); 13C 
NMR (CDCl3) δ 172.1, 134.11, 134.10, 132.1, 129.0, 61.1, 51.0, 31.3, 29.4, 22.2, 14.1, 
13.8. 
Ethyl 2-((4-chlorophenyl)thio)octanoate (74). Treatment of ethyl 2-bromooctanoate 
71b (540 μL, 630 mg, 2.51 mmol) with 4-chlorothiophenol/NaH/DMF as described for 
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the preparation of 72 gave 74 as a colorless oil (664 mg, 84%): 1H NMR (CDCl3) δ 7.39-
7.37 (m, 2H, Ph), 7.27-7.24 (m, 2H, Ph), 4.15-4.07 (m, 2H, CH2), 3.60 (dd, J = 6.7, 8.3 
Hz, 1H, H2), 1.92-1.81 (m, 1H, H3), 1.77-1.68 (m, 1H, H3'), 1.48-1.35 (m, 2H, H4, H4'), 
1.33-1.27 (m, 6H, H5, H5', H6, H6', H7, H7'), 1.18 (t, J = 7.1 Hz, 3H, CH3), 0.87 (“t”, J = 
6.8 Hz, 3H, H8, H8', H8''); 13C NMR (CDCl3) δ 172.0, 134.1, 134.0, 132.2, 129.0, 61.0, 
51.0, 31.6, 31.5, 28.8, 27.2, 22.5, 14.1, 14.0. 
Ethyl 2-((4-methoxyphenyl)thio)hexanoate (75). Treatment of ethyl 2-bromohexanoate 
71a (500 μL, 610.5 mg, 2.74 mmol) with 4-methoxythiophenol/NaH/DMF as described 
for the preparation of 72 gave 75218 as a colorless oil (739.3 mg, 96%): 1H NMR (CDCl3) 
δ 7.36-7.31 (m, 2H, Ph), 6.78-6.74 (m, 2H, Ph), 4.02 (“q”, J = 7.2 Hz, 2H, CH2), 3.41 
(dd, J = 6.6, 8.5 Hz, 1H, H2), 1.82-1.75 (m, 1H, H3), 1.68-1.59 (m, 1H, H3'), 1.42-1.32 
(m, 1H, H4), 1.30-1.21 (m, 3H, H4', H5, H5'), 1.10 (t, J = 7.1 Hz, 3H, CH3), 0.82 (t, J = 
7.1 Hz, 3H, CH3); 13C NMR (CDCl3) δ 172.2, 160.1, 136.2, 123.4, 114.4, 60.7, 55.2, 
51.6, 31.1, 29.3, 22.3, 14.1, 13.8. 
Typical procedure for preparation of ethyl difluoroalkanoate (76 and 77). DBH was 
added to a stirred solution of ester 72 or 73 (0.5 mmol) and Py.9HF (3 mmol) in CH2Cl2 
(2 mL) at ambient temperature. The resulting brown solution was stirred at ambient 
temperature or at 35 oC for the respective times as shown in Table 1. The reaction flask 
was cooled to room temperature, quenched by addition of ice-cold water, diluted with 
CH2Cl2, and neutralized with drop-wise addition of conc. NH4OH. Organic layer was 
separated and aqueous layer was back extracted (2 x CH2Cl2). Combined organic layer 
was washed with 1N HCl, brine, dried (MgSO4) and concentrated in vacuo to give crude 
difluorinated product as a brown oil, with data as reported.219 76219 had: 1H NMR 
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(CDCl3) δ 4.25 (q, 3JH,H = 7.2 Hz, 2H, CH2), 2.09-1.88 (m, 2H, H3, H3'), 1.42-1.30 (m, 
4H, H4, H4', H5, H5'), 1.28 (t, 3JH,H = 7.1 Hz, 3H, CH3), 0.85 (t, 3JH,H = 7.2 Hz, 3H, H6, 
H6', H6''); 13C NMR (CDCl3) δ 164.4 (t, 2JF,C = 33.2 Hz, C1), 116.4 (t, 1JF,C = 249.8 Hz, 
C2), 63.0 (CH2), 34.5 (t, 2JF,C = 23.2 Hz, C3), 23.5 (t, 3JF,C = 4.3 Hz, C4), 22.2 (C5), 13.9 
(CH3), 13.7 (C6); 19F NMR (CDCl3) δ –105.92 ppm (t, 3JF-H = 16.8 Hz); GC-MS (tR = 7.5 
min) 151 (l.1), 124 (11.3), 116 (18.2), 87 (44.9), 67 (20.9), 55 (3.6);  
77219 had: 1H NMR (CDCl3) δ 4.25 (q, 3JH,H = 7.2 Hz, 2H, CH2), 2.03-1.91 (m, 2H), 1.45-
1.18 (m, 11H), 0.81 (“t”, 3JH,H = 6.8 Hz, 3H, H6, H6', H6''); 13C NMR (CDCl3) δ 164.5 (t, 
2JF,C = 33.0 Hz, C1), 116.4 (t, 1JF,C = 249.7 Hz, C2), 62.7 (CH2), 34.5 (t, 2JF,C = 23.2 Hz, 
C3), 31.4, 28.7, 22.4, 21.4 (t, 3JF,C = 4.3 Hz, C4), 13.9; 19F NMR (CDCl3) δ –105.89 ppm 
(t, 3JF-H = 17.0 Hz). 
5-O-Benzyl-2,3-dideoxy-2-fluoro-2-(phenylsulfanyl)ribose (84) and 5-O-Benzyl-2,3-
dideoxy-2-fluoro-2-(phenylsulfinyl)ribose (85). 83 (31 mg, 0.1 mmol) was treated with 
Py.9HF (185 μL, 0.8 mmol) and DBH (114 mg, 0.4 mmol) in anhydrous CH2Cl2 (3 mL) 
according to general desulfurization-difluorination procedure gave 40 mg of yellow oil 
after aqueous workup: 19F-NMR (CDCl3) δ -150.86 (“t”, 1F, J = 26.4 Hz), -149.33 (dd, 
0.4F, J = 20.3, 27.3 Hz), -139.24 to -138.93 (m, 0.6 F); HRMS (ESI) m/z 355.2857 
[M+Na]+, calcd for C18H17FNaO3S+ 355.0775; m/z 371.2611 [M+Na]+, calcd for 
C18H17FNaO4S+ 371.0724. 
2'-S-(4-Chlorophenyl)-2'-thiouridine (87). Slight modification of published 
procedure.133 PPh3 (464.3 mg, 1.77 mmol) was added to a stirred solution of 4-
chlorothiophenol (1.28 g, 8.84 mmol) in anhydrous DMF (10 mL) and the resulting 
solution was stirred at ambient temperature for 30 minutes. 2,2'-anhydro-1-β-D-
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arabinofuranosyluracil220 (1 g, 4.42 mmol) was added to the reaction mixture and the 
resulting solution was refluxed (153 oC) for 18 h. Volatiles were evaporated, co-
evaporated with toluene (2 x). The resultant brown gum was triturated with hexanes (3 x) 
and the liquid was pipetted out. The remaining brownish gummy solid was triturated with 
ether and the resultant pale green solid was vacuum filtered, washed with minimal 
amount of ice-cold methanol to give 2'-S-(4-Chlorophenyl)-2'-thiouridine (87; 1.1 g, 67 
%) as a colorless solid: 1H NMR (DMSO-d6)133  δ 11.14 (br s, 1H, NH), 7.61 (d, J = 8.1 
Hz, 1H, H6), 7.35 (d, J = 8.5 Hz, 2H, Ph), 7.28 (d, J = 8.5 Hz, 2H, Ph), 6.33 (d, J = 9.0 
Hz, 1H, H1'), 5.91 (d, J = 5.6 Hz, 1H, 3'OH), 5.50 (d, J = 8.1 Hz, 1H, H5), 5.11 (t, J = 5.0 
Hz, 1H, 5'OH), 4.34 (t, J = 5.2 Hz, 1H, H3'), 3.94-3.92 (m, 1H, H4'), 3.89 (dd, J = 5.3, 
9.0 Hz, 1H, H2'), 3.59 (“t”, J = 4.4 Hz, 2H, H5', H5''); 13C NMR (DMSO-d6) δ 162.5 
(C4), 150.4 (C2), 139.8 (C6), 133.1 (Ph), 132.3 (Ph), 132.0 (Ph), 128.8 (Ph), 102.3 (C5), 
87.8 (C1'), 86.7 (C4'), 72.1 (C3'), 61.4 (C5'), 54.5 (C2'). 
3',5'-di-O-Acetyl-2'-S-(4-chlorophenyl)-2'-thiouridine (89a). DMAP (18.3 mg, 0.15 
mmol) was added to a stirred suspension of 87 (1.1 g, 2.97 mmol) in Ac2O (842 μL, 909 
mg, 8.91 mmol) and the resulting suspension was stirred at ambient temperature 
overnight (15 h). MeOH was added, the reaction mixture was stirred at ambient 
temperature for 30 min, and volatiles were evaporated (vacuum pump, <25 oC). MeOH 
was added and evaporated, and the resulting gum was partitioned between CHCl3 (50 
mL) and H2O (50 mL). The aqueous layer was extracted with CHCl3, and the combined 
organic phase was washed with NaHCO3/H2O, 1N HCl, brine, and dried (MgSO4). 
Volatiles were evaporated in vacuo and the residue was dried on vacuum pump to give 
3',5'-di-O-Acetyl-2'-S-(4-chlorophenyl)-2'-thiouridine (89a; 1.34 g, 99%) as a colorless 
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foam, with sufficient purity to proceed to next step: 1H NMR (CDCl3) δ 10.12 (br s, 1H, 
NH), 7.27 (d, J = 8.3 Hz, 2H, Ph), 7.22 (d, J = 8.2 Hz, 1H, H6), 7.14 (d, J = 8.4 Hz, 2H, 
Ph), 6.14 (d, J = 8.5 Hz, 1H, H1'), 5.63 (d, J = 8.2 Hz, 1H, H5), 5.38 (“d”, J = 6.0 Hz, 
1H, H3'), 4.30-4.19 (m, 3H, H4', H5', H5''), 3.81 (“dd”, J = 6.3, 8.2 Hz, 1H, H2'), 2.07 (s, 
3H, CH3), 2.00 (s, 3H, CH3); 13C NMR (CDCl3) δ 170.3, 169.9 (2 x C=O), 163.2 (C4), 
150.4 (C2), 139.2 (C6), 134.6 (Ph), 134.2 (Ph), 130.6 (Ph), 129.4 (Ph), 103.4 (C5), 89.0 
(C1'), 81.0 (C4'), 73.7 (C3'), 63.5 (C5'), 53.5 (C2'), 20.7, 20.6 (2 x s, 2 x CH3). 
N3-Benzyl-3',5'-di-O-benzyl-2'-S-(4-chlorophenyl)-2'-thiouridine (89b). NaH (60%, 
dispersion in paraffin liquid; 216 mg, 9 mmol) was added to a stirred solution of 87 
(556.2 mg, 1.5 mmol) in anhydrous DMF (6 mL) at 0 oC. The resulting suspension was 
stirred at 0 oC for 30 minutes and at ambient temperature for 30 minutes, by which time 
bubbles (H2 gas) ceased. The reaction flask was chilled again and benzyl bromide (0.93 
mL, 1.3 g, 7.8 mmol) was added at 0 oC. Bubbles were observed for a few minutes once 
the ice-bath was removed and the resultant pale solution was stirred at ambient 
temperature for 4 hours, by which time TLC showed a major (90%) less polar spot. 
Volatiles were evaporated and co-evaporated with toluene (1 x) (vacuum pump) and the 
resulting syrup was partitioned between CHCl3 (20 mL) and NH4Cl/H2O (20 mL). The 
aqueous layer was extracted with CHCl3 (2 x 5 mL) and the combined organic phase was 
washed with NaHCO3/H2O (25 mL), brine (25 mL), and dried (MgSO4). Volatiles were 
evaporated in vacuo and the residue was column chromatographed (20% EtOAc in 
hexanes) to give 89b (827 mg, 86%) as a colorless foam: 1H NMR (CDCl3) δ 7.53-7.51 
(m, 2H, Ph), 7.43-7.27 (m, 14H, Ph, H6), 7.15-7.11 (m, 2H, Ph), 6.93-6.90 (m, 2H, Ph), 
6.47 (d, J = 8.3 Hz, 1H, H1'), 5.33 (d, J = 8.1 Hz, 1H, H5), 5.05-4.97 (m, 2H, benzylic), 
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4.71-4.64 (m, 2H, benzylic), 4.56 (“d”, J = 11.0 Hz, 1H, benzylic), 4.50 (“d”, J = 11.0 
Hz, 1H, benzylic), 4.33-4.30 (m, 2H, H3', H4'), 3.81-3.77 (m, 2H, H2', H5'), 3.60 (dd, J = 
1.7, 10.4 Hz, 1H, H5''); 13C NMR (CDCl3) δ 162.0, 150.9, 137.4, 137.2, 137.1, 136.8, 
133.9, 133.8, 131.7, 129.5, 129.1, 128.8, 128.6, 128.4, 128.1, 128.0, 127.8, 127.7, 102.3 
(C5), 90.2 (C1'), 82.3 (C4'), 80.3 (C3'), 73.9 (CH2), 72.4 (CH2), 70.6 (C5'), 55.7 (C2'), 
44.1 (CH2). 
N3-Benzyl-3',5'-di-O-benzyl-2'-S-(4-methoxyphenyl)-2'-thiouridine (90b). Treatment 
of 88134 (1.47 g, 4.0 mmol) with NaH (576 mg, 24 mmol) and BnBr (2.5 mL, 3.6 g, 20.8 
mmol) as described for 87 → 89b gave 90b as a colorless foam (2.2 g, 86%): 1H NMR 
(CDCl3) δ 7.58 (“d”, J = 6.9 Hz, 2H, Ph), 7.40-7.23 (m, 13H, Ph), 7.14-7.11 (m, 3H, Ph, 
H6), 6.56 (d, J = 8.8 Hz, 1H, H1'), 6.33 (d, J = 8.7 Hz, 2H, Ph), 5.11 (d, J = 8.1 Hz, 1H, 
H5), 5.04 (“d”, J = 13.5 Hz, 1H, benzylic), 4.95 (“d”, J = 13.5 Hz, 1H, benzylic), 4.64 (s, 
2H, benzylic), 4.49 (“d”, J = 11.0 Hz, 1H, benzylic), 4.39 (“d”, J = 11.0 Hz, 1H, 
benzylic), 4.29 (d, J = 5.3 Hz, 1H, H4'), 4.25 (br s, H3'), 3.70-3.65 (m, 2H, H2', H5'), 
3.60 (s, 3H, OCH3), 3.54-3.51 (“m”, 1H, H5''); 13C NMR (CDCl3) δ 170.8, 162.0, 159.8, 
151.1, 137.4, 136.9, 135.3, 129.8, 128.6, 128.5, 128.3, 128.2, 127.9, 127.8, 127.8, 127.7, 
123.3, 114.6, 102.0 (C5), 90.4 (C1'), 82.0 (C3'), 80.9 (C4'), 73.8 (CH2), 72.2 (CH2), 70.8 
(C5'), 56.3 (C2'), 55.4 (OCH3), 44.1 (CH2). 
N3-Benzyl-3',5'-di-O-benzyl-2'-deoxy-2'-[(4-methoxyphenyl)sulfinyl]uridine [93 
(R/S-S)]. MCPBA (750.7 mg of 70% reagent, 4.35 mmol) in CH2C12 (70 mL) was added 
drop-wise to a stirred solution of 90b (2.2 g, 3.45 mmol) in CH2C12 (35 mL) at -50 oC, 
and the temperature was allowed to rise to -30 oC in ~20 minutes. TLC showed > 80% 
conversion to a more polar product. The solution was poured into NaHCO3/H2O (10 mL). 
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The aqueous layer was extracted with CHCl3 (2 x 5 mL) and the combined organic phase 
was washed with H2O (20 mL), brine (25 mL), and dried (MgSO4). Volatiles were 
evaporated in vacuo and the residue was column chromatographed (25% EtOAc in 
hexanes) to give 93 (2' R/S-S, ~1:1) (1.8 g, 80%) as a colorless foam: 1H NMR (CDCl3) δ 
7.51-7.28 (m, 17.5H, Ph, H6), 7.10 (d, J = 7.8 Hz, 0.5H, H6), 7.03 (d, J = 8.0 Hz, 0.5H, 
H1'), 6.83 (d, J = 8.0 Hz, 0.5H, H1'),  6.49 (d, J = 9.6 Hz, 1H, Ph), 6.44 (d, J = 8.1 Hz, 
1H, Ph), 5.36 (d, J = 7.7 Hz, 0.5H, H5), 5.04 (d, J = 8.1 Hz, 0.5H, H5), 4.96-4.26 (m, 8H, 
benzylic, H2', H3'), 3.86-3.43 (m, 6H, CH3, H4', H5', H5''); 
13C NMR (CDCl3) for major isomer (extracted data): δ 162.9, 161.6, 150.6, 137.11, 
137.10, 137.0, 136.5, 132.5, 129.8, 128.8, 128.6, 128.44, 128.38, 128.2, 127.9, 127.2, 
114.6, 102.5 (C5), 82.9 (C1'), 82.1 (C4'), 80.9 (C3'), 74.0 (CH2), 73.4 (CH2), 72.7 (C5'), 
70.9 (C2'), 55.6 (OCH3), 44.1 (CH2).  
3',5'-di-O-Acetyl-2'-deoxy-2'-[(4-chlorophenyl)sulfonyl]uridine (91a). MCPBA (70% 
reagent, 250 mg, 1.45 mmol) was added to a stirred solution of 89a (227.4 mg, 0.5 mmol) 
in CH2Cl2 (15 mL) and the resultant colorless solution was stirred at ambient temperature 
for 12h. TLC showed complete conversion to a more polar product. The reaction mixture 
was poured into NaHCO3/H2O (10 mL). The aqueous layer was extracted with CHCl3 (2 
x 5 mL) and the combined organic phase was washed with H2O (20 mL), brine (25 mL), 
and dried (MgSO4). Volatiles were evaporated in vacuo to give 91a (241 mg, 99%) as a 
colorless foam. Data for the crude sample: 1H NMR (CDCl3) δ 9.51 (br s, 1H, NH), 7.86 
(d, J = 8.6 Hz, 2H, Ph), 7.55 (d, J = 8.6 Hz, 2H, Ph), 7.17 (d, J = 8.2 Hz, 1H, H6), 6.15 
(d, J = 6.2 Hz, 1H, H1'), 5.72-5.66 (m, 2H, H5, H3'), 4.6 (t, J = 6.7 Hz, 1H, H2'), 4.42 (q, 
J = 4.6 Hz, 1H, H4'), 4.36 (dd, J = 3.7, 12.5 Hz, 1H, H5'), 4.25 (dd, J = 4.9, 12.2 Hz, 1H, 
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H5''), 2.09 (s, 3H, CH3), 2.07 (s, 3H, CH3); 13C NMR (CDCl3) δ 170.4, 169.9 (2 x C=O), 
162.9 (C4), 149.6 (C2), 141.7 (C6), 141.2 (Ph), 136.9 (Ph), 130.2 (Ph), 130.1 (Ph), 103.5 
(C5), 87.7 (C1'), 80.9 (C4'), 71.2 (C3'), 65.1 (C5'), 62.4 (C2'), 20.71, 20.70 (2 x CH3). 
N3-Benzyl-3',5'-di-O-benzyl-2'-deoxy-2'-[(4-chlorophenyl)sulfonyl]uridine (91b). 
MCPBA (250.2 mg of 70% reagent, 1.45 mmol) in CH2C12 (6 mL) was added drop-wise 
to a stirred solution of 89b (320.6 mg, 0.50 mmol) in CH2C12 (4 mL) and the resulting 
clear solution was stirred at ambient temperature overnight. Saturated NaHCO3/H2O (10 
mL) was added, stirring was continued for 10 min, and the organic layer was separated. 
The aqueous layer was extracted with CHCl3 (2 x 5 mL) and the combined organic phase 
was washed with H2O (20 mL), brine (25 mL), and dried (MgSO4). Volatiles were 
evaporated in vacuo and the residue was column chromatographed (20% EtOAc in 
hexanes) to give 91b (269.3 mg, 80%) as a colorless foam: 1H NMR (CDCl3) δ 7.59-7.56 
(m, 2H, Ph), 7.55-7.51 (m, 2H, Ph), 7.48-7.28 (m, 14H, Ph, H6), 6.98-6.94 (m, 2H, Ph), 
6.66 (d, J = 8.6 Hz, 1H, H1'), 5.37 (d, J = 8.2 Hz, 1H, H5), 5.08 (“d”, J = 13.7 Hz, 1H, 
benzylic), 5.02 (“d”, J = 13.7 Hz, 1H, benzylic), 4.68 (“d”, J = 11.5 Hz, 1H, benzylic), 
4.63 (dd, J = 1.8, 5.4 Hz, 1H, H3'), 4.58 (“d”, J = 11.5 Hz, 1H, benzylic), 4.53 (“d”, J = 
10.9 Hz, 1H, benzylic), 4.45 (“d”, J = 11.0 Hz, 1H, benzylic), 4.24 (“d”, J = 1.9 Hz, 1H, 
H4'), 4.09 (dd, J = 5.4, 8.6 Hz, 1H, H2'), 3.70 (dd, J = 2.3, 10.6 Hz, 1H, H5'), 3.46 (dd, J 
= 2.0, 10.6 Hz, 1H, H5''); 13C NMR (CDCl3) δ 161.8, 150.7, 140.7, 137.4, 137.1 (C6), 
136.8, 136.6, 136.4, 130.2, 129.5, 129.1, 128.8, 128.6, 128.5, 128.3, 128.23, 128.16, 
127.8, 103.0 (C5), 84.8 (C1'), 82.5 (C4'), 79.7 (C3'), 74.0 (CH2), 73.1 (CH2), 70.1 (C5'), 
68.9 (C2'), 44.3 (CH2). 
N3-Benzyl-3',5'-di-O-benzyl-2'-deoxy-2'-[(4-methoxyphenyl)sulfonyl]uridine (92b). 
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Treatment of 90b (32 mg, 0.05 mmol) with MCPBA (26 mg of 70% reagent, 0.15 mmol) 
in CH2Cl2 (3 mL) as described for 89b → 91b gave 92b (27 mg, 81%) as a colorless 
foam: 1H NMR (CDCl3) δ 7.61-7.60 (m, 2H, Ph), 7.51-7.48 (m, 2H, Ph), 7.43-7.25 (m, 
13H, Ph), 7.10 (d, J = 8.2 Hz, 1H, H6), 6.75 (d, J = 9.0 Hz, 1H, H1'), 6.39-6.35 (m, 2H, 
Ph), 5.16 (d, J = 8.1 Hz, 1H, H5), 5.07 (“d”, J = 13.5 Hz, 1H, benzylic), 4.99 (“d”, J = 
13.5 Hz, 1H, benzylic), 4.80 (“d”, J = 11.7 Hz, 1H, benzylic), 4.65-4.62 (m, 2H, benzylic, 
H3'), 4.50 (“d”, J = 10.8 Hz, 1H, benzylic), 4.39 (“d”, J = 10.8 Hz, 1H, benzylic), 4.22 
(“d”, J = 1.6 Hz, 1H, H4'), 4.05 (dd, J = 5.2, 9.0 Hz, 1H, H2'), 3.67-3.63 (m, 4H, OCH3, 
H5'), 3.45 (dd, J = 2.0, 10.5 Hz, 1H, H5''); 13C NMR (CDCl3) δ 171.1, 163.9, 161.9, 
150.7, 137.2 (C6), 137.0, 136.9, 136.6, 130.6, 130.4, 129.8, 128.8, 128.5, 128.4, 128.2, 
128.1, 127.9, 114.2, 102.7 (C5), 85.0 (C1'), 82.6 (C4'), 80.0 (C3'), 73.9 (CH2), 73.1 
(CH2), 70.4 (C5'), 68.4 (C2'), 55.8 (OCH3), 44.3 (CH2). 
N3-Benzyl-3',5'-di-O-benzyl-2'-fluoro-2'-S-(4-methoxyphenyl)-2'-thiouridine (94b). 
DAST (0.15 mL, 183 mg, 1.14 mmol) was added to a mixture of 93 (2'-R/S-S, ~1:1) 
(326.4 mg, 0.5 mmol) and SbC13 (23 mg, 0.1 mmol) in CH2Cl2 (10 mL), and the 
resulting pale solution was stirred at ambient temperature overnight (13 h). Cold 
saturated NaHCO3/H2O (10 mL) was added carefully, stirring was continued for 30 min, 
the organic layer was separated. The aqueous layer was extracted with CHCl3 (2 x 5 mL) 
and the combined organic phase was washed with H2O (20 mL), brine (25 mL), dried 
(MgSO4) and evaporated in vacuo to give yellow oil. Gradient flash chromatography (0 
→ 30% EtOAc in hexanes) gave 94b as a mixture of diastereomers (2'-R/S-S, ~ 4:1) (pale 
yellow foam 186.6 mg, 57%): 1H NMR (CDCl3) δ 7.55-7.26 (m, 18H, Ph, H6), 6.84 (“d”, 
J = 8.7 Hz, 2H, Ph), 6.51 (d, J = 14.7 Hz, 0.8H, H1'), 6.40 (br s, 0.2H, H1'), 5.68 (d, J = 
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8.1 Hz, 0.8H, H5), 5.41 (d, J = 8.2 Hz, 0.2H, H5), 5.14-5.01 (m, 1H, benzylic), 4.93-4.87 
(m, 1H, benzylic), 4.68-4.43 (m, 4H, benzylic), 4.23-4.18 (m, 2H, H3', H4'), 3.91-3.79 
(m, 4H, CH3, H5'), 3.72-3.60 (m, 1H, H5''); 19F NMR (CDCl3) δ –132.53 ppm (br s, 
0.8F), –131.16 ppm (br s, 0.2F). 
13C NMR (CDCl3) for major isomer (extracted data): δ 162.3, 161.0, 150.2, 138.8, 137.6, 
137.1, 136.6, 135.1, 135.0, 129.0, 128.59, 128.57, 128.4, 128.3, 128.1, 127.80, 127.6, 
118.84, 118.82, 114.8, 109.1 (d, 1JC2'-F = 237.1 Hz, C2'), 102.0, 90.5 (d, 2JC1'-F = 47.9 Hz, 
C1'), 80.1 (C4'), 79.6 (d, 2JC3'-F = 18.1 Hz, C3'), 73.5 (CH2), 73.1 (CH2), 67.5 (C5'), 55.4 
(CH3), 44.1 (CH2). 
N3-Benzyl-3',5'-di-O-benzyl-2'-deoxy-2'-fluoro-2'-[(4-
methoxyphenyl)sulfonyl]uridine (95b). MCPBA (241.6 mg of 70% reagent, 1.4 mmol) 
in CH2C12 (5 mL) was added drop-wise to a stirred solution of 94 (327.4 mg, 0.50 mmol) 
in CH2C12 (3 mL) and the resulting clear solution was stirred at ambient temperature 
overnight. Saturated NaHCO3/H2O (10 mL) was added, stirring was continued for 10 
min, and the organic layer was separated. The aqueous layer was extracted with CHCl3 (2 
x 5 mL) and the combined organic phase was washed with H2O (20 mL), brine (25 mL), 
and dried (MgSO4). Volatiles were evaporated in vacuo and the residue was column 
chromatographed (20% EtOAc in hexanes) to give 95b as a mixture of diastereomers (2'-
R/S-S, ~ 3:1) (colorless foam, 298.7 mg, 87%): 1H NMR (CDCl3) δ 7.90 (d, J = 8.4 Hz, 
0.5H, Ph), 7.78 (d, J = 8.3 Hz, 1.5H, Ph), 7.54 (d, J = 7.9 Hz, 1H, H6), 7.55-7.12 (m, 
15H, Ph), 6.95 (“d”, J = 8.9 Hz, 1.5H, Ph), 6.89 (“d”, J = 8.5 Hz, 0.5H, Ph), 6.70 (br s, 
0.25H, H1'), 6.30 (d, J = 18.6 Hz, 0.75H, H1'), 5.73 (d, J = 8.1 Hz, 0.75H, H5), 5.27 (br 
s, 0.25H, H5), 5.06 (d, J = 13.7 Hz, 0.75H, benzylic), 5.00 (“d”, J = 13.7 Hz, 0.25H, 
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benzylic), 4.92-4.80 (m, 2H, benzylic, H3'), 4.58 (d, J = 11.6 Hz, 1H, benzylic), 4.49-
4.27 (m, 3H, benzylic), 4.11-4.06 (m, 1H, H4'), 3.90 (s, 2.25H, CH3), 3.86 (s, 0.75H, 
CH3), 3.81-3.87 (m, 0.25H, H5'), 3.75 (dd, J = 2.3, 11.2 Hz, 0.75H, H5'), 3.54 (“dd”, J = 
3.7, 11.1 Hz, 1H, H5''); 19F NMR (CDCl3) δ –158.89 ppm (“t”, J = 16.3 Hz, 0.75F), –
156.50 ppm (d, J = 19.5 Hz, 0.25F). 
13C NMR (CDCl3) for major isomer: δ 165.0, 150.2, 139.3 (C6), 137.3, 136.8, 136.2, 
131.38, 131.37, 129.1, 128.9, 128.6, 128.51, 128.50, 128.44, 128.36, 128.3, 128.1, 127.8, 
127.7, 126.5, 114.5, 108.3 (d, 1JC2'-F = 237.0 Hz, C2'), 101.8 (C5), 87.8 (d, 2JC1'-F = 38.1 
Hz, C1'), 79.5 (C4'), 75.5 (d, 2JC3'-F = 15.2 Hz, C3'), 73.8 (CH2), 73.5 (CH2), 67.1 (C5'), 
55.9 (CH3), 44.1 (CH2). 
5-Bromo-3',5'-di-O-acetyl-2'-S-(4-chlorophenyl)-2'-thiouridine (96a) and 5-Bromo-
3',5'-di-O-acetyl-2'-deoxy-2'-[(4-chlorophenyl)sulfinyl]uridine [97 (R/S-S)]. Py.9HF 
(352 μL, 1.53 mmol) was added to a chilled solution of DBH (20.8 mg, 0.073 mmol) in 
dry CH2Cl2 (1 mL) at -78 oC. The resulting pale solution was stirred at -78 oC for 10 
minutes and a solution of substrate 89a (30mg, 0.066 mmol) in dry CH2Cl2 (2 mL) was 
added via syringe. The resultant orange solution was stirred at -78 oC for 2h and was 
brought to -30 oC over 45 minutes. The reaction mixture was diluted with CH2Cl2 (5 mL), 
washed with NaHCO3/H2O (5 mL), H2O (5 mL), brine (5 mL), dried (MgSO4). Volatiles 
were evaporated in vacuo and the yellow residue was column chromatographed (30% → 
60% EtOAc in hexanes) to give 96a (14.4 mg, 41%) as a colorless oil. Also isolated were 
97 (6.5 mg, 18%, faster moving isomer) as a colorless oil and 97 (10.9 mg, 30%, slower 
moving isomer) as a colorless oil. 
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96a had: 1H NMR (CDCl3) δ 8.48 (br s, 1H, NH), 7.09-7.06 (m, 2H, Ph), 7.02-6.99 (m, 
2H, Ph), 6.98 (s, 1H, H6), 5.94 (d, J = 8.1 Hz, 1H, H1'), 5.12 (dd, J = 2.6, 5.9 Hz, 1H, 
H3'), 4.12 (dd, J = 4.0, 12.9 Hz, 1H, H5'), 4.06-4.02 (m, 2H, H4', H5''), 3.47 (dd, J = 5.9, 
8.0 Hz, 1H, H2'), 1.893-1.891 (“m”, 6H, 2 x CH3); 13C NMR (CDCl3) δ 170.03 (C=O), 
169.98 (C=O), 158.3, 149.5, 138.2 (C6), 135.2, 134.3 (Ph), 130.4, 129.7 (Ph), 98.0 (C5), 
89.3 (C1'), 81.3 (C4'), 73.6 (C3'), 63.5 (C5'), 54.5 (C2'), 20.9 (CH3), 20.6 (CH3).    
97 (faster moving isomer) had: 1H NMR (CDCl3) δ 8.38 (br s, 1H, NH), 7.56-7.50 (m, 
4H, Ph), 7.10 (s, 1H, H6), 5.89 (d, J = 4.0 Hz, 1H, H1'), 5.51 (t, J = 8.2 Hz, 1H, H3'), 
4.45 (dd, J = 2.8, 12.3 Hz, 1H, H5'), 4.40-4.36 (m, 1H, H4'), 4.23 (dd, J = 4.8, 12.3 Hz, 
1H, H5''), 3.92 (dd, J = 4.2, 8.2 Hz, 1H, H2'), 2.29 (s, 3H, CH3), 2.12 (s, 3H, CH3); 13C 
NMR (CDCl3) δ 170.6 (C=O), 170.4 (C=O), 157.9, 148.1, 140.6 (C6), 138.5, 138.4, 
130.1 (Ph), 125.5 (Ph), 97.3 (C5), 85.3 (C1'), 80.3 (C4'), 72.1 (C3'), 67.3 (C2'), 62.1 
(C5'), 20.8 (CH3), 20.6 (CH3).    
97 (slower moving isomer) had: 1H NMR (CDCl3) δ 8.55 (br s, 1H, NH), 7.59-7.56 (m, 
2H, Ph), 7.42-7.39 (m, 2H, Ph), 7.15 (s, 1H, H6), 6.13 (d, J = 8.4 Hz, 1H, H1'), 5.51 (dd, 
J = 2.6, 6.2 Hz, 1H, H3'), 4.30 (dd, J = 3.2, 12.1 Hz, 1H, H5'), 4.25 (q, J = 2.9 Hz, 1H, 
H4'), 4.17 (dd, J = 2.9, 12.1 Hz, 1H, H5''), 3.72 (dd, J = 6.2, 8.3 Hz, 1H, H2'), 2.13 (s, 
3H, CH3), 2.11 (s, 3H, CH3); 13C NMR (CDCl3) δ 169.8 (C=O), 169.7 (C=O), 157.5, 
148.7, 139.8 (C6), 139.0, 137.6, 130.1 (Ph), 127.1 (Ph), 98.2 (C5), 83.1 (C1'), 81.6 (C4'), 
73.4 (C3'), 69.8 (C2'), 63.4 (C5'), 21.0 (CH3), 20.6 (CH3). 
3',5'-di-O-Acetyl-5-iodo-2'-S-(4-chlorophenyl)-2'-thiouridine (96b). NIS (68 mg, 0.42 
mmol) was added to a stirred solution of 89a (46 mg, 0.1 mmol) and DAST (80 μL, 0.6 
mmol) in anhydrous CH2Cl2 (2 mL) at 0 oC and the resulting purple solution was stirred 
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at 0 oC for 6 h and at ambient temperature for 32 h (total reaction time: 36 h). The 
reaction was quenched by addition of sat. Na2S2O3 (5 mL), diluted with CH2Cl2 (5 mL). 
Organic layer was separated and aqueous layer was back extracted (2 x CH2Cl2). 
Combined organic layer was washed with NaHCO3/H2O (10 mL), brine (10 mL), dried 
(MgSO4), and filtered. Volatiles were evaporated in vacuo and the brown residue was 
column chromatographed (25% → 50% EtOAc in hexanes) to give 96b (42.5 mg, 73%) 
as a colorless oil.  
 Analogous treatment of 89a (46 mg, 0.1 mmol) with NIS (68 mg, 0.42 mmol) and 
DAST (80 μL, 0.6 mmol) at 35 oC for 24 h gave 96b (35 mg, 60%) as a pale-yellow oil. 
1H NMR (CDCl3) δ 9.07 (br s, 1H, NH), 7.60 (s, 1H, H6), 7.39-7.35 (m, 2H, Ph), 7.31-
7.28 (m, 2H, Ph), 6.23 (d, J = 8.4 Hz, 1H, H1'), 5.43 (dd, J = 2.2, 5.8 Hz, 1H, H3'), 4.44-
4.31 (m, 3H, H4', H5', H5''), 3.77 (dd, J = 5.9, 8.3 Hz, 1H, H2'), 2.21 (s, 3H, CH3), 2.19 
(s, 3H, CH3); 13C NMR (CDCl3) δ 171.3, 170.0 (2 x C=O), 159.2 (C4), 149.8 (C2), 143.3 
(C6), 135.2 (Ph), 134.3 (Ph), 130.4 (Ph), 129.8 (Ph), 89.0 (C1'), 81.3 (C4'), 73.7 (C3'), 
69.7 (C5), 63.6 (C5'), 54.5 (C2'), 21.1, 20.7 (2 x s, 2 x CH3). 
3-N-benzyl-3',5'-di-O-benzyl-5-bromo-2'-deoxy-2'-fluoro-2'-S-(4-chlorophenyl)-2'-
thiouridine (98). 89b (255 mg, 0.4 mmol) was treated with Py.9HF (920 μL, 4 mmol) 
and DBH (572 mg, 2 mmol) in anhydrous CH2Cl2 (10 mL) according to general 
desulfurization-difluorination procedure gave 405 mg of yellow oil after aqueous 
workup. Column chromatography (10% → 70% EtOAc in hexanes) gave a major fraction 
of 118 mg as a pale-yellow oil: 19F-NMR (CDCl3) δ -127.53 to -127.24 (m, 1F), -130.84 
to -130.62 (m, 1F). 
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3-N-benzyl-3',5'-di-O-benzyl-5-iodo-2'-S-(4-methoxyphenyl)-2'-thiouridine (100) 
and 3-N-benzyl-3',5'-di-O-benzyl-2'-fluoro-2'-S-(4-methoxyphenyl)-2'-thiouridine 
(94b). NIS (95 mg, 0.42 mmol) was added to a stirred solution of 18 (128 mg, 0.2 mmol) 
and Py.9HF (138 μL, 0.6 mmol) in anhydrous CH2Cl2 (3 mL) at -78 oC in a poly 
propylene vessel and the resulting brown solution was brought to ~5 oC overnight (16 h). 
Stirring was continued at ambient temperature for 7 h (total reaction time: 23 h). The 
reaction was quenched by addition of ice-cold water (10 mL), diluted with CH2Cl2 (5 
mL), neutralized with drop-wise addition of conc. NH4OH. Organic layer was separated 
and aqueous layer was back extracted (2 x CH2Cl2). Combined organic layer was washed 
with 1N HCl (10 mL), brine (10 mL), dried (MgSO4), and filtered. Volatiles were 
evaporated in vacuo and the brown residue was column chromatographed (5% → 20% 
EtOAc in hexanes) to give 100 (44 mg, 29%) as a colorless oil and 94b (16 mg, 12%) as 
a pale-yellow oil (2'-R/S-S, ~ 1:1).  
 Analogous treatment of 18 (128 mg, 0.2 mmol) with NIS (95 mg, 0.42 mmol) and 
DAST (160 μL, 1.2 mmol) followed by aqueous workup (sat. Na2S2O3, sat. NaHCO3, 
brine, MgSO4) and column chromatography gave 94b (58 mg, 44%) as a pale-yellow oil 
(2'-R/S-S, ~ 1:1). 
100 had: 1H NMR (CDCl3) δ 7.66-7.63 (m, 2H, Ph), 7.56 (s, 1H, H6), 7.44-7.31 (m, 13H, 
Ph), 7.12-7.10 (m, 2H, Ph), 6.51 (d, J = 8.9 Hz, 1H, H1'), 6.33-6.30 (m, 2H, Ph), 5.15 
(“d”, J = 13.4 Hz, 1H, benzylic), 5.02 (“d”, J = 13.3 Hz, 1H, benzylic), 4.68-4.52 (m, 4H, 
benzylic), 4.33-4.25 (m, 2H, H4', H3'), 3.76-3.67 (m, 2H, H2', H5'), 3.66 (s, 3H, OCH3), 
3.51 (dd, J = 2.0, 10.5 Hz, 1H, H5''); 13C NMR (CDCl3) δ 159.8, 159.1, 150.8, 142.2 
(C6), 137.22, 137.16, 136.2, 135.2, 130.4, 128.8, 128.6, 128.4, 128.2, 128.1, 128.06, 
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127.8, 127.7, 123.0, 114.7, 90.2 (C1'), 82.1 (C3'), 80.7 (C4'), 73.8 (CH2), 72.3 (CH2), 
70.5 (C5), 68.9 (C5'), 56.4 (C2'), 55.5 (OCH3), 46.0 (CH2). 
3-N-benzyl-3',5'-di-O-benzyl-5-bromo-2'-fluoro-2'-S-(4-methoxyphenyl)-2'-
thiouridine (101). Treatment of 94b (131 mg, 0.2 mmol) with DBH (172 mg, 0.6 mmol) 
and Py.9HF (280 μL, 1.2 mmol) at -78 oC according to the procedure described for 89a 
→ 96a/97 followed by column chromatography (15% EtOAc in hexanes) gave 101 as a 
mixture of diastereomers (2'-R/S-S, ~ 65:35)  (pale-yellow oil, 82 mg, 56%):  1H NMR 
(CDCl3) δ 7.84 (s, 1H, H6), 7.81 (d, J = 2.1 Hz, 0.2H, Ph), 7.66 (d, J = 2.2 Hz, 0.8H, Ph), 
7.49-7.23 (m, 17H, Ph), 6.78 (d, J = 8.7 Hz, 0.8H, Ph), 6.75 (d, J = 8.7 Hz, 0.2H, Ph), 
6.44 (d, J = 13.9 Hz, 0.8H, H1'), 6.27 (br s, 0.2H, H1'), 5.09 (“d”, J = 13.6 Hz, 1H, 
benzylic), 4.92-4.80 (m, 1H, benzylic), 4.73-4.65 (m, 1H, benzylic), 4.62-4.41 (m, 3H, 
benzylic), 4.18-4.09 (m, 2H, H3', H4'), 3.92 (s, 0.6H, CH3), 3.91 (s, 2.4H, CH3), 3.82-
3.72 (m, 1H, H5'), 3.61-3.53 (m, 1H, H5''); 19F NMR (CDCl3) δ –133.52 ppm (br s, 0.8F), 
–131.57 ppm (br s, 0.2F). 
13C NMR (CDCl3) for major isomer (extracted data): δ 158.4, 157.2, 149.4, 138.1, 
137.79, 137.76, 137.3, 136.8, 135.9, 134.1, 134.0, 129.3, 128.6, 128.5, 128.4, 128.3, 
128.2, 128.1, 128.0, 127.9, 120.24, 120.23, 112.2, 112.0, 108.7 (d, 1JC2'-F = 239.1 Hz, 
C2'), 96.9, 90.4 (d, 2JC1'-F = 47.3 Hz, C1'), 80.3 (C4'), 79.7 (d, 2JC3'-F = 17.7 Hz, C3'), 73.5 
(CH2), 73.1 (CH2), 67.0 (C5'), 56.4 (CH3), 45.7 (CH2). 
5'-O-Acetyl-2',3'-dideoxy-2',3'-didehydro-2'-[(4-chlorophenyl)sulfonyl]uridine (or) 
1-[5'-O-Acetyl-2',3'-dideoxy-2'-(4-chlorophenyl)sulfonyl-β-ᴅ-glycero-pent-2'-
enofuranosyl]uracil (102). mCPBA (70% reagent, 250 mg, 1.45 mmol) was added to a 
stirred solution of 89a (227.4 mg, 0.5 mmol) in CH2Cl2 (15 mL) and the resultant 
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colorless solution was stirred at ambient temperature for 12h. TLC showed complete 
conversion to a more polar product. The reaction mixture was poured into NaHCO3/H2O 
(10 mL). The aqueous layer was extracted with CHCl3 (2 x 5 mL) and the combined 
organic phase was washed with H2O (20 mL), brine (25 mL), and dried (MgSO4). 
Volatiles were evaporated in vacuo to give 91a (241 mg, 99%) as a colorless foam. 
Purification of this material on silica gel chromatography (50% EtOAc in hexanes) gave 
102 contaminated with 40% of 91a (184 mg, 1.5:1 ratio of 102:91a): 1H NMR (CDCl3) δ 
10.04 (s, 0.6H, NH), 9.99 (s, 0.4H, NH), 7.89-7.85 (m, 0.8H, Ph), 7.84-7.81 (m, 1.2H, 
Ph), 7.57-7.53 (m, 2H, Ph), 7.36 (d, J = 8.1 Hz, 0.6H, H6), 7.28-7.27 (“m”, 0.6H, H1'), 
7.19 (d, J = 8.2 Hz, 0.4H, H6), 7.01 (“d”, J = 1.9 Hz, 0.6H, H3'), 6.21 (d, J = 6.4 Hz, 
0.4H, H1'), 5.72-5.66 (m, 1.4H, H3', H5), 5.15-5.11 (m, 0.6H, H4'), 4.64 (t, J = 6.8 Hz, 
0.4H, H2'), 4.46-4.22 (m, 2.4H, H4', H5', H5''), 2.09 (s, 1.8H, CH3), 2.08 (s, 1.2H, CH3), 
2.07 (s, 1.2H, CH3).  
3-N-Benzyl uracil (103) and 3,5-di-O-benzyl-1,2-dideoxy-1,2-didehydro-2-[(4-
chlorophenyl)sulfonyl]ribose (104). A stirred solution of 91b (30 mg, 0.045 mmol) and 
selectfluor (24 mg, 0.067 mmol) in dry DMF (2 mL) was added to a chilled suspension of 
KH (30 wt% dispersion in mineral  oil; 2.5 mg, 0.0613 mmol) in dry THF (5 mL) at -78 
oC. TLC after 30 minutes showed complete consumption of starting material and two new 
spots. The reaction mixture was slowly warmed to 0 oC. Crude reaction mixture was 
partitioned between CHCl3 (5 mL) and ice-cold NH4Cl/H2O (5 mL). The aqueous layer 
was extracted with CHCl3 (2 x 2 mL) and the combined organic phase was washed with 
NaHCO3/H2O (10 mL), brine (10 mL), and dried (MgSO4). Volatiles were evaporated in 
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vacuo and the residue was column chromatographed (5% → 50% EtOAc in hexanes) to 
give 103 (5.7 mg, 63%) as colorless oil and 104 (14.9 mg, 71%) as a colorless foam.  
Analogously, treatment of substrate (30 mg, 0.045 mmol) in dry THF (2 mL) with 
a chilled suspension of KH (30 wt% dispersion in mineral  oil; 2.5 mg, 0.0613 mmol) in 
dry THF (5 mL) at 0 oC for 15 minutes  followed by aqueous workup and column 
chromatography also gave 103 and 104 in similar yields. 
103 had:221 1H NMR (CDCl3) δ 9.48 (1H, br s, NH), 7.45-7.42 (m, 2H, Ph), 7.34–7.24 
(m, 3H, Ph), 6.50 (dd, J = 3.7, 7.5 Hz, 1H, H6), 5.79 (d, J = 7.7 Hz, 1H, H5), 5.10 (s, 2H, 
CH2). 
104 had: 1H NMR (CDCl3) δ 7.71 (d, J = 8.6 Hz, 2H, Ph), 7.38 (s, 1H, H1), 7.31-7.13 (m, 
10H, Ph), 6.99-6.97 (“m”, 2H, Ph), 4.81 (d, J = 2.9 Hz, 1H, H3), 4.73-4.70 (m, 1H, H4), 
4.45-4.39 (m, 2H, CH2), 4.37-4.30 (m, 2H, CH2), 3.42 (dd, J = 5.4, 10.3 Hz, 1H, H5), 
3.34 (dd, J = 5.7, 10.3 Hz, 1H, H5'); 13C NMR (CDCl3) δ 160.7 (C1), 140.6 (Ph), 139.4 
(Ph), 137.2 (Ph), 137.0 (Ph), 129.2 (Ph), 128.9 (Ph), 128.6 (Ph), 128.4 (Ph), 128.1 (Ph), 
128.0 (Ph), 127.9 (Ph), 127.8 (Ph), 118.8 (C2), 90.5 (C4), 80.6 (C3), 73.7 (CH2), 71.0 
(CH2), 68.7 (C5). HRMS (ESI) m/z 493.0846 [M+Na]+, calcd for C25H23ClNaO5S+ 
493.0847. 
[4-[(4-Methoxyphenyl)sulfonyl]furan-2-yl]methyl acetate (105), (106) and 5'-O-
Acetyl-2',3'-dideoxy-2',3'-didehydro-2'-[(4-methoxyphenyl)sulfonyl]uridine (107). 
TDAE (0.24 mL, 1.04 mmol) was added to a stirred solution of 91a (100 mg, 2.07 mmol) 
in DMF (2 mL) at -78 oC and the reaction mixture was brought to ambient temperature 
over 1h 15 minutes  and a 10% HCl solution (2 mL) was added. The crude was extracted 
with EtOAc (3 x) and the combined organic phase was dried (Na2SO4). Volatiles were 
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evaporated in vacuo and the residue was column chromatographed (Petroleum ether (PE) 
100% → EtOAc/PE 2/1 → 100% EtOAc) to give 105 (34.5 mg, 54%), 106 (21 mg, 
24%), and 107 (35 mg, 40%) as colorless oils. 
105 had: 1H NMR (CDCl3) δ 7.93 (d, J = 0.8 Hz, 1H, H1), 7.85-7.89 (m, 2H, Ph), 6.96-
7.00 (m, 2H, Ph), 6.56 (s, 1H, H3), 4.97 (s, 2H, H5, H5'), 3.85 (s, 3H, OCH3), 2.05 (s, 
3H, Ac); 13C NMR (CDCl3) δ 170.3 (C=O), 163.8 (Ph), 152.4 (C4), 145.7 (C1), 132.9 
(C2), 131.1 (Ph), 129.8 (Ph), 114.7 (Ph), 108.7 (C3), 57.4 (C5), 55.8 (OCH3), 20.8 (CH3); 
MS (ESI) m/z 328.17 [M+NH4]+, calcd for C14H18NO6S+ 328.08.  
106 had: 1H NMR (CDCl3) δ 9.00 (br, 1H, NH), 7.76 (d, J = 8.8 Hz, 2H, Ph), 7.58 (s, 1H, 
H1'), 6.97-6.99 (m, 3H, Ph, H6), 5.69 (br s, 1H, OH), 5.62 (dd, J = 1.2, 8 Hz, 1H, H5), 
4.93-4.79 (m, 1H, H3'), 4.27 (dd, J = 4.4, 12.4 Hz, 1H, H5'), 4.21 (dd, J = 4.8, 12.4 Hz, 
1H, H5''), 3.86 (s, 3H, OCH3), 1.95 (s, 3H, Ac); 13C NMR (CDCl3) δ 170.4 (C=O), 164.2 
(Ph), 162.6 (C4), 160.3 (C6, C2), 150.3 (C4’), 140.2 (C2'), 131.5 (Ph), 129.9 (Ph), 116.9 
(C1'), 114.9 (Ph), 103.7 (C5), 88.7 (C3'),  63.4 (C5'), 55.6 (OCH3), 20.5 (CH3). MS (ESI) 
m/z 440.04 [M+NH4]+, calcd for C18H22N3O8S+ 440.11. 
107 had: 1H NMR (CDCl3) δ 9.23 (br, 1H, NH), 7.79-7.75 (m, 2H, Ph), 7.24 (d, J = 8.4 
Hz, 1H, H6), 7.18 (t, J = 1.6 Hz, 1H, H3'), 7.03-6.99 (m, 3H, Ph, H1'), 5.55 (dd, J = 2.0, 
8.4 Hz, 1H, H5), 5.12-5.09 (m, 1H, H4'), 4.41 (dd, J = 4.0, 12.4 Hz, 1H, H5'), 4.29 (dd, J 
= 3.6, 12.4 Hz, 1H, H5''), 3.87 (s, 3H, OCH3), 2.09 (s, 3H, Ac); 13C NMR (CDCl3) δ 
170.1 (C=O), 164.9 (Ph), 162.9 (C4), 150.3 (C2), 142.1 (C6),  141.9 (C2'), 139.5 (C3'), 
130.8 (Ph), 129.1 (Ph), 115.2 (Ph), 103.2 (C5), 87.5 (C1'), 82.8 (C4'), 63.9 (C5'), 56.1 
(OCH3), 20.8 (Ac). HRMS (ESI) m/z 423.0856 [M+H]+, calcd for C18H19N2O8S+ 
423.0857. 
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[4-[(4-Methoxyphenyl)sulfonyl]furan-2-yl]methyl acetate (105) and uracil (105a). In 
a glove box, SED (31 mg, 0.1 mmol) was added to a solution of 91a (50 mg, 0.1 mmol) 
in anhydrous DMF (4 mL) and stirred at ambient temperature for 15 minutes. Reaction 
flask was brought out of the glove box and water was added to the crude reaction 
mixture. The aqueous phase was extracted with CH2Cl2 (3 x), the combined organic 
phase was dried with Na2SO4 and volatiles were evaporated in vacuo to give 105 (29.4 
mg, 95%) as a colorless oil.  
Acidification of the aqueous phase (pH ~ 5-6) followed by a second extraction 
with CH2Cl2 (2 x) gave a white solid. 1H NMR (MeOD) of the white solid revealed the 
presence of uracil 105a along with other impurities. 
3,5-di-O-Benzyl-1,2-dideoxy-1,2-didehydro-2-[(4-methoxyphenyl)sulfonyl]ribose 
(108), 2-[(benzyloxy)methyl]-4-[(4-methoxyphenyl)sulfonyl]furan (109) and 3-N-
benzyluracil (103). In a glove box, SED (22 mg, 0.067 mmol) was added to a stirred 
solution of 91b (45 mg, 0.07 mmol) in DMF (4 mL) and the reaction mixture was stirred 
at ambient temperature for 15 minutes. Reaction flask was brought out of the glove box 
and water was added to the crude reaction mixture. The aqueous phase was extracted 
with CH2Cl2 (3 x) and the combined organic phase was dried with Na2SO4. Volatiles 
were evaporated in vacuo and the residue was column chromatographed (PE 100% → 
PE/EtOAc 9/1 → EtOAC 100%) to give 108 (22 mg, 70%) as a white gum and 103 (9.4 
mg, 69%) as a white solid.  
108 had: 1H NMR (CDCl3) δ 7.83-7.79 (m, 2H, Ph), 7.42 (s, 1H, H1), 7.37-7.31 (m, 3H, 
Ph), 7.26-7.24 (m, 5H, Ph), 7.09-7.07 (m, 2H, Ph), 6.86-6.84 (m, 2H, Ph), 4.86 (d, J = 3.2 
Hz, 1H, H3), 4.77 (td, J = 3.2, 5.6 Hz, 1H, H4), 4.49 (d, J = 2.4 Hz, 2H, CH2), 4.40 (s, 
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2H, CH2), 3.81 (s, 3H, OCH3), 3.48 (dd, J = 5.6, 10.4 Hz, 1H, H5), 3.40 (dd, J = 5.6, 10.4 
Hz, 1H, H5); 13C NMR (CDCl3) δ 163.3 (CPh), 159.7 (C1), 137.4 (CPh), 137.3 (CPh), 
133.6 (CPh), 129.8 (2 CHPh), 128.7 (2 CHPh), 128.4 (2 CHPh), 128.1 (3 CHPh), 128.0 
(CHPh), 127.9 (2 CHPh), 119.7 (C2), 114.2 (2 CHPh), 90.3 (C3), 80.7 (C4), 73.7 (CH2), 
70.8 (CH2), 68.9 (C5), 55.7 (OCH3); HRMS (ESI) m/z 484.1789 [M+NH4]+, calcd for 
C26H30NO6S+ 484.1788. 
Analogous treatment of and 91b (50 mg, 0.075 mmol) with SED (64 mg, 0.22 
mmol) in DMF (4 mL) for 30 minutes at room temperature gave 109 as a mixture with 
108 (7.4 mg, 2:1 ratio of 109:108) as a colorless oil and 103 (13 mg, 86%) as a white 
solid. 
109 had: 1H NMR (200MHz, CDCl3) δ 7.93 (s, 1H, H1), 7.91-7.84 (m, 2H, Ph), 7.36-
7.30 (m, 5H, Ph), 7.01-6.96 (m, 2H, Ph), 6.49 (s, 1H, H3), 4.53 (s, 2H, CH2), 4.42 (s, 2H, 
CH2), 4.14-4.03 (m, 2H, H5), 3.86 (s, 3H, OCH3); MS (ESI) m/z 376.17 [M+NH4]+, calcd 
for C19H22NO5S+ 376.12. 
5'-O-Acetyl -2',3'-didehydro-2',3'-dideoxy-2'-fluorouridine (111) and  1-(5-O-Acetyl-
2-deoxy-2-fluoro-β,D-arabinofuranosyl)uracil (114). TDAE (0.06 mL, 50.1 mg, 0.25 
mmol) was added drop-wise via syringe to a stirred solution of 95a (95 mg, 0.19 mmol) 
in dry THF (5 ml) at -70°C under sunlamp irradiation. After 1 h, Selectfluor (131 mg, 
0.37 mmol) was added and the sunlamp was turned off. The resulting mixture was stirred 
for 1 h at -70°C and then overnight at ambient temperature. The reaction mixture was 
quenched with 3 ml of aqueous NH4Cl and stirred for 30 min and then extracted with 
EtOAc. The combined organic layer was washed with Na2CO3/H2O, brine and dried over 
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MgSO4. Evaporation and column chromatography (5% MeOH in CHCl3) gave 111 (10 
mg: 18%) and 114 (5 mg: 10%).  
111 was also obtained by another procedure (see Scheme 22). In a glove box, 
SED (68 mg, 0.24 mmol, 3 equiv.) was added to a stirred solution of 95a (40 mg, 0.08 
mmol) in anhydrous DMF (4 mL) and the resulting dark brown solution was stirred at 
120 oC for 18 h. Reaction flask was brought out of the glove box, and 10% HCl solution 
was added to the crude reaction mixture. Aqueous layer was extracted with CH2Cl2 (2 x). 
Combined organic layer was dried (Na2SO4), filtered, and concentrated in vacuo to give a 
brown solid. Et2O was added to the solid and was filtered. Filtrate was concentrated in 
vacuo to give 111 (<10 mg, ~ 46%) along with other impurities. 1H NMR of the black 
solid (DMSO-d6) showed similar peaks to the ones obtained for the oxidized form of the 
SED (SED2+).  
111173 had: 1H  NMR  (CDCl3) δ 8.47 (br s, 1H, NH), 7.52 (dd, J = 1.0, 8.1 Hz, 1H, H6), 
6.90-6.88 (m, 1H, H1'), 5.78 (d, J = 8.1 Hz, 1H, H5), 5.69 (m, 1H, H3'), 5.06-5.02 (m, 
1H, H4'), 4.35-4.21 (m, 2H, H5',5"), 2.11 (s, 3H, Ac); 19F NMR (CDCl3) δ -133.76 (t, J = 
4.6 Hz, F2'); MS (EI) m/z 271.09 [M+H]+. calcd for C11H12FN2O5+ 271.07. 
114 had: 1H NMR (CDCl3) δ 8.32 (br s, 1H, NH), 7.51-7.53 (m, 1H, H6), 6.22-6.28 (m, 
1H, H1'), 5.76 (d, J = 8.1 Hz, 1H, H5), 5.06 (d, J = 51.3 Hz, 1H, H2'), 4.43-4.29 (m, 3H, 
H3', H5', H5''), 4.21-4.19 (m, 1H, H4'), 2.12 (s, 3H, Ac); 13C NMR (150 MHz, CDCl3) δ 
170.9 (C=O), 162.7 (C4), 150.1 (C2), 140.9 (C6), 102.2 (C5), 94.4 (d, J = 191.8 Hz, 
C2’), 84.7 (d, J = 16.5 Hz,  C1’), 82.9 (C4’), 75.4 (d, J = 26.5 Hz, C3’), 63.1 (C5’), 20.9 
(CH3); 19F NMR (CDCl3) δ -199.91 (s, F2'); MS (EI) m/z 288.9 [M+H]+, calcd for 
C11H14FN2O6+ 289.08. 
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3-(benzyloxy)-2-[(benzyloxy)methyl]-4-[(4-methoxyphenyl)sulfonyl]furan (112). In a 
glove box, SED (62 mg, 0.22 mmol) was added to a solution of 95b (50 mg, 0.073 mmol) 
in anhydrous DMF (4 mL) and the resulting solution was stirred at 120 oC for 3 h. 
Reaction flask was brought out of the glove box, and water was added to the crude 
reaction mixture.  The aqueous phase was extracted with CH2Cl2 (3 x) and the combined 
organic phase was dried with Na2SO4. Volatiles were evaporated in vacuo and the residue 
was column chromatographed (PE/EtOAc 9/1 → EtOAC 100%) to give 112 (19.6 mg, 
58%) as a white gum and 103 (12.4 mg, 84%) as a white solid. 
Analogous treatment of 95b (58.3 mg, 0.085 mmol) with SED (72 mg, 0.25 
mmol) at ambient temperature for 4 h showed only trace amounts of 112 and 103 on 
TLC. Addition of degazed water (0.5 mL, 500 mg, 27.75 mmol) followed by heating at 
80 oC for 30 minutes gave, after workup and silica gel chromatography, 112 (31.7 mg, 
80%) and 103 (10.1 mg, 60%). 
112 had: 1H NMR (200MHz, CDCl3) δ 7.94-7.87 (m, 2H, Ph), 7.83 (s, 1H, H1), 7.37-
7.24 (m, 10H, Ph), 6.95-6.88 (m, 2H, Ph), 5.07 (s, 2H, CH2), 4.41 (s, 2H, CH2), 4.17 (s, 
2H, CH2), 3.84 (s, 3H, OCH3); 13C NMR (50 MHz, CDCl3) δ 163.6 (C3), 144.8 (C1), 
142.4 (Ph), 140.7 (Ph), 137.4 (Ph), 136.2 (Ph), 132.8 (C4), 130.0 (Ph), 128.55(Ph), 
128.53 (Ph), 128.48 (Ph), 128.0 (Ph), 127.9 (Ph), 125.6 (C2), 114.3 (Ph), 77.3 (CH2), 
72.4 (CH2), 61.1 (CH2), 55.7 (OCH3). HRMS (ESI) m/z 482.1632 [M+NH4]+ calcd for 
C26H28NO6S+ 482.1632. 
3-N-Methyl-2'-deoxy-2'-fluoro-2'-[(4-methoxyphenyl)sulfonyl]uridine (115). TDAE 
(0.036 mL, 0.155 mmol) was added drop-wise via syringe to a stirred solution of 95a 
(15.4 mg, 0.031 mmol) in dry THF or DMF (0.5 ml) at -70°C under N2.  UV sunlamp 
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was switched on and after 1 h, CH3I (44.4 mg, 0.31 mmol) was added. The resulting 
mixture (yellowish with white fine solid) was stirred for 1 h at -70°C and then overnight 
at ambient temperature. The reaction mixture was quenched with 3 ml of aqueous MeOH, 
stirred for 30 min and concentrated in vacuo. The crude product (100.8 mg), a yellowish 
solid, was washed with dichloromethane (2 x 5 mL), filtered and the filtrate concentrated 
in vacuo to recover 42.9 mg of a viscous orange. 19F-NMR of this crude product 
indicated no starting material (a triplet centred at - 157 ppm) and a triplet centred at -
161.42 ppm with additional resonances at in the region -122 to -126 ppm. Column 
chromatography (5% MeOH in CHCl3) gave 115 (10.2 mg, ~ 79%) that was 
contaminated with an impurity, as the fastest moving fraction. 
1H NMR (300 MHz, CDCl3) δ 7.75 (d, 2H, J = 6.9 Hz, Ph), 7.68 (d, 1H, J = 8.7 Hz, H6), 
6.98 (d, 2H, J = 6.9 Hz, Ph), 6.40 (d, 1H, J = 20.4 Hz, H1'), 5.85 (d, 1H, J = 8.7 Hz, H5), 
5.04 (m, 1H, H3'), 3.98-4.11 (m, 3H, H4' and H5',5''), 3.89 (s, 3H, OCH3); 3.15 (s, 3H, 
NCH3); 19F NMR (282 MHz, CDCl3) δ -160.41 (t, J = 19.5 Hz, F2') and -160.75 (t, J = 
19.8 Hz, F2') (ratio 1:0.16); MS (ESI) m/z 431.1 [M+ H]+, 453.1 [M+Na]+. 
General Procedure for cyclic voltammetry. Electrochemical measurements were 
performed using an EG & G-Princeton Applied Research 263A all-in-one potentiostat, 
using a standard three-electrode setup with a glassy carbon electrode (working electrode, 
diameter = 3 mm), platinum wire auxiliary electrode and a non-aqueous Ag/Ag+ (0.01 M 
AgNO3 + 0.1 M n-Bu4NClO4) system in acetonitrile as the reference electrode. All 
solutions under the study were 0.1 M in the supporting electrolyte n-Bu4NPF6 (Fluka 
puriss electrochemical grade) with the voltage scan rate of 0.2 V s-1. Anhydrous DMF 
was obtained from Fisher Scientific. Solutions (2.5 mL) were thoroughly bubbled with 
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dry argon for 15 minutes to remove oxygen before any experiment and kept under 
positive pressure of argon. Under these experimental conditions the ferrocene/ferricinium 
couple, used as internal reference for potential measurements, was located at E1/2 = + 0.05 
V in DMF. 
4-Benzylamino-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (122a). BnBr (345 μL, 
496 mg, 2.9 mmol) was added to a stirred solution of tubercidin (19a; 266 mg, 1 mmol) 
in dried DMF (5 mL). After stirring for 48 hours at 40 oC, TLC showed almost complete 
conversion to a more polar product. Volatiles were evaporated to ~1 mL (< 40 oC, 
vacuum pump) and the resulting syrup was added dropwise to dried acetone (30 mL) with 
vigorous stirring. Et2O (60 mL) was added to the suspension, which was chilled for 20 
min at 0 oC and vacuum filtered. The hygroscopic precipitate was quickly dissolved in 
MeOH (10 mL) and Me2NH/THF (2 M, 8 mL) was added. The resulting solution was 
stirred at reflux (65 ˚C, oil bath) for 20 h. TLC showed ~80% conversion to less polar 
spot, and volatiles were evaporated and coevaporated with MeOH (2 ×). The residue was 
dissolved in warm MeOH (10 mL), H2O (60 mL) was added, and the solution was 
extracted with EtOAc (5 × 20 mL). The combined organic phase was dried (Na2SO4), 
concentrated in vacuo, coevaporated (2 × EtOH) and flash chromatographed (EtOAc) to 
give 122a (238 mg, 67%) as a colorless oil: UV (MeOH) λmax 276 nm , λmin 244 nm; 1H 
NMR (DMSO-d6) δ 8.09-8.13 (m, 2H, NH, H2), 7.38 (d, J = 3.7 Hz, 1H, H6), 7.29-7.35 
(m, 4H, Ph), 7.22-7.25 (m, 1H, Ph), 6.67 (d, J = 3.4 Hz, 1H, H5), 6.01 (d, J = 5.9 Hz, 1H, 
H1'), 5.27-5.32 (m, 2H, 2'-OH, 5'-OH), 5.12 (d, J = 4.3 Hz, 1H, 3'-OH), 4.70-4.78 (m, 
2H, CH2), 4.44 (q, J = 5.7 Hz, 1H, H2'), 4.09 (“q”, J = 4.1 Hz, 1H, H3'), 3.90 (q, J = 3.4 
Hz, 1H, H4'), 3.60-3.65 (m, 1H, H5'), 3.50-3.56 (m, 1H, H5''); 13C NMR (DMSO-d6) δ 
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156.1, 151.4, 149.5, 140.1, 128.2 (Ph), 127.1 (Ph), 126.6, 122.3 (C6), 103.4, 99.2 (C5), 
87.6 (C1'), 85.1 (C4'), 73.7 (C2'), 70.7 (C3'), 61.8 (C5'), 43.1 (CH2); MS (ESI) m/z 357 
(100%, MH+), HRMS (ESI) m/z 357.1581 (MH+), calcd for C18H29N4O4 357.1563.  
4-(4-Nitrobenzylamino)-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (122b). 
Method A. Tubercidin (19a; 266 mg, 1.0 mmol) was treated with 4-nitrobenzyl bromide 
(648 mg, 3.0 mmol) at 80 ˚C for 24 h as described above for 122a followed by addition 
of MeOH (15 mL) and Me2NH/THF (2 M, 8 mL). The reaction mixture was stirred at 
reflux for 20 h; TLC showed ~85% conversion to a less polar product 122b (244 mg, 
56%, yellow oil): UV (MeOH) λmax 278 nm, λmin 240 nm; 1H NMR (DMSO-d6) δ 8.30 (t, 
J = 6.1 Hz, 1H, NH), 8.19 (“d”, J = 8.8 Hz, 2H, Ph), 8.12 (s, 1H, H2), 7.58 (d, J = 8.8 Hz, 
2H, Ph), 7.43 (d, J = 3.7 Hz, 1H, H6), 6.69 (d, J = 3.5 Hz, 1H, H5), 6.04 (d, J = 6.3 Hz, 
1H, H1'), 5.28-5.30 (m, 2H, 2 × OH), 5.14 (s, 1H, OH), 4.80-4.91 (m, 2H, CH2), 4.45 
(“d”, J = 4.4 Hz, 1H, H2'), 4.11- 4.13 (m, 1H, H3'), 3.92 (q, J = 3.5 Hz, 1H, H4'), 3.64 
(dt, J = 3.9, 11.8 Hz, 1H, H5'), 3.52-3.57 (m, 1H, H5''); 13C NMR (DMSO-d6-D2O) δ 
155.8, 151.0, 148.8, 147.9, 146.3, 127.9 (Ph), 123.4 (Ph), 122.8 (C6), 103.6, 99.3 (C5), 
87.5 (C1'), 84.9 (C4'), 73.5 (C2'), 70.4 (C3'), 61.6 (C5'), 42.7 (CH2); MS (ESI): m/z 402 
(100%, MH+). Anal. Calcd for C18H19N5O6•1.25 H2O (423.89): C, 51.00; H, 5.11; N, 
16.52. Found: C, 51.05; H, 5.06; N, 16.03. 
Method B. Step a. Ac2O (377 μL, 408 mg, 4 mmol) was added to a stirred suspension of 
19a (266 mg, 1 mmol) in dried pyridine (5 mL) at 0 oC (ice bath) and stirring was 
continued at 0 oC for 12 h and then at ambient temperature for 9 h (total reaction time: 21 
h). MeOH was added, the reaction mixture was stirred at ambient temperature for 30 min, 
and volatiles were evaporated (vacuum pump, <25 oC). MeOH was added and 
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evaporated, and the resulting gum was partitioned between CHCl3 (50 mL) and 2% 
AcOH/H2O (50 mL). The aqueous layer was extracted with CHCl3, and the combined 
organic phase was washed with NaHCO3/H2O, brine, and dried (MgSO4). Volatiles were 
evaporated in vacuo and the residue was column chromatographed (EtOAc) to give 
2',3',5'-tri-O-acetyltubercidin (123; 337 mg, 86%) as a colorless foam with data as 
reported.222 
Step b. NaNO2 (66 mg, 0.95 mmol) was added to a solution of 123 (150 mg, 0.38 mmol) 
in freshly prepared ~55% HF-pyridine192 (1.9 mL) at –10 oC in a sealed polypropylene 
vessel. The mixture was stirred at –10 oC for 15 min, and TLC showed almost complete 
conversion to a less polar spot. Ice/H2O was added and the mixture was extracted with 
CH2Cl2. The combined organic phase was washed with NaHCO3/H2O, brine, and dried 
(Na2SO4). Volatiles were removed in vacuo, and the resulting brown oil was column 
chromatographed (30% EtOAc in hexanes) to give 7-(2,3,5-tri-O-acetyl-β-D-
ribofuranosyl)-4-fluoropyrrolo[2,3-d]pyrimidine (124; 124 mg, 82%) as a colorless oil: 
UV (MeOH) λmax 258 nm, λmin 233 nm; 1H NMR (CDCl3) δ 8.53 (d, 4JH-F = 0.5 Hz, 1H, 
H2), 7.37 (d, J = 3.8 Hz, 1H, H8), 6.66 (d, J = 3.8 Hz, 1H, H7), 6.45 (d, J = 6.0 Hz, 1H, 
H1'), 5.74 (t, J = 5.8 Hz, 1H, H2'), 5.55 (dd or m, J = 4.1, 5.6 Hz, 1H, H3'), 4.32-4.42 (m, 
3H, H4', H5', H5''), 2.12 (s, 3H, CH3), 2.13 (s, 3H, CH3), 2.02 (s, 3H, CH3); 19F NMR 
(CDCl3) δ –64.81 ppm (s); 13C NMR (CDCl3) δ 170.2, 169.6, 169.4 (3 x C=O), 162.3 (d, 
1JC-F = 253.8 Hz, C4), 155.1 (d, 3JC-F = 11.9 Hz, C7a), 151.1 (d, 3JC-F = 14.5 Hz, C2), 
125.7 (d, 4JC-F = 2.6 Hz, C6), 105.4 (d, 2JC-F = 33.4 Hz, C4a), 99.6 (d, 3JC-F = 4.9 Hz, C5), 
86.1 (C1'), 79.9 (C4'), 73.1 (C2'), 70.1 (C3'), 63.3 (C5'), 20.7, 20.5, 20.3 (3 x s, 3 x CH3); 
MS (ESI): m/z 396 (100%, MH+). 
117 
 
Step c. Freshly distilled Et3N (113 μL, 82 mg, 0.81 mmol) was added to a stirred 
suspension of 124 (93 mg, 0.23 mmol) and 4-nitrobenzylamine hydrochloride (67 mg, 
0.35 mmol) in MeOH (3 mL) and stirring was continued for 5 h at ambient temperature. 
Volatiles were evaporated in vacuo and the residue was column chromatographed (50% 
EtOAc in hexanes) to give 2',3',5'-tri-O-acetyl-4-N-(4-nitrobenzyl)tubercidin (125; 58 
mg, 47%) as a colorless oil: UV (MeOH) λmax 277 nm, λmin 238 nm. 1H NMR (CDCl3)  δ 
8.36 (s, 1H, H2), 8.17 (d, J = 8.7 Hz, 2H, Ph), 7.51 (d, J = 8.7 Hz, 2H, Ph), 7.12 (d, J = 
3.768 Hz, 1H, H6), 6.42-6.46 (dd, 3.8, 6.0 Hz, 2H, H1', H5), 5.73 (t, J = 5.8 Hz, 1H, H2'), 
5.54-5.59 (m, 2H, H3', NH), 4.95 (d, J = 6.1 Hz, 2H, CH2), 4.31-4.40 (m, 3H, H4', H5', 
H5''), 2.14 (s, 6H, 2 × CH3), 2.04 (s, 3H, CH3); 13C NMR (CDCl3) δ 170.4, 169.7, 169.5 
(3 x C=O), 156.0 (C4), 152.3 (C2), 150.8 (C7a), 147.3 (Ph), 146.7 (Ph), 128.0 (Ph), 123.9 
(Ph), 121.5 (C6), 103.8 (C4a), 99.4 (C5), 85.4 (C1'), 79.5 (C4'), 73.1 (C2'), 70.8 (C3'), 
63.5 (C5'), 44.2 (CH2), 20.8, 20.6, 20.4 (3 x s, 3 x CH3). MS (ESI): m/z 528 (100%, 
MH+). 
Step d. NH3/MeOH (5 mL) was added to a stirred solution of 125 (54 mg, 0.1 mmol) in 
MeOH (1 mL) and stirring was continued at ambient temperature for 20 h. Volatiles were 
evaporated and the residue was column chromatographed with a 2 → 4% gradient of the 
upper phase of EtOAc/i-PrOH/H2O (4:1:2) in EtOAc to give 122b (35 mg, 85%) as a 
yellow oil. 
5-Carboxamido-4-(4-nitrobenzylamino)-7-(β-D-ribofuranosyl)pyrrolo[2,3-
d]pyrimidine (122c). Sangivamycin (19b; 155 mg, 0.5 mmol) was treated with 4-
nitrobenzyl bromide (162 mg, 1.5 mmol) for 26 h at 40 oC as described for 19a → 122a 
and the alkylated intermediate was then stirred with Me2NH/THF (2 M, 6 mL) and 
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MeOH (12 mL) for 45 h at ambient temperature. Me2NH/THF (2 M, 2 mL) was added 
and the mixture was stirred at reflux for 32 h (total reaction time: 77 h). TLC showed 
~80% conversion to the less polar 122c, which was obtained as off-white crystals (101 
mg, 45%) after recrystallization from EtOH: mp 154-158 oC (dec.); UV (MeOH) 286 nm 
(ε 23 100), λmin 229 nm (ε 8700); 1H NMR (DMSO-d6)  δ 10.29 (t, J = 6.0 Hz, 1H, NH), 
8.17-8.21 (m, 4H, Ph, H2, H6), 8.11 and 7.47 (2 × s, 2 x 1H, CONH2), 7.59 (brd, J = 8.8 
Hz, 2H, Ph), 6.06 (d, J = 6.0 Hz, 1H, H1'), 5.43 (d, J = 6.3 Hz, 1H, 2'-OH), 5.20 (d, J = 
5.0 Hz, 1H, 3'-OH), 5.09 (t, J = 5.8 Hz, 1H, 5'-OH), 4.90 (“d”, J = 6.2 Hz, 2H, CH2), 4.37 
(q, J = 5.8 Hz, 1H, H2'), 4.10 (“q”, J = 4.5 Hz, 1H, H3'), 3.93 (q, J = 4.0 Hz, 1H, H4'), 
3.61-3.67 (m, 1H, H5'), 3.53-3.58 (m, 1H, H5''); 13C NMR (DMSO-d6) δ 166.5, 156.5, 
152.6, 150.4, 148.0, 146.4, 128.0 (Ph), 125.7, 123.6, 110.9, 101.7, 87.2 (C1'), 85.3 (C4'), 
73.9 (C2'), 70.5 (C3'), 61.9 (C5'), 42.9 (CH2); MS (ESI) m/z 445 (100%, MH+). Anal. 
Calcd for C19H20N6O7•1.5 H2O (471.42): C, 48.41; H, 4.92; N, 17.83. Found: C, 48.59; 
H, 4.66; N, 17.65. 
5-Cyano-4-(4-nitrobenzylamino)-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 
(122d). Toyocamycin (19c; 146 mg, 0.5 mmol) was heated with 4-nitrobenzyl bromide 
(364 mg, 1.5 mmol) in dried DMF (3 mL) at 40 oC for 63 h (TLC showed ~85% 
conversion to a less polar product). Volatiles were evaporated to ~1 mL (< 40 oC, 
vacuum pump) and this material was added dropwise to 20 mL of vigorously stirred dried 
acetone. Et2O (40 mL) was added to the stirred suspension, which was chilled at 0 oC for 
20 minutes and the precipitate was collected by vacuum filtration. Recrystallization from 
MeOH gave 122d (99 mg, 46%) as colorless crystals: mp 214-216 oC; UV (MeOH) λmax 
274, 236 nm (ε 22 100, 18 900), λmin 250, 228 nm (ε 12 800, 18 000); 1H NMR (DMSO-
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d6) δ 8.35 (s, 1H, H2), 8.19-8.23 (m, 3H, H6, Ph), 7.59 (d, J = 8.6 Hz, 2H, Ph), 6.87 (s, 
1H, NH), 5.93 (d, J = 5.6 Hz, 1H, H1'), 5.47 (d, J = 6.0 Hz, 1H, 2'-OH), 5.35 (“s”, 2H, 
CH2), 5.21 (d, J = 5.0 Hz, 1H, 3'-OH), 5.09 (t, J = 5.4 Hz, 1H, 5'-OH), 4.31 (q, J = 5.5 
Hz, 1H, H2'), 4.08 (q, J = 4.6 Hz, 1H, H3'), 3.92 (q, J = 3.7 Hz, 1H, H4'), 3.62-3.68 (m, 
1H, H5'), 3.53-3.58 (m, 1H, H5''); 13C NMR (DMSO-d6-D2O) δ 152.6, 149.4, 146.7, 
144.9, 142.7, 129.4, 128.5 (Ph), 123.5 (Ph), 115.2, 105.0, 87.7 (C1'), 85.8 (C4'), 85.5, 
74.6 (C2'), 70.1 (C3'), 61.1 (C5'), 48.8 (CH2); MS (ESI): m/z 427 (100%, MH+). Anal. 
Calcd for C19H18N6O6•0.5 H2O (435.39): C, 52.41; H, 4.40; N, 19.30. Found: C, 52.17; 
H, 4.29; N, 19.30. 
8-azidotoyocamycin (129). NaN3 (158.1 mg, 2.43 mmol) was added to a stirred solution 
of 55 (300 mg, 0.810 mmol) in anhydrous DMF (10 mL) in a flame dried flask and the 
resulting colorless solution was stirred at room temperature in the dark for 16 h, by which 
time the solution turned a brown-red color and UV showed 6 nm bathochromic shift in 
the λmax, indicating the conversion to product. Volatiles were removed from the clear, 
brown-red solution using high vacuum rotary evaporator on a hot water bath (<80 oC) 
while in a dark room. The resulting brown gummy oil was purified using column 
chromatography in the dark (5%, MeOH/EtOAc) to give 129 as an off white solid (123.2 
mg, 46%): HRMS (ESI): m/z [M+Na]+ calcd for C12H12N8NaO4+: 355.0874; found 
355.0952. 
Click product (132). Cyclooctyne 130 (9.04 mg, 0.060 mmol) was added to a stirred 
solution of 129 (20 mg, 0.060 mmol) in ACN and H2O (3:1) in a flask and the resulting 
clear, colorless solution was stirred at room temperature for 4 h, by which time TLC 
showed >80% conversion to product to a more polar product. Volatiles were removed 
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using high vacuum rotary evaporator and a hot water bath (<80 oC). The resulting yellow 
oil was purified using column chromatography (10%, EtOAc/MeOH) giving 132 as an 
off white solid (17 mg, 59%). This solid was then re-purified using RP-HPLC (20% CAN 
in H2O) to give 132 as an off white gummy solid (9.6 mg, 33%). Rf (EtOAc:iPrOH:H2O, 
4:1:2) 0.49; HRMS (ESI): m/z [M+H]+ calcd for C22H27N8O5+: 483.2099; found 
483.2087. 
Click product (133). Cyclooctyne 131 (16.6 mg, 0.060 mmol) was added to a stirred 
solution of 129 (20 mg, 0.060 mmol) in ACN and H2O (3:1) in a flask and the resulting 
clear, pale red solution was stirred at room temperature for 4 h, by which time TLC 
showed >80% conversion to product to a more polar product almost on the baseline. 
Volatiles were removed using high vacuum rotary evaporator and a hot water bath (<80 
oC). The resulting pale red oil was purified using column chromatography (17.5%, 
EtOAc/MeOH) giving 133 as an off white gummy solid (17.1 mg, 47%). Rf 
(EtOAc:iPrOH:H2O, 4:1:2) 0.13; HRMS (ESI): m/z [M+H]+ calcd for C30H29N10O5+: 
609.2317; found 609.2352. 
2',3',5'-tri-O-acetyltoyocamycin. (138). Ac2O (380μL, 4 mmol) was added to a stirred 
solution of 19c (292 mg, 1 mmol) in anhydrous pyridine (5 mL) at 0 oC (ice bath) and 
stirring was continued at 0 oC for 1 h and then at ambient temperature for 3 h (total 
reaction time: 4 h). MeOH was added, the reaction mixture was stirred at ambient 
temperature for 30 min, and volatiles were evaporated (vacuum pump, <25 oC). MeOH 
was added and evaporated, and the resulting gum was partitioned between CHCl3 (25 
mL) and 2% AcOH/H2O (25 mL). The aqueous layer was extracted with CHCl3, and the 
combined organic phase was washed with NaHCO3/H2O, brine, and dried (MgSO4). 
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Volatiles were evaporated in vacuo and the residue was column chromatographed (70% 
EtOAc in hexanes) to give 2',3',5'-tri-O-acetyltoyocamycin (138; 405 mg, 97%) as a 
colorless foam: 1H NMR (CDCl3) δ 8.24 (s,1H, H2), 7.72 (s, 1H, H8), 6.37 (s, 2H, NH2), 
6.30 (d, J = 5.4 Hz, 1H, H1'), 5.66 (d, J = 5.5 Hz, H2'), 5.48 (d, J = 5.1 Hz, H3'), 4.38 
(“q”, J = 3.9 Hz, H4'), 4.33-4.32 (“m”, 2H, H5', H5''), 2.08 (s, 3H, CH3), 2.06 (s, 3H, 
CH3), 2.00 (s, 3H, CH3). 
8-Bromo-2',3',5'-tri-O-acetyltoyocamycin (139). DBH (157 mg, 0.55 mmol) was added 
to a stirred solution of 138 (209 mg, 0.5 mmol) in CH2Cl2 (4 mL) and the resulting brown 
solution was stirred at ambient temperature for 18 hours. The reaction mixture was 
partitioned between CH2Cl2 (16 mL) and NaHCO3/H2O (25 mL). The aqueous layer was 
extracted with CH2Cl2, and the combined organic phase was washed with brine and dried 
(MgSO4). Volatiles were evaporated in vacuo and the residue was column 
chromatographed (50% EtOAc in hexanes) to give 139 (195 mg, 79%) as a brown oil 
with data as reported.223 
2',3',5'-tri-O-(tert-butyldimethylsilyl)toyocamycin (141). Imidazole (1.02 g, 15 mmol) 
and TBDMSCl (1.09 g, 7.2 mmol) was added to a stirred solution of 19c (583 mg, 2 
mmol) in anhydrous DMF (6 ml) and the resulting suspension was stirred at ambient 
temperature for 24 h and then at 35 oC for 12 h, by which time TLC showed ~40% 
unchanged substrate and two less polar spots. A second portion of imidazole (1.02 g, 15 
mmol) and TBDMSCl (1.09 g, 7.2 mmol) were added and the resulting suspension was 
stirred at 35 oC for 24 h (total reaction time: 60 h), by which time TLC showed 80% 
conversion to a major less polar spot. Volatiles were evaporated and co-evaporated with 
toluene (high vacuum rotavap, <40 oC). Crude pale gum was partitioned between CHCl3 
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(50 mL) and brine (50 mL). The aqueous layer was extracted with CHCl3, and the 
combined organic layer was dried over anhydrous MgSO4. Volatiles were evaporated in 
vacuo and the residue was column chromatographed (25% EtOAc in hexanes) to give 
141 (736 mg, 58%) as a colorless oil: 1H NMR (CDCl3) δ 8.30 (s,1H, H2), 8.13 (s, 1H, 
H8), 6.27 (s, 2H, NH2), 6.18 (d, J = 4.1 Hz, 1H, H1'), 4.32 (d, J = 4.2 Hz, H2'), 4.21 (d, J 
= 4.4 Hz, H3'), 4.12-4.10 (“m”, 1H, H4'), 4.02 (dd, J = 2.8, 11.6 Hz, 1H, H5'), 3.78 (dd, J 
= 1.8, 11.6 Hz, 1H, H5''), 0.97 (s, 9H, tBut), 0.89 (s, 9H, tBut), 0.80 (s, 9H, tBut), 0.16 (s, 
3H, CH3), 0.15 (s, 3H, CH3), 0.06 (s, 3H, CH3), 0.05 (s, 3H, CH3), -0.04 (s, 3H, CH3), -
0.14 (s, 3H, CH3). 
8-Iodo-2',3',5',-tri-O-(tert-butyldimethylsilyl)toyocamycin (142). LDA (2 M solution 
in THF, 560 μL, 1.1 mmol) was added to a stirred solution of 141 (139.5 mg, 0.22 mmol) 
in dry THF (2 mL) at -78 oC. After ~1 h at -78 oC, iodine (84 mg, 0.33 mmol). The 
resultant brown solution was stirred at -78 oC for 2 h and at ambient temperature for 48 
hours (total reaction time: 51h). Reaction mixture was portioned between EtOAc (10 mL) 
and 2% AcOH/H2O (10 mL). Aqueous layer was extracted with EtOAc. Combined 
organic layer was washed with brine (20 mL), dried (MgSO4), filtered and concentrated 
in vacuo, and column chromatographed (10% EtOAc in hexanes) to give 142 (27.3 mg, 
16%) and 141 (82.3 mg, 58%) as brown oils. 
142 had: 1H NMR (CDCl3) δ 8.40 (s,1H, H2), 8.07 (s, 1H, NH2), 6.15 (d, J = 4.5 Hz, 1H, 
H1'), 4.78 (s, 1H, NH2), 4.27 (d, J = 4.3 Hz, H2'), 4.16 (d, J = 4.3 Hz, H3'), 4.06-4.03 
(“m”, 1H, H4'), 3.94 (dd, J = 3.0, 11.5 Hz, 1H, H5'), 3.72 (dd, J = 2.1, 11.5 Hz, 1H, H5''), 
0.91 (s, 9H, tBut), 0.84 (s, 9H, tBut), 0.74 (s, 9H, tBut), 0.10 (s, 3H, CH3), 0.09 (s, 3H, 
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CH3), 0.00 (s, 3H, CH3), 0.01 (s, 3H, CH3), -0.12 (s, 3H, CH3), -0.24 (s, 3H, CH3); 
HRMS (ESI) m/z 745.4651 [M-CH3+H]+, calcd for C29H52IN5O4Si3 745.9249.  
7-(1H-benzo[d][1,2,3]triazol-1-yl)tubercidin (144). Tert-butyl hydroperoxide (85 μL, 
0.75 mmol) and iodine (38 mg, 0.15 mmol) were added to a stirred suspension of 19a 
(100 mg, 0.38 mmol) and benzotriazole (89.5 mg, 0.75 mmol) in anhydrous DMF (2mL). 
The resulting dark brown solution was stirred at 35 oC for 72 h, by which time TLC 
showed ~10% conversion to a less polar product. A second portion of TBHP (85 μL, 0.75 
mmol) was added and the resulting dark brown solution was stirred at 35 oC for 24 h 
(total reaction time: 96 h). Volatiles were evaporated and co-evaporated with toluene 
(high vacuum rotavap, <50 oC). The resulting brown gum was column chromatographed 
(5% MeOH in EtOAc) to give 144 (26 mg, 18%) as a brown gum. This brown gum was 
then injected into a semi-preparative HPLC column (Phenomenex Gemini RP-C18 
column; 5µ, 25 cm x 1 cm) via a 5 mL loop and was eluted with an isocratic mobile 
phase mixture 20% CH3CN in H2O at a flow rate of 1.5 mL/min to give 144 (tR = 21 min) 
as a white powder: UV (MeOH) λmax 278 nm (ε = 16700), λmin 240 nm (ε = 8000); 1H 
NMR (DMSO-d6) δ 8.50 (d, 1H, J = 8.3 Hz, Ph), 8.22 (s,1H, H2), 7.70-7.67 (m,1H, Ph), 
7.62-7.52 (m, 4H, Ph, NH2), 7.04 (s, 1H, H8), 5.58 (dd, J=3.5,8.8, 3H, 5'-OH), 5.23 (d, 
J=6.9 Hz, 1H, H1'), 5.20 (d, J=6.4 Hz, 1H,2'-OH), 4.92 (“dd”, J=6.4,11.2 Hz, 3'-OH, 
H2'), 3.82 (“brs”, 1H, H3'), 3.75 (“d”, J=3.7, 6.2 Hz, H4'), 3.43 (dt, J=3.6,11.9 Hz, H5'), 
3.28-3.22 (m, 1H, H5''); 13C NMR (DMSO-d6): δ 158.22, 153.13 (C2), 148.82, 144.52, 
135.13, 129.42 (Ph), 125.63, 125.10 (Ph), 119.70 (Ph), 110.51 (Ph), 102.04, 99.48 (C8), 
88.20 (C1'), 85.97 (C4'), 71.31 (C2'), 70.77 (C3'), 62.12 (C5'); HRMS (ESI): m/z 
384.1391 [M+H]+, calcd for C17H17N7O4 384.1415. 
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5. CONCLUSION 
 In conclusion, I developed a novel desulfurization-difluorination method for the 
synthesis of α,α-difluoro esters from the corresponding α-arylthio esters, wherein the 
thiol group is present on the secondary internal carbon. 1,3-Dibromo-5,5-
dimethylhydantoin (DBH) was used as the oxidant (Br+) and Py.9HF was the fluoride ion 
(F-) source. Arylthio esters with hydrogen as well as a ring deactivating chloro substituent 
at the para position of the aromatic ring were converted to the corresponding gem-
difluoro esters under mild reaction conditions. However, the presence of a ring activating 
methoxy substituent on the para position of the aromatic ring caused the reaction to be 
sluggish and the difluorination was observed in low yields. Expansion of this 
desulfurization-difluorination methodology towards the thioether substrates having 
aldehyde, ketone, and unactivated alkane functional groups on the adjacent carbon was 
unsuccessful. Also, treatment of lactones under similar reaction conditions gave low yield 
conversion to the corresponding α-fluoro sulfides and α-fluoro sulfoxides. Attempted 
synthesis of gem-difluorouridine derivatives from the corresponding 2'-arylthio uridine or 
2'-fluoro-2'-arylthio uridine precursors was unsuccessful and resulted mostly in 
halogenation of the pyrimidine ring at the C-5 and monofluorination at C2', without 
desulfurization. However, treatment of the fully benzylated uridine substrate bearing a p-
methoxyphenylthioether substituent at the C2' with combination of NIS and DAST gave 
a moderate but encouraging yield (44%) of the corresponding monofluorinated thioether 
without any appreciable oxidation of thioether and iodination of the pyrimidine ring. 
Chemical reduction protocols in combination with cyclic voltammetry were 
employed for reductive desulfonylation of 2'-arylsulfonyl-2'-deoxyuridines as a possible 
125 
 
alternative process towards incorporation of fluorine and other substituents at the C2'.  A 
critical impact on the outcome of these reactions was the choice of the protecting groups. 
Thus, 3',5'-O-diacetylated substrates 91a were found to decompose readily into the 
corresponding vinyl sulfone 102 during silica gel column purification, whereas the fully 
benzylated substrate 91b was prone to uracil elimination in the presence of strong base. 
The cleavage of the C2'-S was found to occur at a relatively high cathodic potential close 
to - 2.4 V vs SCE, with the expulsion of the corresponding sulfinate, meaning that strong 
chemical reducing agents or selective electrochemical reductions were required. 
Interestingly the protecting group (Bn or Ac) had no impact on the reduction potential. 
Reactions of 2'-arylsulfonyl-2'-deoxy-2'-fluorouridines with using Organic Electron 
Donors (OEDs) under different conditions (excess of reducing agents, temperature, uv 
light activation) gave products resulting from the elimination of either acetate anion from 
C3' position or uracil from C1' upon reduction of the C2'-S bond leading to furan-type 
products. Interestingly, less powerful reducing-agent TDAE under UV light activation 
was found to cleave the C2'-sulfonyl bond to give 2',3'-unsaturated 2'-fluorouridine (18%) 
and 2'-fluoro-2'-deoxyuridine (10%) products. Tentative trapping of the resulting C2'-
anion under these uv light conditions either with Selectfluor or MeI were however 
unsuccessful.  
Bromination at C5-position of pyrimidine nucleosides such as uridine, 2'-
deoxyuiridine, arabinouridine, cytidine, and N4-benzoylcytidine were achieved under 
mild reaction conditions using DBH. Also, transformation of purine nucleosides such as 
adenosine, 2'-deoxuadenosine, guanosine, and 2'-deoxyguanosine to their corresponding 
8-brominated counterparts with DBH. Although purine nucleosides required higher 
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amounts of reagents and produced brominated products in lower yields when compared 
to that of the pyrimidine counterparts (47-98% vs 70-98%). Increase in temperature and 
presence of Lewis acids such as TMSOTf and TsOH increased the rate of bromination 
reaction and reduced the equivalents of DBH reagent required. The DBH bromination 
protocol is bench friendly, with most conversions taking place at ambient temperature 
and producing the brominated products in moderate to high yields. Also, acid labile 
protection groups such as isopropylidine, and base labile protection groups such as acetyl, 
benzoyl, and silyl were found to be stable during the course of bromination. In addition, I 
developed novel NBS or DBH mediated bromination methodology for the synthesis of 
previously known 8-bromotoyocamycin and 8-bromosangivamycin. This methodology 
offers mild and improved synthetic alternative from previous reaction conditions. I also 
found that DBH-bromination of various unprotected nucleosides proceeded efficiently in 
MeOH, avoiding the need to use high-boiling and expensive solvent DMF.  
Novel 6-N-benzyltubercidin and 6-N-(4-nitrobenzyl) analogues of tubercidin and 
sangivamycin were synthesized by initial alkylation at N1 with respective benzyl 
bromide followed by Me2NH mediated Dimroth rearrangement. However, no evidence of 
formation of an initial N1-alkylated cationic intermediate was observed on TLC upon 
treatment of toyocamycin with 4-nitrobenzyl bromide. Isolated less polar product 
indicated direct alkylation on the exocyclic amino group to give 4-N-(4-
nitrobenzyl)toyocamycin. Alternatively, 6-N-(4-nitrobenzyl)tubercidin was also prepared 
by (i) conversion of acetylated tubercidin to its 6-fluorocounterpart via Balz-Schiemann 
type fluoro-diazotization with NaNO2/Py.9HF (55% HF); (ii) SNAr displacement of the 
6-fluoro group by 4-nitrobenzylamine; (iii) deacetylation with NH3/MeOH. The 6-N-(4-
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nitrobenzyl) derivatives of tubercidin and sangivamycin inhibited cross-membrane 
transport of labelled uridine by the human equilibrative nucleoside transporter hENT1 at 
>1 µM and ~120 nM, respectively. Inhibition of the proliferation of L1210, HeLa, and 
PC-3 tumor cells in culture was observed with 6-N-benzyltubercidin and the 6-N-(4-
nitrobenzyl) derivatives of sangivamycin and toyocamycin at 0.92–9.4 µM 
concentrations. 
Novel 8-azidotoyocamycin was synthesized by treatment of 8-bromotoyocamycin 
with sodium azide. But the azide product was light sensitive and decomposed after 
exposure to light. Strain promoted click chemistry of 8-azidotoyocamycin with 
cyclooctynes gave the corresponding 8-triazolyl derivatives in moderate yields. Iodine 
mediated CH arylation of tubercidin with benzotriazole gave the corresponding 7-
substituted benzotriazolyl product, which showed emission at 420 nm with a quantum 
yield of 0.002 s. 
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